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Abstract
The extracellular matrix (ECM) is a highly organized, dynamic structure that maintains
tissue integrity and regulates biological processes involved in organ development and
function. To explore the role of ECM proteins in ovarian physiology and pathology, my
thesis characterizes ECM proteins aberrantly overexpressed in the Estrogen Receptor
(ER)β-null (βERKO) mouse ovary and epithelial ovarian cancer (EOC). The ECM
undergoes extensive physical changes, and influences numerous cell functions,
throughout folliculogenesis. This study identifies a role for ERβ in ovarian development
earlier than previously believed. Nidogen 2 and Collagen 11a1 are aberrantly
overexpressed in βERKO ovaries as early as postnatal day 13, and this dysregulation
continues into adulthood, as determined by qPCR and immunofluorescence. Collagen IV,
Nidogen 1 and Laminin are also more highly expressed in the βERKO ovary than in the
wildtype ovary, suggesting that the repression of several ECM proteins in the ovary is
ERβ-dependent. The molecular mechanisms that initiate gene repression by ERβ are not
well understood; therefore a potential mechanism by which ERβ may act as a
transcriptional repressor in the ovary is investigated. I characterized a novel ERβ
transcriptional corepressor – transcription factor 21 (TCF21). In transient transfection
and reporter assays, TCF21 represses ERβ transactivation of synthetic and natural
estrogen-responsive promoters in various cell lines. As in the βERKO ovary, when the
mechanisms regulating ECM dynamics during normal organ function are disrupted, the
ECM becomes disorganized. This disorganization is associated with various pathologies,
including cancers. The ECM protein, Spondin 1 (SPON1), is overexpressed in ovarian
cancers and has been identified as a promising ovarian cancer marker, particularly for
high-grade serous carcinomas; yet, its cellular functions and related mechanisms in EOC
progression remain unknown. This study shows that SPON1 is expressed and secreted by
immortalized EOC cell lines and human primary ascites-derived EOC cells. Treatment
with exogenous SPON1 reduces EOC cell adhesion, viability and proliferation but not
migration. Experiments utilizing a non-adherent culture surface suggest SPON1 does not
effect EOC spheroid formation but is involved in spheroid anchoring and cell dispersion.
These findings support an important role for ECM proteins in ovarian development and
progression of ovarian carcinomas.
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Chapter 1

1

Introduction

1.1 Overview of Chapter 1
This thesis examines the role of extracellular matrix (ECM) proteins in ovarian follicle
development and ovarian cancer progression.
This chapter begins with an overview of folliculogenesis (Section 1.2) describing:
a) the formation and growth of follicles, b) the events necessary for a follicle to mature
into a preovulatory follicle capable of releasing a fertilizable oocyte, and c) the role of
ECM components in follicular development. The next section (Section 1.3) describes
Estrogen Receptor β (ERβ), its structure, mechanisms of action and the phenotype of the
ERβ knockout mouse. The following two sections focus on the 17β-estradiol-regulated
ECM proteins Collagen11A1 (Section 1.4) and Nidogen 2 (Section 1.5); in Chapter 2, I
show data exploring the expression and localization of these two proteins in the ovaries
of wildtype and ERβ knockout mice. Section 1.6 focuses on Transcription Factor 21
(TCF21); data suggesting a novel role for TCF21 as a co-regulator of ERβ-transcriptional
activity is shown in Chapter 3. Spondin1, another 17β-estradiol-regulated ECM protein
that is also implicated in ovarian cancer, is the focus of Section 1.7. Ovarian cancer is
described in Section 1.8, with a focus on its origins, classification and the role of ECM
components in ovarian cancer progression. The relevance of Spondin 1 to ovarian cancer
progression is supported by my data in Chapter 4. The final section of Chapter 1 (Section
1.9) provides the rationale for these studies.

1.2 Folliculogenesis
1.2.1

Introduction to folliculogenesis
Folliculogenesis is a highly regulated process in the ovary by which an immature

primordial follicle develops into a mature preovulatory follicle capable of releasing a
mature oocyte. The ovary is also an important site of steroid production, including

2

testosterone, 17β-estradiol and progesterone, which are essential for the development of
secondary sex characteristics and the maintenance of pregnancy.
The ovarian follicle is the basic functional unit of the ovary (Figure 1-1A). It
consists of the oocyte and two somatic cell types, granulosa cells (GCs) and theca cells
(TCs). GCs, an actively differentiating cell type, surround the oocyte and are essential for
its growth. As GCs proliferate and the follicle grows, the GC layer becomes surrounded
by a basement membrane and TCs. A fluid-filled cavity known as the antrum then forms,
resulting in the development of a mature, preovulatory follicle. This cascade of events
culminates in the rupture of one or more mature preovulatory follicles, and the release of
a fertilizable oocyte. Although the timing of specific stages in folliculogenesis may differ,
the overall pattern appears to be fairly well conserved in mammals.

1.2.2

Formation of primordial follicles
During mammalian embryonic development, primordial germ cells (PGCs)

differentiate from the epiblast [1]. PGCs migrate to the genital ridge, then differentiate
into oogonia once they reach the gonads [2]. Upon their arrival in the gonads, the germ
cells undergo several rounds of mitosis until meiosis is initiated, which occurs
approximately 13.5 days post coitum (dpc) in mice [3] and after 13 weeks of gestation in
humans [4]. Just prior to the initiation of meiosis the germ cells are arranged into clusters
connected by intercellular bridges. These clusters are known as oocyte “nests” or “cysts”.
These nests break down to form primordial follicles, which are single oocytes surrounded
by a layer of epithelial pre-granulosa cells [1] (Figure 1-1B). The first primordial follicles
are histologically detected as early as postnatal day (PND) 1 in mice [5] and 15 weeks of
gestation in humans [6]. Although many mechanisms involved in the assembly of
primordial follicles remain to be elucidated, studies have identified a variety of genes
involved in this process, including transcription factors, meiosis-specific enzymes,
growth factors and proteins of the zona pellucida (the glycoprotein layer that surrounds
the plasma membrane of the oocyte) [7]. This initial pool of primordial follicles is the
stock from which all growing follicles are derived. Once primordial follicles are formed
they remain dormant until they are activated at puberty [8].
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Figure 1-1: Folliculogenesis
A) A representative antral follicle. An antral follicle consists of an antrum as well as an
oocyte, surrounded by granulosa cells, a basement membrane and thecal cells.
B) Stages of folliculogenesis. Growth of the follicle from the primordial to secondary
stage is gonadotropin-independent. FSH is required for the formation of a large
preovulatory follicle, which is capable of ovulation and forming a corpus luteum in
response to an LH surge.
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1.2.3

Primordial follicle to secondary follicle
Primordial follicles remain quiescent until they are selected for activation to

become primary follicles. The factors controlling the activation of primordial follicles,
i.e. why a particular follicle enters the growing pool while an adjacent one remains
dormant, remain largely unknown, although it is well accepted that this is a multifaceted
process involving the oocytes, somatic cells, ECM proteins and growth factors [9, 10].
According to studies using transgenic mouse models, inhibitory proteins and
pathways exist to maintain primordial follicles in a dormant state. Anti-Mullerian
hormone (AMH) controls the recruitment of primordial follicles [11]. An increased
number of follicles are activated in AMH null mice [11], whereas overexpression of
AMH suppresses primordial follicle recruitment and decreases the sensitivity of follicles
to follicle stimulating hormone (FSH) [12]. Premature activation of primordial follicles is
also observed following the loss of forkhead box O3 (Foxo3a) [13] or the oocyte-specific
deletion of phosphatase and tensin homolog (Pten) [14], which leads to total depletion of
the ovarian reserve and infertility in both animal models. It is ultimately the coordinated
actions of inhibitory and activating signals within the ovary that initiate the recruitment
of primordial follicles into the growing pool [2].
Once a primordial follicle enters the growing pool the squamous pre-granulosa
cells differentiate into a single layer of cuboidal GCs surrounding the oocyte, forming a
primary follicle. The transcription factor forkhead box L2 (FOXL2) is required for GC
differentiation. Mice expressing an inactive form of FOXL2 do not complete the
morphological transition from flattened pre-granulosa cells to cuboidal GCs, and the
absence of functional GCs leads to an arrest at the primary stage and oocyte atresia [15].
The progression from primary to secondary follicles requires further GC proliferation
(two or more layers), and the formation of both a basement membrane and a distinct layer
of TCs. The oocyte-derived growth differentiation factor 9 (GDF9) mediates
communication between the oocyte and GCs and is considered obligatory for this stage of
growth, given that mice null for Gdf9 are infertile, and lack secondary follicles or TCs
around the basement membrane [16]. The factors involved in the recruitment of TCs are
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not well understood; however it is believed that GC-derived signals are involved in the
recruitment and differentiation of stromal cells into TCs [17]. Follicle growth up to the
secondary stage is gonadotropin independent, as evidenced by transgenic mouse models
and clinical studies in patients with FSH deficiency. Both Fshb-/- mice [18], which lack
the follicle stimulating hormone (FSH) beta subunit and therefore cannot produce FSH,
and women with inactivating mutations in Fshb [19] show follicular growth up to the
secondary stage.

1.2.4

Secondary follicle to preovulatory follicle
Unlike the transition from the primordial to the secondary stage, the development

of a large antral preovulatory follicle is dependent on the ability of GCs and TCs to
respond to the gonadotropins, FSH and luteinizing hormone (LH). Mice with the inability
to produce FSH (Fshb-/-) or respond to FSH due to a loss of FSH receptor (Fshr-/-) are
infertile because follicles arrest at the secondary stage [18, 20]. Mice that lack the ability
to respond to LH due to lack of LH receptor (Lhcgr-/-) or produce it (Lhb-/-) are also
infertile, with folliculogenesis arrested at the early antral stage and a complete lack of
preovulatory follicles [21, 22]. Therefore, FSH and LH are absolutely required for the
careful coordination of mechanisms regulating the development of preovulatory follicles,
steroid production and formation of a fluid-filled antrum.
Fluid collects in growing secondary follicles between the GC layers. Once these
fluid-filled spaces coalesce to form the antrum, the follicle is termed antral [23]. The fluid
within the antrum is similar in composition to serum but contains fewer proteins with a
molecular weight above 100 kDa than serum [24]. Follicles at the antral stage have
increased vascularization within the TC layer compared to follicles at the pre-antral stage,
along with continued growth of the oocyte and proliferation of the somatic cells.
The primary role of TCs after the secondary stage of folliculogenesis is to
produce androgens, specifically androstenedione and testosterone, to serve as precursors
for 17β-estradiol production in GCs. The increase in androgens stimulates GC expression
of FSHR. FSH then promotes GC proliferation and the expression of steroidogenic genes
involved in the conversion of androgens to 17β-estradiol. The expression of Cyp19a1
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(cytochrome P450, family 19, subfamily A, polypeptide 1) in GCs is the rate-limiting
step in estrogen biosynthesis. Cyp19a1, commonly referred to as aromatase, converts TCderived androgens to 17β-estradiol in GCs [25].
Early in FSH-dependent follicle growth the GCs produce low levels of 17βestradiol, which suppresses GnRH (gonadotropin-releasing hormone) secretion by the
hypothalamus, thereby reducing FSH secretion by the pituitary. As the follicle grows and
the number of GCs increases, the production of 17β-estradiol is also increased, which
raises GnRH levels and favours the production of LH [26]. In addition to 17β-estradiol
GCs produce members the TGFβ family, activin and inhibin, named for their effect on
FSH production. Activin, expressed by small and early antral follicles, stimulates FSH
biosynthesis and release. Conversely, inhibin is expressed by late antral/pre-ovulatory
follicles and has an inhibitory effect on follicle growth [27].
As GCs continue to proliferate in the early antral stage, they differentiate into two
specialized GC subtypes, mural and cumulus. Layers of mural GCs are located along the
basement membrane and are responsible for most of the follicle’s steroidogenic activity,
producing increasing amounts of 17β-estradiol as the follicle grows. Cumulus cells
surround and are closely associated with the oocyte. They have lower steroidogenic
activity than mural cells but promote oocyte growth by providing nutrients via gap
junctions [28]. A defining feature of cumulus cells is their ability to undergo expansion
later in folliculogenesis, a requirement for ovulation and therefore essential for fertility
[29].
1.2.4.1

Selection of a dominant preovulatory follicle

Of the several thousand follicles in mice present at birth [30] or several million
present in humans [31], only about 0.01% eventually develop into an ovulating dominant
follicle while the rest undergo atresia, an apoptotic process [32]. The number of follicles
selected to be dominant varies between species, from a select few in rodents to only a
single follicle in humans. As noted earlier, the cyclical release of FSH at the antral stage
initiates the growth of a cohort of follicles. Growth and follicle survival is FSHdependent at this stage. As the follicle grows and the number of GCs increases, so do the
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numbers of LHCGR expressed on mural cells. Gradually the mature follicle becomes
more responsive to LH and less responsive to FSH. Furthermore, the expression of
LHCGR leads to increased aromatase expression as well as abundant 17β-estradiol and
inhibin production. The follicle that first acquires these characteristics is selected to
become the dominant follicle because it is able to release 17β-estradiol more quickly and
cause a switch in the gonadotropin output by the anterior pituitary, namely suppressing
FSH levels and promoting LH production [30]. As follicle growth becomes LHdependent and FSH levels fall, the remaining subordinate follicles in the growing pool
that lack the LHCGR, and consequently the necessary LH responsiveness, undergo
atresia. It has also been observed that dominant follicles are larger and faster growing
than non-dominant follicles [31].

1.2.5

The “LH surge” and ovulation
As the dominant follicle continues to grow, it secretes high levels of 17β-estradiol

and inhibin. Once a threshold concentration of estradiol is reached an acute surge of LH
is released from the anterior pituitary [32]. The LH surge acts on the preovulatory follicle
to initiate oocyte maturation, cumulus cell expansion, ovulation and the terminal
differentiation of GCs and TCs to form the corpus luteum (CL). LH rapidly acts on the
mural GCs to change gene expression and activate several pathways required for these
events to occur [33]. The LH surge activates multiple pathways including protein kinase
A (PKA), phosphoinositide-3 kinase/protein kinase B (PI3K/AKT), and RAS signaling
cascades, all of which are critical for ovulation [34]. The epidermal growth factor (EGF)like factors amphiregulin (AREG), epiregulin (EREG) and betacellulin (BTC) are
secreted from the mural GCs following the LH surge and activate EGF receptors (EGFR)
in cumulus GCs [35]. The loss of these EGFR ligands in mice impairs ovulation,
demonstrating that these signaling pathways are essential for ovulation to occur following
the LH surge [36].
1.2.5.1

Oocyte maturation

During primordial germ cell formation, oocytes arrest at Prophase I of meiosis.
The LH surge triggers oocyte reentry into the cell cycle; however, the exact mechanisms
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involved are not well understood. It has been demonstrated that oocytes removed from
follicles and placed in culture spontaneously resume meiosis [37], suggesting that
follicle-derived factors are involved in maintaining the oocyte in meiotic arrest. It is
generally accepted that high levels of the cyclic nucleotides, cAMP and cGMP, are
involved in the maintenance of meiotic arrest because meiotic resumption coincides with
either a reduction in cAMP [38] or cGMP [39] levels. It is expected that the oocyte
produces cAMP itself [40], whereas cGMP is likely derived from somatic cells [41]. It
has also been shown that GPR3 (G-protein coupled receptor 3) and GPR12 are necessary
for the regulation of oocyte meiosis in mice [42] and rats [43], respectively. Oocytes from
the Gpr3-/- knockout mouse resume meiosis independent of LH, while treatment of mouse
oocytes with the GPR3/12 ligands SPC and S1P delayed meiotic resumption.
1.2.5.2

Cumulus expansion

Following the LH surge, cumulus GCs produce a hyaluronan (HA)-rich ECM that
surrounds the oocyte, in preparation for ovulation [44]. This process is called cumulus
expansion as a result of the increase in cumulus cell-oocyte complex (COC) volume. The
HA-rich matrix contains various ECM proteins including laminin, collagen IV,
fibronectin, and proteoglycans [45, 46]. The production of these proteins is dependent on
the expression of both oocyte- and cumulus cell-derived factors. Many of the genes
critical for COC expansion have been identified using knockout mouse models, including
Has2 (hyaluronan synthase 2), Ptgs2 (prostaglandin endoperoxide synthase 2), Tnfaip6,
and Ptx3 (pentraxin 3). Prostaglandin signaling is necessary for the production of ECM
proteins by cumulus cells and COC expansion, as mice lacking Ptgs2 [47] or Ptger2
(prostaglandin E2 receptor) [48] expression have impaired COC expansion and are
infertile or subfertile, respectively. Tumour necrosis factor, alpha induced protein 6
(Tnfaip6)-null mice are also infertile [49]. Further studies have shown that isolated COCs
that demonstrate poor expansion are unfertilizable because sperm are unable to degrade
the HA-rich matrix, while oocytes isolated without cumulus GCs are unfertilizable due to
reduced viability [29].
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1.2.5.3

Follicle rupture

Ovulation involves the release of the COC from the follicle and ultimately from
the ovary, as an oocyte surrounded by a single layer of expanded cumulus GCs. Before
successful ovulation can occur the apical surface of the follicle must associate with the
periphery of the ovary, and by proteolytic degradation weaken the follicle wall for follicle
rupture. Following the LH surge, the follicle expresses proteases, including MMPs
(matrix metalloproteinases) [50] and ADAMTSs (a disintegrin and metallopreoteinase
with thrombospondin motifs) [51], involved in ECM degradation. Studies have indicated
that members of both families are upregulated during follicle rupture in various species
[52-55]; however, only the subfertile Adamts1-/- mice have exhibited a reproductive
phenotype [56]. Several transgenic mouse models that lack genes encoding LH-induced
proteases do not exhibit reproductive phenotypes, suggesting certain proteases may have
a redundant role and may be compensated for by other proteins [57-60], thereby adding
another level of complexity. The specific mechanisms responsible for selected ECM
degradation remain to be elucidated although it has been proposed that localized
expression of TIMPs (tissue inhibitors of metalloproteinases) may be involved [61].
1.2.5.4

Luteinization and formation of the corpus luteum

After the release of the oocyte, the remaining somatic cells differentiate into
granulosa lutein (GL) and theca lutein (TC) cells in a process called luteinization. The
new structure formed from the luteal cells is termed the corpus luteum (CL), and
produces high levels of progesterone to prepare the endometrium for implantation and
pregnancy. The follicular phase is now concluded and the luteal phase begins,
characterized by the formation of the CL and consequent steroid production.
The CL produces high levels of 17β-estradiol and inhibin, which act on the
pituitary to suppress FSH secretion [62]. The model of estrogen production by the follicle
appears to be conserved by the CL because reminiscent of the GC and TC, the GL and
TL cells have different roles in the CL. It is suggested that the GL and TL are the primary
sites of estradiol synthesis and androgen production, respectively [63-65]. Furthermore,
CYP11A1 (cytochrome P450, family 11, subfamily A, polypeptide 1) and HSD3B
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(hydroxyl-delta-5-steroid dehydrogenase, 3 beta and steroid delta-isomerase) have been
immunolocalized in GL and TL, demonstrating that both luteal cell types produce
progesterone [65].
During the luteal phase, the CL also undergoes extensive neovascularization,
which is required for the acquisition of large amounts of cholesterol as a substrate for
progesterone. In the follicular phase, only the vasculature of the theca is well developed
and does not penetrate the basement membrane. After ovulation, endothelial cells form
new capillaries that invade the follicle. This process is primarily driven by vascular
endothelial growth factor (VEGF) [66]. It has also been speculated that the antiangiogenic factors, thrombospondin-1 (TSP-1) and TSP-2, are required for normal CL
vascularization [67, 68].
If fertilization occurs the CL continues to produce progesterone until the placenta
is able to produce its own. Throughout pregnancy, the CL continues to produce endocrine
factors that suppress FSH secretion [62]. If fertilization does not occur the luteal cells
become apoptotic and the CL regresses to become a corpus albicans. Consequently, the
levels of 17β-estradiol and inhibin decrease and their suppressive effect on FSH is
removed. The surge of FSH recruits a new cohort of preantral follicles, which initiates the
follicular phase and another ovarian cycle begins.

1.2.6

ECM in follicular development
The ECM is composed of a diverse network of macromolecules with distinct

properties; certain proteins are strictly structural components while others serve as
signaling molecules. An important feature of the ECM is that it can be actively and
specifically remodeled to serve its function in a certain tissue, at a particular
physiological state. As described above, a developing follicle undergoes extensive
morphological and biochemical changes during folliculogenesis. In addition to the HArich matrix produced during COC expansion (1.2.5.2), the composition of the ECM is
dynamically remodeled throughout follicle growth, ovulation and atresia. The ovarian
ECM has been characterized in several mammals, including bovine [69-73], human [7476], mice [77, 78] and ovine [79, 80]. There are two main types of ECM observed in the
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follicle: the basal lamina and the basal lamina-like focimatrix (abbreviated from focal
intraepithelial matrix) [69]. Granulosa cells are thought to produce many of the ECM
components within the follicle [78, 81].
The basal lamina, often referred to as the basement membrane (BM), is a
specialized sheet of ECM that underlies the epithelial cells and separates them from the
interstitial matrix. The formation of a BM is required for normal tissue development and
function, as BMs are able to regulate cell differentiation and proliferation as well as
maintain the selective passage of cells and molecules [82]. The follicular BM is primarily
composed of collagen type IV and laminin networks, which are connected and stabilized
by nidogens [83]. The follicular BM possesses molecular exclusion capabilities and is
necessary for the maintenance of the blood-follicle barrier, although its exact mechanism
of accomplishing this remains largely unknown. Studies have suggested that not only is
size a determinant (the mass cut-off of the follicular BM is between 100 and 500 kDa), so
also is the charge of the molecule, because negatively charged molecules are excluded
from movement across the barrier [84].
The focimatrix contains typical basal lamina components; however, it is neither
basal nor laminate. Unlike basal laminas that envelop cells or groups of cells, the
focimatrix develops as aggregates between the granulosa cells. Due to its morphology,
the focimatrix is unable to perform the typical functions of the basal lamina, such as
filtering material or creating microenvironments around cells. Instead, the focimatrix is
predicted to be involved in initiating or assisting in the depolarization of granulosa cells,
which is a prerequisite for luteinization [69]. Focimatrix aggregates are more abundant in
apical than in basal GCs [73], and the amount of focimatrix increases as the follicle
grows [69]. The expression of focimatrix genes has also been correlated with expression
of steroidogenesis genes [72, 73].
Other proteins in follicles not associated with the basal lamina include
proteoglycans (typically heparan sulphate proteoglycans such as perlecan, and small
leucine-rich repeat proteoglycans such as decorin [71]), the matricellular glycoprotein
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SPARC (secreted protein acidic and rich in cysteine) [85] as well as proteins involved in
cumulus expansion and ovulation, including MMPs and TIMPs [86].
The presence and composition of the ECM influences numerous cell functions
throughout follicle growth and atresia, including morphology, steroidogenesis, survival
and proliferation [87, 88]. GCs in vivo have a rounded, epithelial morphology; however,
when seeded onto uncoated tissue culture plastic they become flattened, resembling
fibroblasts, and undergo rapid cell death. Interestingly, modifying the culture
environment in vitro can greatly impact the features of isolated GCs. When GCs are
plated on different matrices of ECM proteins, such as Matrigel (a gelatinous BM mixture
rich in ECM proteins and growth factors), or individual BM components, they maintain
their spherical morphology, are protected against apoptosis and proliferate more rapidly
[79, 89-91].
The ECM also affects the production of steroids by somatic cells. When human
GCs are cultured on serum-coated tissue culture plastic they produce significantly lower
levels of estradiol, following treatment with the substrate androstenedione, than GCs
cultured in the presence of collagen type I (50% higher) [92]. Furthermore, specific ECM
proteins have been shown to influence GC production of progesterone in several species
[87].
The presence of ECM components also impacts isolated follicles cultured in vitro
[88]. For example, human ovarian tissue slices cultured on Matrigel possess a greater
number of viable follicles over time than tissues cultured in the absence of ECM proteins
[93], and mouse ovaries have higher follicle densities and growth initiation following
culture on collagen type IV or laminin than on poly-L-lysine [10].

1.3 Estrogen Receptor Beta
1.3.1

Estrogen receptor discovery and structure
In 1958, Elwood Jensen discovered the existence of a receptor protein that

mediated the actions of estrogen, and the corresponding gene was cloned in 1985 [94]. A
novel subtype of the estrogen receptor (ER) was later cloned from the rat prostate and

13

ovary in 1996 [95]. This necessitated the renaming of the previously discovered ER to
ERα, while the newly discovered ER was accordingly designated ERβ. The human ERα
(ESR1) and ERβ (ESR2) genes are located on different chromosomes, 6q25.1 and
14q23.2, respectively. The human (and mouse) ERα and ERβ proteins have molecular
weights of approximately 66 kDa and 54 kDa, respectively. As members of the nuclear
receptor superfamily, ERs are found primarily in the nucleus, but also in the cytoplasm
and mitochondria.
The ERs consist of five domains with distinguishable functions, designated
domains A-F: an N-terminal domain (NTD) which includes the (A/B) domains, the
DNA-binding (C) domain (also known as the DBD), a hinge (D) domain, a ligandbinding domain (LBD) (E), and a C-terminal (F) domain of unknown function that is
unique to the ERs within the steroid receptor family (Figure 1-2). ERα and ERβ share the
highest amino acid identity in the DBD (96%), while the NTD is the least conserved
(30%) [96]. Interestingly, the LBDs are only ~ 50% identical, yet crystallographic studies
indicate that the ligand binding pockets of both ERs have a similar structure [97]. ERα
and ERβ show similar binding affinities towards most physiological and synthetic
ligands, with some minor differences [98-100]. The ERs also possess two activation
function (AF) domains that interact with distinct groups of coactivators: a ligandindependent AF1 in the NTD and a ligand-dependent AF2 in the DBD [96].
Several naturally-occurring splice variants have been described for both ER
subtypes, with at least 3 ERα and 4 ERβ human isoforms known; however it is unclear
whether all the variants are expressed as functional proteins and biologically active. The
530 amino acid (aa)-long human ERβ isoform is considered to be the wild type ERβ (rat
and mouse, 549 aa), while the ERβ splice variants are referred to as ERβcx/2, ERβ3,
ERβ4 and ERβ5 [94, 101]. All ERβ splice variants possess an altered C-terminus, and are
unable to bind estrogens, coactivators, or other investigated ligands [94]. The full length
and alternatively spliced forms of ERβ have been described in the normal ovary and
ovarian tumours [102-104]. It is generally considered that ERβ2 is endogenously
expressed only in rodents [102]; however, Fujimura et al. have detected expression of
ERβ2 in human prostatic cancer, which makes it the only ERβ isoform identified at the
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Figure 1-2: Comparison of the amino acid sequences of human ERα and ERβ.
Schematic of human ERα and ERβ receptors. The amino acid sequence is numbered and
steroid receptor domains are indicated. The protein sequence identity is shown between
the ERα and ERβ diagrams as %. NTD: N-terminal domain, DBD: DNA-binding domain,
LBD: Ligand-binding domain. AF: Activation function

15

protein level in human tissues [105]. The functional significance of these isoforms
continues to be elucidated.

1.3.2

Classic mechanisms of ER action
The classic mechanism of ER action is similar to that of other receptors in the

nuclear receptor superfamily. In the absence of ligand, the ERs are present in an inactive
state within the nuclei, sequestered in a multiprotein inhibitory complex. Ligands are able
to freely diffuse across the plasma and nuclear membranes, and bind the receptor. Ligand
binding induces a conformational change within the ER and a release of chaperone
proteins [106], which allows the receptors to dimerize and bind with high affinity to
specific sequences, termed estrogen response elements (ERE) [100, 106, 107]. The
consensus ERE is a 13 nucleotide inverted palindrome with a 3 base pair spacer of
variable bases. Mutant variants/ imperfect EREs typically have a reduced ability to bind
the ER and decreased transcriptional potency [106]. EREs are found throughout the
genome, with only about 4% of ER binding sites mapped to 1-kb promoter-proximal
regions [108]. ChIP-seq analysis has shown that the majority of ERβ binding sites (76%)
are located within 50 kb of a gene. Approximately 25% of these sites are within a gene,
13% in proximal promoter regions of genes, 2% at the 3’-end of a gene, 36% elsewhere
in a more distal region (5-50 kb), and the remaining 24% are over 50 kb from a gene
[109]. Furthermore, ER binding sites are generally found overlapping Forkhead box
(FOX) binding motifs [108]. Several studies have shown that FOXA1, for example, is a
key determinant of ER function, and knockdown of FOXA1 decreases ER binding,
cofactor recruitment and estrogen-stimulated transcription [110-113].
Once the ligand-ER complex is tethered to the ERE, coregulatory proteins are
recruited and the receptors interact with the general transcription machinery either
directly or indirectly via cofactor proteins [100, 114]. The cell and promoter involved
will determine whether the ER will exert a positive or negative effect on the expression
of the downstream target gene [114]. To activate transcription of a target, the structure of
chromatin is disrupted through histone acetylation and other modifications, followed by
initiation of transcription by RNA polymerase II. The molecular processes involved in
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gene repression are not as well understood and continue to be elucidated; however, it is
known that corepressor proteins recruit histone deacetylases (HDACs), which remove
acetyl groups and restrict access of transcription factors to the promoter [115].
When acting through the classic ERE-driven mechanism, ERα homodimers and
ERα/ERβ heterodimers tend to be stronger activators of transcription compared to ERβ
homodimers. ERβ demonstrates lower binding affinity for ERE half-sites than ERα [116].
Both ERs contain a functional AF2 domain; however, the AF1 domain is only
constitutively active in ERα whereas it contains a repressor function in ERβ. Once the
AF1 domain is removed from ERβ, estradiol-ERβ-mediated transcriptional activity is
increased [117]. Furthermore, it has been suggested that the effects of estrogen in a given
tissue are a function of the relative levels of ERα and ERβ. Studies have shown that ERβ
generally represses ERα-mediated gene transcription by competing with ERα for access
to the DNA target [117-119]. For example, estradiol treatment of U2OS osteosarcoma
cells engineered to express either ERα or ERβ demonstrated that each ER regulates a
distinct and overlapping set of genes [120, 121]. Estradiol-treated U2OS cells expressing
both ERs had a unique transcriptional profile compared to U2OS cells expressing either
ERα or ERβ alone [122]. A study using ChIP-chip showed that the ratio between ERα
and ERβ levels affects the ERβ-binding regions in MCF7 breast cancer cells, with ERα
displacing ERβ when both ERs were present [123]. Lastly, T47D breast cancer cells that
endogenously express ERα were engineered to also express ERβ. The expression of ERβ
antagonized ERα-mediated transcription of the ERα target genes pS2 and PR [124].
Interestingly, although a role for ERβ2 has yet to be revealed, it has been shown to
dimerize with wildtype ERs and dose dependently suppress ERα and ERβ1-mediated
transcriptional activation in vitro, suggesting it to be a negative regulator of estrogen
action [102, 104].
As mentioned previously, the cell and promoter involved will determine the
nature of ER action on specific genes. For example, ERβ is a less potent transcriptional
activator of both a consensus ERE and imperfect EREs than ERα in Chinese Hamster
Ovary (CHO) cells [116]. Conversely, ERβ is a more potent transcriptional activator of a
consensus ERE in response to estradiol in an osteoblast cell line, as compared to ERα
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[125]. The different responses to the ERs by gene promoters in different cell types are
most commonly attributed to the coregulatory proteins, which vary within cell lines and
tissues.

1.3.3

Recruitment of transcriptional coregulators by ERβ
Coregulator proteins bind directly with nuclear receptors and general

transcriptional machinery to regulate gene transcription. Two major groups of
coregulators exist: coactivators that enhance transcription and corepressors that repress
transcription [126]. Nuclear receptors interact with coregulatory proteins via two putative
motifs: the NR box (LXXLL) and the CorNR box (L/IXXI/VI), which are present in
coactivators and corepressors, respectively [127, 128].
Coregulators have enzymatic activities that produce posttranslational
modifications of chromosomal proteins involved in gene regulation. For example,
coactivator histone acetyltransferases (HATs) lead to the acetylation of histones, whereas
HDACs are recruited by corepressors and modify chromatin in such a way that
transcription is inhibited. It is well understood that multiple HDACs exist, each
contributing their own combination of enzymatic requirements to the repression complex
[114, 129]. Another level of complexity is added when other transcription factors are able
to modify the stability of the transcription complex and/or suppress the enzymatic
activities of the coregulatory proteins [130]. Coregulators can also function as bridging
factors or adaptor proteins, by linking protein-binding partners together and facilitating
the formation of larger signaling complexes [131].
In general, much less is known about the molecular processes involved in gene
repression than gene activation. The best-characterized nuclear receptor corepressors are
NCOR1 (nuclear hormone receptor-corepressor) and NCOR2/SMRT (silencing mediator
of retinoid and thyroid hormone receptors). Both are conserved transcriptional repressors
known to interact with several transcription factors, including ER [120]. They do not
appear to have intrinsic repressive activity; rather they function as part of a larger
repressor complex by recruiting other proteins involved in mediating the molecular
actions required for repression, such as HDACs. HDACs act as corepressors in their own
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right and may bridge between transcription factors to silence gene activity [129]. Nuclear
receptors usually bind corepressors in the absence of ligand or in the presence of
antagonists. The recruitment of NCOR1 and NCOR2 appears to be essential for the
antagonist activity of ERα [132]; however, little is known regarding their ability to inhibit
ERβ-mediated transcription. Interestingly, Webb et al. have shown by GST binding and
mammalian two-hybrid assays that ERβ, through its AF-2 domain, binds to NCOR1 and
NCOR2 in the presence of agonists, but not antagonists, via an LXXLL-like motif in the
NCOR C-terminus [133].
Many coregulators that either enhance or inhibit ERα transactivation have been
identified; however, ERβ coregulators have generally been understudied, and only a
handful of coregulators have been shown to bind and affect transactivation by both ERs
[96]. Furthermore, few studies have shown that ERβ recruits coregulators to endogenous
genes. A U2OS cell line stably expressing a tetracycline-regulated ERβ was used to show
that ERβ-specific agonists recruit NCOA2 to the endogenous TNFα promoter, thereby
repressing TNFα gene expression [134]. Unliganded ERβ is also recruited to a known
E2-induced gene in ERβ-expressing U2OS cells [135]. However, because U2OS cells do
not endogenously express ERβ, it is unclear whether the effects observed in this artificial
model would also be observed in primary bone cells.
Only a few coregulators that specifically regulate ERβ but not ERα transcriptional
activity have recently been identified. A yeast two-hybrid assay using the ERβ A/B
domain as "bait" found NM23-H2 to be an ERβ-associated protein, and its
overexpression to increase ERβ-mediated transcription [136]. Whether NM23-H2
interacts with ERα or affects ERα-mediated transcription was not investigated. A
comparable yeast-two hybrid assay identified HSP27/HSPB2 as an ERβ-binding protein,
which subtly affects ERβ-mediated transcription [137]. Coimmunoprecipitation assays
demonstrated that HSP27 specifically interacts with ERβ and not ERα. Although the role
of coregulators in transcriptional regulation by ERs continues to be explored, there
remains limited information in the literature regarding corepressors specifically involved
in ERβ-mediated transcription or transactivation, and much remains to be revealed.
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1.3.4

Alternative “non-classic” mechanisms of ERβ action
Over the years it has become apparent that ER can act through alternative

signaling mechanisms that diverge from the classic model. These include the regulation
of genes that lack an ERE (1.3.4.1), ER action in the absence of ligand (1.4.3.2), and
membrane signaling often referred to as “nongenomic” action (1.4.3.3). These
mechanisms are described briefly below.
1.3.4.1

Cross-talk with other transcription factors (ERE independent)
Ligand-bound ERs can also interact with other transcription factor complexes to

stimulate the transcription of genes that are not regulated by ER binding to an ERE. This
mechanism of ERE-independent ER activation involves “tethering” of the ER to other
transcription factors, such as AP-1, SP-1 (GC-rich SP-1 motifs) or NFκB, that are directly
bound to DNA by their respective response elements [106, 115]. ChIP-chip studies
strongly suggest that this is a common mechanism of transcriptional regulation for both
ERs [108, 123]. As with the classic model of ER action, ERα and ERβ differentially
regulate target genes when acting via this mechanism [96]. Interestingly, ERβ interacts
with SP-1 within the ERα promoter region and represses ERα expression [119].
1.3.4.2

Ligand-independent signaling

In addition to being activated by ligands, ERs can also be activated via ligandindependent pathways. Growth factors and intracellular messengers are able to activate
ER-mediated gene transcription in the absence of ligand. Ligand-independent activation
of ERs relies on the activation of kinases, which may phosphorylate the ER and/or its
associated coregulators [138].
1.3.4.3

Membrane-associated ER signaling (nongenomic ER action)

The models of ER action described so far influence changes within a cell by
acting in the nucleus and modulating the expression of target genes. This is a relatively
lengthy process unlikely to offer measurable effects for hours following cell exposure to
steroid. Yet rapid effects of estradiol treatment have been observed, within seconds or
minutes of ligand treatment [139], which cannot be explained by the nuclear mechanism.
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These rapid effects include activation of kinases, increases in ion fluxes across
membranes and activation of nitric oxide synthase in endothelial cells [96]. The rapid
responses of ER action are often attributed to a nongenomic mechanism, in which ligands
bind to an ER localized to the membrane or cytoplasm. Although membrane ERs are
becoming more accepted by the scientific community, they continue to be controversial,
and it remains uncertain whether the classic ERs are involved or whether a distinct
membrane-associated ER exists [96, 140, 141].

1.3.5

Localization of ERβ
The ERs exhibit species-, tissue-, and cell-specific patterns of expression and

localization. ERβ is detected in the ovary, cardiovascular system, central nervous system,
male reproductive organs, prostate, lung, colon, kidney and bone, whereas ERα is
expressed in testis, ovary, mammary gland, uterus, breast, white adipose tissue, bone,
heart and liver [94, 142]. Based on its broad expression ERβ regulates numerous
physiological processes, such as bone density, the cardiovascular system, inflammation,
and reproductive organ development and function [142].
ERβ is present in the ovaries of numerous species, including rodents, sheep,
hamster, baboon, cow, pig and human [98], and total ERβ mRNA is more abundantly
expressed than ERα mRNA in the rat ovary [143]. ERβ is predominantly expressed in the
granulosa cells (GCs) of the ovary, while ERα is expressed in the ovarian theca cells [98].
An examination of immature and adult rat ovaries by in situ hybridization showed that
ERβ is expressed in the GCs of small, growing and preovulatory follicles, with weak
expression in a subset of corpora lutea (CL) [144]. Low levels of ERβ mRNA are
detected as early as postnatal day (PND) 1 in the ovaries of mice [145] and PND 4 in the
ovaries of rat [143], with levels increasing over time as the follicle grows. ERβ protein is
detected in the primary follicles of mice on PND 4 [146]. It remains unclear whether ERβ
is responsive to 17β-estradiol in these early follicles and influences the primordial to
primary follicle transition; one study suggests it may be indirectly involved in the
primordial to primary transition in rats by acting through various growth factors [146],
whereas another shows 17β-estradiol has no effect in the ovaries of rats at this age or
stage of follicle development [147]. Although it remains unclear at what precise stage
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ERβ begins to influence folliculogenesis, it is well accepted that it has a critical role in
the postnatal ovary, as it is required for optimal preovulatory follicle development,
antrum formation, and ovulation [148, 149].

1.3.6

ERβ knockout mice
Both ERs are expressed within the ovary and the absence of either receptor affects

ovarian function. ERβ knockout mice (βERKO) are subfertile [150-152] or infertile
[153], ovulate less frequently and have smaller litters than wildtype females. The βERKO
mouse has no distinct differences in the size or morphology of the ovary, and contains
follicles at all stages of development (primordial to antral). However, it has been noted
that there are fewer large antral follicles and CL, as well as a higher frequency of atretic
follicles in the βERKO ovary than in the wildtype ovary [150, 152]. The GCs of βERKO
preovulatory follicles have an impaired response to FSH-induced differentiation, as
evidenced by decreased aromatase activity and estradiol synthesis, as well as a
diminished LH surge and reduced expression of the LH receptor [149, 154, 155]. The
attenuated response to FSH also affects the ovarian response to gonadotropins,
consequently reducing the rate of follicle rupture, cumulus-oocyte expansion as well as
the expression of prostaglandin synthase (Ptgs) and the progesterone receptor, which are
essential for follicle rupture [149, 154]. Therefore due to an impaired response to the LH
surge, ovaries of superovulated βERKO mice have numerous unruptured, preovulatory
follicles [150, 154]. Furthermore ERβ is required for the production of cyclic adenosine
monophosphate (cAMP) in GCs of preovulatory follicles, and insufficient cAMP levels
may explain the reduced levels of estradiol synthesis in βERKO females [156].
The ERα knockout (αERKO) females are infertile [157]. The adult ovaries
contain hemorrhagic, cystic follicles and no indication of ovulation. Folliculogenesis in
αERKO ovaries progresses normally until the antral stage, but arrests before reaching the
preovulatory stage [158]. FSH receptor and LH receptor mRNA expression is increased
in αERKO ovaries compared to wildtype ovaries, while ovarian androgen receptor and
progesterone receptor mRNA as well as ERβ protein levels are similar to wildtype levels
[158]. Based on the ovarian phenotypes of the αERKO and βERKO mice it is evident that
the receptors have different roles in folliculogenesis. It has been hypothesized that the
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proliferative action of estrogen is carried out by ERα, whereas the differentiating effects
of estrogen are mediated predominantly by ERβ [159].
Interestingly, the ovarian phenotype of the αβERKO mouse is different from that
of either αERKO or βERKO mice [152]. The αβERKO mice are infertile, and while
superovulation of immature females leads to the growth of antral follicles, no
preovulatory follicles or CL are observed. The antral follicles in αβERKO ovaries are
much smaller than those of wildtype or single mutant females. Furthermore, αβERKO
ovaries possess fewer GCs than wildtype ovaries, and consequently the ovarian wall is
abnormally thin due to the decreased number of mural GCs. The ovaries also have
tubule-like structures that resemble seminiferous tubules of the testis, which are likely
transdifferentiated from GCs [152, 160].
The identification of ERβ and its detection in numerous tissues expanded our
understanding of estrogen signaling, physiology and pathophysiology [159]. The ERs
have nearly a ubiquitous tissue distribution therefore it is not surprising that estrogens are
involved in a variety of mechanisms in physiology and pathology. It is clear that ERβ
plays a crucial role in the ovary, and changes in its expression may have clinical
consequences, such as in infertility or cancer [98, 159]. ERβ levels decrease during the
progression of many cancer types and it has been described as a potential tumour
suppressor in epithelial ovarian cancer [161, 162].
We have shown that the mRNA levels of several ECM genes are disrupted in the
ovaries of βERKO mice compared to their wildtype controls (Section 2.2.6, Table S2-1)
[163]. Two of these genes identified in a microarray study by Dr. Deroo are Col11a1 and
Nid2, which I further investigated in this thesis (Chapter 2).

1.4 Collagen 11A1
1.4.1

Overview
Collagen is one of the most important components of the ECM. The collagen

superfamily consists of 28 different types encoded by more than 40 genes [164]. All
collagens are trimeric molecules consisting of three polypeptide chains that form a triple
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helix structure. There are three subgroups within this diverse superfamily: fibrillar
collagens, non-fibril collagens and fibril-associated collagens. Fibrillar collagens, capable
of forming highly ordered fibrils in the ECM, are the most abundant subgroup. Fibrilassociated collagens are targeted to the surface of collagen fibrils and help regulate
fibrillar collagens. Non-fibril forming collagens are found in the basement membrane and
do not form or associate with fibrils [165]. Collagen XI is a fibrillar collagen found in
both cartilage and non-cartilaginous tissues [166, 167]. The mRNA levels of Col11a1,
which encodes the collagen α1(XI) chain (COL11A1), is 1.7-fold higher in GCs of eCGtreated ERβ-null mice, than in eCG-treated ERβ heterozygous mice [156]. COL11A1
will be the focus of this section because the expression of COL11A1/Col11a1 in the
ovary is examined in Chapter 2 of this thesis.

1.4.2

Protein structure
Collagen XI is a heterotrimeric protein consisting of three alpha chains: α1(XI),

α2(XI) and α3(XI). The α1(XI) and α2(XI) chains are unique gene products, whereas the
α3(XI) chain is an overglycosylated form of the collagen α1(II) chain [168]. The alpha
chains are initially synthesized as procollagens, with their amino and carboxyl termini
subject to proteolysis to produce mature trimers [169].
The α1(XI) chain is encoded by the Col11a1 gene, which consists of 67 exons
[170]. COL11A1 has a globular amino terminal domain (NTD) that consists of the
amino-propeptide (Npp), the variable region (Vr) and a minor triple helix (mh) (Figure 13A) [166, 171]. The structure of the α1(XI) chain is modulated by alternative splicing of
the exons that make up the Vr domain (exons 6-8), which is both tissue-dependent and
developmentally regulated [170, 172-174]. Due to the alternative splicing of the mRNA
within this region, considerable structural diversity is generated, and at least eight
different protein variants can be produced [170, 175, 176]. The Npp domain (exons 1-5)
is common to all isoforms of the collagen α1(XI) chain irrespective of how the mRNA is
spliced [169].
Proteolytic processing of procollagen 11A1 gradually removes the Npp [177];
however, the Vr region is maintained in the mature collagen XI and often localized to the
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fibril surface [167, 178]. Preliminary data have suggested that the rate of proteolytic
removal of the COL11A1 Npp is dictated by the splice forms in the Vr [169]. The
presence of the Vr on the surface of the fibril indicates that the NTD will be exposed on
the surface for an extended period of time after biosynthesis [167, 171]. This surface
location of the NTD enables immunohistochemical analysis without requiring the
disruption of fibril structure to access the major triple helix. Following secretion and
proteolytic cleavage, the mature collagen molecules self-assemble into fibrils [179].

1.4.3

Binding partners and regulation
Collagen XI is best characterized for its copolymerization with collagen II and

collagen IX to form an extensive network of thin fibrils in cartilage [168, 171, 180].
Collagen XI is located in the interior of the fibril; however, its NTD is located on the
surface of collagen fibrils (Figure 1-3A) and therefore can interact with other proteins
[168, 181]. The NTD of COL11A1 associates with several ECM components including
collagens type II, IX, XI, XII and XIV; the proteoglycans perlecan, fibromodulin,
epiphycan, and biglycan; the thrombospondins 1 and 5 (cartilage oligomeric matrix
protein); chondroadherin and the matrilins 1 and 3 [182].
Surprisingly little is known about Col11a1 regulation. Two research groups have
shown that Nuclear factor Y (NF-Y) regulates the proximal promoter activity of Col11a1
in cartilage and non-cartilage cells [183, 184]. Lymphocyte enhancer-binding factor 1
(Lef1), a transcription factor involved in the Wnt signaling pathway as well as
mesenchymal/epithelial interactions during the development of several tissues [185],
indirectly activates Col11a1 transcription and negatively regulates osteoblast maturation
[186]. The expression of Col11a1 is also affected by TGF-β signaling [187]. Recently,
Wu and colleagues showed that TGF-β1 treatment increases binding of NF-Y to the
Col11a1 promoter, which increases Col11a1 expression [188].

1.4.4

Tissue distribution
Cartilage fibrils exist in distinct populations of thick and thin fibrils, and collagen

XI is a minor fibrillar collagen restricted to the thin fibril group [178]. Collagen XI is
most abundantly expressed in cartilage, but also found in several non-cartilaginous
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tissues, including brain, skeletal muscle, placenta, lung, heart valve, skin, and vitreous
fluid [166, 167, 173, 189]. Col11a1 is detected in human fetal tissues [189], in the fetal
mouse as early as embryonic day 11 [190], and in chick embryos on day 17 [168]. The
α1(XI) transcripts are primarily found in cartilaginous tissues such as the chondrocranium
and the developing limbs. They also accumulate in fetal non-cartilaginous sites, including
odontoblasts, trabecular bones, the tongue, the atrioventricular valve of the heart, and the
intestine [190]. Within the cartilage fibril the α1(Xl) chain forms a heterotrimer with
α2(XI) and α1(II) [174]. In contrast, in non-cartilaginous tissues collagen α1(Xl)
associates with chains of collagen V [174, 191].

1.4.5

Collagen XI function
Collagen XI is best characterized for its copolymerization with collagen II and

collagen IX to form an extensive network of thin fibrils in cartilage [168, 171, 180]. The
fibrils are composed of approximately 80% type II, 10% type IX and 10% type XI [192].
Although it makes up a relatively small amount of the total collagen in these fibrils,
COL11A1 plays a critical role in cartilage assembly, organization and development
[167].
It has been proposed that collagen XI regulates collagen II fibrillogenesis by steric
hindrance, specifically through the COL11A1 NTD [193]. The major triple helical
domains of collagen XI are sequestered within the collagen fibril, whereas the molecular
dimensions of the NTD prevent it from being accommodated within the interior region;
therefore, the Npp and Vr are localized on the fibril surface [167, 178]. Retention of the
NTD at the surface of collagen II fibrils is postulated to restrict lateral growth by
sterically hindering further addition of collagen II onto the fibril [167, 193], though the
precise mechanism remains unclear.
The critical role of collagen XI in fibrillogensis is evidenced by the phenotype of
chondrodystrophic (cho) mice, which present with a spontaneous mutation in the
Col11a1 gene that results in premature termination of the procollagen 11A1 (due to the
introduction of a premature translation-termination codon), and therefore lack of a
functional Col11a1 [180]. The absence of Col11a1 disrupts the columnar arrangement
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Figure 1-3: Collagen 11A1
A) Structure of the collagen 11a1 amino terminal domain (NTD). The NTD of the
collagen XI chain contains an amino propeptide (Npp), a variable region (Vr)
modulated by alternative splicing, and a minor collagen triple helix (mh). The Npp is
coded by exons 1 through 5; the variable region is coded by exons 6 through 9.
B) Schematic of a cartilage collagen thin fibril. Collagen II (green), IX (orange) and XI
(blue) copolymerize to form thin collagen fibrils. Collagen XI is located in the core
of the fibril, and its NTD extends from the interior onto the fibril surface.
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and maturation of growth plate chondrocytes, leads to thicker fibrils, and reduces the
cohesive strength of the fibril matrices. The homozygous cho mutation is perinatal lethal,
and a disproportionate frequency of dwarfism, short snouts and cleft palate are observed.
Mice heterozygous for the cho mutation have no obvious phenotype. [180]
Mutations in the Col11a1 gene are also associated with numerous human
diseases, including Stickler and Marshall syndromes, which are characterized by altered
facial appearance, eye abnormalities, joint alterations, and hearing loss [194, 195].
Col11a1 mutations are also related to osteoarthritis [196], lumbar disc herniation [197],
limbus vertebra [198], Achilles tendinopathy [199], and fibrochondrogenesis, a lethal
form of dwarfism [200]. Furthermore, Col11a1/ COL11A1 is highly expressed in human
invasive carcinomas of the ovary [188, 201], breast [202-204], stomach [205], pancreas
[206], colon [207, 208], lung [209], head and neck [210], esophagus [211] and oral
cavity/pharynx [212]. Changes in COL11a1 expression have been associated with
carcinoma aggressiveness, progression and metastasis. Therefore, COL11A1 is not only
an important stabilizing factor of cartilage fibrils, these studies suggest it plays a
structural and organizational role in various tissues.

1.5 Nidogen 2
1.5.1

Overview
The vertebrate nidogen family consists of two members, nidogen 1 and nidogen 2,

which are distinct gene products of Nid1 and Nid2 respectively. They are both ubiquitous
BM components that have similar structure and affinity for other ECM proteins [213215]. The predominant nidogen, nidogen 1, also known as entactin 1, is a 150 kDa
protein originally isolated from the ECM of differentiating mouse embryonal carcinoma
cells [216]. The second member of the nidogen family, nidogen 2, was initially cloned
and isolated from human osteoblasts and named osteonidogen [83]. Once it was realized
that this 200 kDa glycoprotein had a much broader expression pattern than osteoblasts
alone, it was renamed to nidogen 2 or entactin 2 [83, 217]. Amino acid sequence
similarity between nidogens 1 and 2 is species-dependent. For example, whereas mouse
nidogens 1 and 2 are 27% similar, human nidogens 1 and 2 are 46% similar [218].
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Nid2 expression is 3.9-fold higher in GCs of eCG-treated ERβ-null mice than in,
eCG-treated ERβ heterozygous mice [156], and the expression of Nidogen 2/Nid2 in the
ovary is examined in Chapter 2 of this thesis. The nidogens have very similar protein
structure, binding partners and expression patterns; therefore both proteins will be
described in this section.

1.5.2

Protein structure
The nidogens share a similar domain structure, with three globular domains (G1-

G3), separated by a link region between G1 and G2, and a rod region between G2 and G3
(Figure 1-4). A structural comparison between mouse nidogen 1 and nidogen 2 domains
revealed 24%, 31.2% and 38.4% homology (common ancestry and similar structure)
between G1, G2 and G3 domains, respectively. The rod domains showed 33.7%
homology and the link region was least conserved with only 8% homology [217].
The N-terminal G1 globular domain is made up of a NIDO domain that resembles
globular domains in the two ECM proteins α-tectorin and the transmembrane
glycoprotein MUC4 [216]. G1 is often cleaved because its neighbouring link region is
highly susceptible to proteolysis [219]. The G2 globular domain, which is important for
perlecan and collagen IV interactions, contains EGF repeats as well as a G2F domain that
is also found in fibulin-6 [216, 220]. The rod domain has four additional EGF-like
repeats. There are consensus sequences for calcium binding within the second and fourth
EGF-like repeats, followed by two thyroglobulin-like motifs (TY) in nidogen 2 and one
TY motif in nidogen 1. Both mouse isoforms have an RGD motif within the rod domains,
which acts as a site for potential integrin interaction. The RGD motif is present in the first
EGF-like repeat in mouse nidogen 1, and the last EGF-like repeat in mouse nidogen 2,
but absent in human nidogen 2. The G3 domain contains a low density lipoprotein (LDL)
receptor-homology region, formed from six LY modules. Nidogen 1 has an additional
EGF-like motif at the G3 C-terminal [216].
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Figure 1-4: Comparison of Nidogen 1 and Nidogen 2 domains
Nidogens have three globular domains (G1-G3), a link region between G1 and G2, and a
rod region between G2 and G3. The protein sequence homology between mouse Nidogen
1 and 2 is shown as %. NIDO: Nidogen like domain, EGF: Epidermal growth factor like
module, G2F: G2 nidogen and fibulin module, TY: thyroglobulin-like motifs, LY: low
density lipoprotein receptor module.
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1.5.3

Binding partners
Both nidogen isoforms have been shown to interact with many binding partners,

particularly the other BM components collagen IV, laminin, perlecan and fibulin [83,
213, 214]. These interactions suggest that nidogens are essential for BM organization
[216]. Nidogen 1 and 2 show similar binding affinity towards collagen IV and perlecan
through the central G2 domain [83, 220]. In contrast, in vitro binding assays for human
nidogen 2 demonstrate that its affinity for laminin-1 is 100- to 1000-fold lower than for
nidogen 1 [83]. Furthermore, mouse nidogen 2 binds laminin-111 with approximately 20fold lower affinity than mouse nidogen 1 [214]. This differential affinity to laminin is
unexpected since the interacting amino acids of the G3 domain are completely conserved
in mammalian nidogens; therefore it has been speculated that the differences may be due
to unconserved residues further from the interacting surfaces [83, 216]. Unlike nidogen 1,
nidogen 2 is unable to bind fibulin -1 and -2 [83]. Interestingly nidogen 2, but not
nidogen 1, binds strongly to endostatin, tropoelastin and the carboxyl-terminal domain of
collagen XVIII [216].
The pericellular location of nidogens in the BM has prompted a search for
specific cell receptors; however, limited information is available regarding nidogen 2-cell
interactions. Salmivirta and colleagues showed that several human and rodent cell lines
bind to recombinant nidogen 2 more efficiently than recombinant nidogen 1, and that
nidogen 2-mediated binding primarily occurs through α3β1 integrin (also a receptor for
nidogen 1) with a minor role for α6β1 integrin [214].

1.5.4

Tissue distribution
Both nidogen isoforms are found in all BMs of adult tissues, though they show

variation in expression levels, and in particular nidogen 2 shows more restricted
expression patterns throughout development and some tissue specificity in mature
basement membranes than nidogen 1 [83, 214, 217, 221-223]. Nidogen 1 predominates in
the adult mouse, as there is only a 3-18% molar equivalent of nidogen 2 protein [214];
however, the levels of the two nidogen proteins are more comparable in human tissues
[83].
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Nidogens are involved in mouse [221] and human [224] organogenesis. During
human embryonic development both nidogen isoforms are ubiquitously expressed in BM
zones underneath developing epithelia of most major organ systems as early as
gestational week 6.5 [224]. Only nidogen 1, but not nidogen 2, is detected in the
developing intestine and pancreas. Of note, gonadogenesis was not investigated in this
screen [224].
Nidogen 2 is expressed in many adult mouse tissues, as demonstrated by Northern
blots [83, 217] and immunofluorescence analyses [83]. Nidogen 2 is particularly enriched
in blood vessels [83]. It is also strongly expressed in heart, lung, kidney, skeletal muscle,
testis, placenta, and liver, with lower levels in the brain and spleen [83, 217]. Unlike
nidogen 1, nidogen 2 is also expressed in non-BM matrices such as cartilage and the
elastic tissues surrounding larger vessels [83, 214]. Double immunofluoresence
microscopy demonstrated nidogen -1 and -2 colocalization in kidney, skin, and testis
[83]. In the peripheral nervous system both nidogens are found in the BM of myelinated
axons while nidogen 2 alone is found in the ECM surrounding unmyelinated axons [216].
Conversely, nidogen 2 is not expressed in certain BMs of the developing gastrointestinal
tract, specifically the glands in the pancreas and in the small intestine [224].

1.5.5

Nidogen functions
Numerous in vivo and in vitro studies have examined the biological significance

of nidogens. Both isoforms are primarily known for their role in maintaining the
assembly and structural integrity of the BM, serving as the critical link between the
collagen IV and laminin network during embryonic development and in adult tissues
[214, 216, 218, 221, 225, 226]. Nid1/Nid2 double-knockout mice die perinatally with
abnormalities in heart, lung and limb development, directly related to BM defects [225,
227]. However, certain tissues, such as kidney [225] and skin [228], form in the absence
of nidogens with ultrastructurally normal BMs, demonstrating that the requirements for
nidogens are tissue specific. Interestingly single knockout mice have shown that absence
of nidogen 1 or nidogen 2 alone does not affect BM formation or overall organ
development [222, 223]. Mice lacking either nidogen 1 or 2 are generally, healthy, fertile,
and have a normal life span. Nidogen 2 knockout mice do not have a known phenotype,
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and no obvious change in the expression pattern of nidogen 1 or other BM components is
observed [223]. In nidogen 1-null mice, nidogen 2 expression is redistributed; its level is
higher in skeletal and cardiac tissues than in wildtype mice, suggesting that nidogen 2 can
generally compensate for the loss of nidogen 1 in BM assembly [222]. Nidogen 1-null
mice show specific neurological phenotypes [229, 230] and wound-healing defects [231]
not observed in nidogen 2-null animals, indicating only partial redundancy and isoform
specific function of the two proteins.
Based on the subtle phenotype of the nidogen 1 knockout mouse and lack of
phenotype of the nidogen 2 knockout mouse it is not surprising that the majority of work
in the literature has focused on the functional role and signaling events related to nidogen
1. For example, nidogen 1 has been shown to rescue mammary epithelial cells from
apoptosis [232], and regulate laminin-dependent gene expression and differentiation in
the mammary gland [233]. It accelerates epidermal wound healing [231], may regulate
conformational changes to laminin [234] and regulates the formation and/or maintenance
of neuromuscular junctions in C. elegans [235]. Some of these effects are likely mediated
by signalling through integrin α3β1 or αvβ3, to which nidogen 1 has been shown to bind
[236, 237].
Few roles for nidogen 2 have been established. It has been shown that
recombinant human nidogen 2 promotes cell adhesion and spreading of multiple cell lines
more strongly than nidogen 1 [83]. After corneal injury stromal keratocytes upregulate
nidogen 2 protein, which contributes to the regeneration of epithelial BM [238]. Several
studies have implied that nidogen 2 may play a role in reducing tumour metastasis. For
instance, the loss of nidogen 2, but not nidogen 1, significantly promotes lung metastasis
of melanoma cells [239]. The loss of nidogen 2 expression may also have a pathogenic
role in colon and stomach tumourigenesis [240]. It has been proposed that the absence of
nidogen 2 likely causes subtle changes in the BM, weakening its strength and
accelerating the passage of tumour cells across the BM, ultimately leading to a higher
rate of metastasis and larger tumours [239, 240]. Conversely, elevated serum nidogen 2
levels are detected in ovarian cancer patients [241], however, the role of nidogen 2 in
ovarian cancer is not known.
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1.6 Transcription Factor 21
1.6.1

Discovery
Transcription Factor 21 (TCF21), encoded by Tcf21, was initially cloned in 1998

by four independent laboratories and shown to be expressed in the embryonic
mesenchymal cells of developing organs, including the heart, lung, kidney, spleen and
gonads [242-245]. At this time TCF21 was known by three different names based on the
tissues in which each group originally identified it: “entactin” for its expression in the
epicardium [245], “podocyte-1” (POD-1) for its presence in the podocytes of the
developing kidney [244] and the term “capsulin” was derived from its expression pattern
in the mesenchyme that “encapsulates” the developing organs [242, 243]. POD1/Capsulin/Entactin has become most commonly referred to as TCF21 because of its
predicted molecular weight of 21 kDa. TCF21 is member of the basic helix-loop-helix
(bHLH) transcription factor family (Section 1.6.2) and as such is critical for the cellular
differentiation and tissue development for a number of organ systems (Section 1.6.3).

1.6.2

Protein structure
Basic helix-loop-helix (bHLH) transcription factors are named for their functional

domains. The helix-loop-helix (HLH) domain, composed of two amphipathic alpha
helices separated by a loop region of variable length, is necessary for the formation of
homo- and heterodimers between these proteins [242, 246, 247]. Immediately upstream
of the HLH domain is a basic region, which mediates sequence-specific DNA binding.
Once bHLH proteins dimerize the basic regions form a bipartite DNA-binding domain
that recognizes a consensus CANNTG sequence known as the E-box. bHLH proteins
must dimerize to exert their effects. Class I proteins are ubiquitously expressed and
capable of binding to DNA on their own as homodimers, whereas Class II bHLH proteins
have a more tissue-specific pattern of expression and require heterodimerization with a
Class I factor to bind at the conserved E-box sequence of the target gene [246].
TCF21 contains an evolutionarily conserved 50 amino acid bHLH domain (Figure
1-5) and belongs to the Class II bHLH proteins [242-245]. It consists of 179 amino acids,
and human and mouse TCF21 sequences are 95% identical – 92% within the amino-
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terminal domain, 100% within the bHLH domain and 96% within the carboxyl-terminal
domain [244]. A phylogenetic analysis and classification of the bHLH gene family has
recently developed a unified nomenclature resulting in Tcf21 being renamed as bHLHa23
[247]. This analysis also found that the Tcf21 gene is highly conserved between species.
Interestingly, it was recently shown that TCF21 is phosphorylated at three sites within the
N-terminal region on residues that are evolutionarily conserved across species,
suggesting these post-translational modifications may play a functional role [248].

1.6.3

TCF21 functions during embryogenesis
Members of the bHLH family play important roles in cell fate specification,

differentiation, and morphogenesis of several tissues during development [249-253]. Cell
type-specific bHLH transcription factors, a group to which TCF21 belongs, are key
regulators of organ development. TCF21 is a nuclear protein [254] expressed in
mesenchymal cells at sites of epithelial-mesenchymal interactions in the developing
urogenital, gastrointestinal, respiratory, and cardiovascular systems [242-245].
Furthermore, it promotes mesenchymal-to-epithelial (MET) transition of cells during
organogenesis [252].
Tcf21 is first detectable in the mouse on embryonic day 8 (E8) in small clusters of
cells in the branchial region [245], and has been detected in the gonads at E9.5 by in situ
hybridization [253]. Throughout the mouse lifespan, it is expressed at the highest levels
during embryogenesis, and its expression rapidly decreases in most postnatal tissues, with
the exception of kidney, lung, heart and ovary [242, 245, 253, 255].
Phenotypic analysis of TCF21-knockout mice (Tcf21-/-) demonstrates that it plays
an important role in the formation of the spleen [256], kidney and lung [252], facial
skeletal muscle development [257], and is critical for sexual differentiation [258]. Mice
lacking TCF21 die in the perinatal period, and show male-to-female sex reversal [258].
Although TCF21 has a mesenchymal cell-specific pattern of expression during
development, its loss results in major phenotypic defects in the adjacent epithelia.
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Figure 1-5: TCF21
Schematic representation of human TCF21. The amino acid sequence is numbered.
bHLH: basic helix-loop-helix domain
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1.6.3.1

Heart development

TCF21 is primarily studied for its role in heart development and function, and is
often used for the identification of proepicardial and epicardial cells [242, 259-262].
During development, TCF21 is highly expressed in epicardial progenitor cells and recent
studies have demonstrated that TCF21 determines whether a precursor cell is fated to
become a differentiated coronary smooth muscle cell (SMC) or a cell of the cardiac
fibroblast lineages [259, 260]. Specifically, TCF21 is downregulated in cells that will
become SMC while its expression is required for cardiac fibroblast development, as
fibroblasts fail to develop in mice lacking TCF21. Interestingly, TCF21-null epicardial
cells are unable to undergo epithelial-to-mesenchymal transition (EMT) suggesting
TCF21 is also required for epicardial EMT [259].
1.6.3.2

Kidney development

Following its original discovery in podocytes, TCF21 continues to be studied in
the kidney because it is one of only six transcription factors that are well characterized
regulators of podocyte specification [263]. Unlike the heart, in the kidney TCF21 is not
required for cell fate decisions of the mesenchyme or podocyte lineages [252]. However,
it is clearly essential for kidney development as loss of TCF21 results in severely
hypoplastic kidneys, decreased tubulogenesis and glomerulogenesis, as well as a failure
of cells to undergo MET [252, 255, 264, 265].
1.6.3.3

Gonadal development

Several laboratories have shown that TCF21 is essential for normal development
of the ovaries and testes [253, 258, 266, 267]. TCF21 is one of the earliest genes
expressed in the mesodermal cells that later become the gonads [253]. It is the first Class
II bHLH transcription factor with a sex and stage-dependent pattern of expression during
gonadogenesis, with much higher expression in embryonic testes than the ovaries [253,
258]. Initially at E11.5 the levels of Tcf21 expression are the same between the gonads of
male and female mice; however at E13.5 the expression becomes stronger in the male
gonad compared to the female [253]. Interestingly, a time course of Tcf21 expression in
the gonads from E13.5 to postnatal stages demonstrates that the testis and ovary have
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opposite patterns of expression. Tcf21 expression remains higher in the testis during
embryonic development and slowly decreases over time at postnatal stages. Conversely,
expression in the ovary remains relatively low during gonadogenesis but increases
markedly after birth and becomes higher than in the testis by PND 21 [253]. Throughout
testis development TCF21 is detected in the nucleus of somatic cells adjacent to germ
cells (E13.5), Sertoli cells (E13) and Leydig cells (E16), but is absent in germ cells [266].
The gonads of TCF21-null mice are markedly hypoplastic, slightly shortened in
length and have an irregular surface [258]. Although XX and XY Tcf21-/- mice are born
in the expected 50:50 ratio the external genitalia are feminized in XY Tcf21-/- pups. The
testes of XY mice begin to resemble ovaries at E12.5 and the urogenital tracts of XX and
XY mice are indistinguishable for the latter part of gonadal development. Aspects of
normal ovarian development are initiated by somatic and germ cells in XX Tcf21-/- mice,
but are disrupted by E18.5 because no meiotic cells are observed at this stage. Although
the ovaries of Tcf21-/- mice are similar in size to wildtype ovaries, their shape and
location relative to the kidney are more variable. The ovaries of TCF21-null mice also
lack a distinct mesenchymal zone [258]. Interestingly, when TCF21 is over-expressed in
an embryonic E13 ovary culture system it promotes in vitro sex reversal and induces the
expression of anti-Müllerian hormone (AMH), which is normally expressed by Sertoli
cells in the embryonic testis but not expressed by the embryonic ovary [258]. These data
suggest that TCF21 is involved in male sex determination and testis differentiation.
Both TCF21-null ovaries and testis express higher levels of steroidogenic factor 1
(SF1/ Ad4BP) and the cholesterol side chain cleavage enzyme (P450SCC) than wildtype
mice [253, 258]. SF1 is an orphan nuclear receptor that regulates multiple genes involved
in gonadal development and sexual differentiation, as well as steroidogenesis in adult
mice [258]. It is proposed to be an essential regulator of P450SCC, an early marker for
Leydig cell differentiation and a mitochondrial enzyme responsible for the initial reaction
in the steroidogenic pathway [268]. Although P450SCC is required for the synthesis of
steroid hormones in the postnatal ovary, it is not normally expressed during ovarian
development; however, its expression is higher in fetal TCF21-null ovaries than in
wildtype ovaries [258]. SF1 is localized to many of the same cell types as TCF21 within
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the developing gonads, and has an interesting pattern of expression comparable to that of
TCF21, namely that SF1 levels are similar in male and female gonads at E11.5, higher in
the male gonad than the female gonads at E13.5, then higher in the ovary than the testis
after birth [269].
Interestingly, initial reports of how TCF21 regulates SF1 activity indicated that
TCF21 represses SF1 expression in an indirect manner because TCF21 is unable to bind
to the E-box located within the SF1 promoter [258]. Since TCF21 was unable to bind
directly to the SF1 promoter it was suggested that instead, TCF21 interacts with USF1, a
known activator of SF1 [270], thereby preventing USF1 promoter binding and activation
of SF1 expression [258]. Of note, the group also failed to show by coimmunoprecipitation that TCF21 directly interacts with USF1. More recently, however,
TCF21 was successfully shown to bind to the SF1 E-box sequence and inhibit its
expression [271]. The discrepancy in results is likely due to the different approaches used
by each laboratory to analyze protein-DNA interactions; Franco et al. used chromatin
immunoprecipitation (ChIP) assays, an in vivo method, whereas the earlier study by Cui
et al. utilized electrophoretic mobility shift assay (EMSA), an in vitro method of
analyzing protein-DNA interactions.
Lastly, TCF21 is a direct downstream target of the male sex-determining factor
SRY, further supporting the essential role of TCF21 in sex determination [266]. SRY
binds to the TCF21 promoter and initiates a cascade of transcriptional events related to
Sertoli cell differentiation and testis development. Mutation of the SRY response
elements within the TCF21 promoter disrupts the actions of SRY in fetal rat testis
development.
Collectively, these data demonstrate that TCF21 is critically involved in gonadal
development and part of a transcriptional network that coordinates cell fate decisions in
gonadal progenitor cells.
1.6.3.4

Spleen, lung and skeletal muscle development

TCF21 regulates differentiation and cell fate decisions during the development of
spleen, lung and skeletal muscles; however, its role in these tissues has not been
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investigated as extensively as the organ systems discussed above. Briefly, in the absence
of TCF21, splenic precursors undergo apoptotic cell death and TCF21-null mice fail to
form a spleen, demonstrating that TCF21 controls a critical early step in spleen
development [256]. The lungs of TCF21-null mice are severely hypoplastic and lack
alveoli [252]. Furthermore, the expression of TCF21 in the mesenchyme is required for
the appropriate expression of bone morphogenetic protein-4 (BMP-4) in the adjacent
epithelium, otherwise the airway epithelium does not differentiate [252]. Lastly, TCF21
is closely related to the bHLH transcription factor MyoR, which acts as a transcriptional
repressor and blocks myoblast differentiation [254]. TCF21-null mice do not have a
musculature phenotype; however, specific facial muscles are absent in mice lacking both
TCF21 and MyoR, demonstrating TCF21 is a negative regulator of myoblast
differentiation [254, 257].

1.6.4

TCF21 functions in postnatal tissues
In addition to its essential role in embryonic development, TCF21 has recently

been identified as a tumour suppressor, and deregulated in several types of cancer.
TCF21 was first shown to function as a tumour suppressor in head and neck squamous
cell carcinomas and non-small cell lung cancer in 2006 [272]. Since then, the loss or
reduced expression of TCF21 has been found in many types of human cancers, including
kidney [273, 274], lung [275-277], melanoma [278], urological [279], colon [280],
gastric [281] and breast [282]. Decreased expression of TCF21 is often due to promoter
hypermethylation and has been correlated with larger tumour size and decreased survival
in patients [282]. It has also been suggested that histone modifications may be involved
in TCF21 silencing [278], which requires further investigation.
Multiple studies have shown that restoration of TCF21 in cancer cells results in a
reduction of tumour properties in vitro. For example, overexpression of TCF21 inhibits
cell proliferation, induces apoptosis and suppresses migration and invasion in colorectal
cancer [280], decreases cancer cell growth and colony formation in lung cancer [272],
reduces motility of melanoma cells [278] and inhibits cell proliferation and epithelial-tomesenchymal transition (EMT) in breast cancer [282]. As mentioned earlier, an important
function of TCF21 in normal tissues is to promote mesenchymal-to-epithelial transition
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(MET) during organogenesis [252]. The reversal of this process, EMT, is vital for tumour
dissemination and progression [283]. Therefore, it is significant that the overexpression
of TCF21 in cancer cells results in reduced expression of mesenchymal markers (SNAI1
and VIM) and increased expression of an epithelial factor (CDH1), as it suggests that
TCF21 induces differentiation, likely through MET, in vitro [272, 282]. These studies
suggest that TCF21 may act as a potential therapeutic target in certain cancers and its
hypermethylation suggests is could be a useful methylation marker in various tumour
types.
In addition to its role as a tumour suppressor, TCF21 is a coronary artery disease
(CAD)-associated transcription factor. Briefly, it is suggested that following vascular
injury, which is believed to be critical for vascular disease, TCF21 regulates the
differentiation state of SMC precursor cells in the adult by a similar mechanism to the
regulation of the developing epicardium [261]; i.e. TCF21 determines whether epicardial
progenitor cells will give rise to SMCs or cardiac fibroblasts [260]. The SMC precursors
in which TCF21 is expressed migrate into vascular lesions, and contribute to the
stabilization of these lesions and prevent heart attacks [261]. It has also recently been
found that a SNP of Tcf21 is a susceptible locus for hypertension, a major risk factor for
CAD [284].
Therefore, although TCF21 was identified for its role in embryonic development,
it is apparent that it continues to play critical, yet largely undetermined, roles in postnatal
tissues.

1.6.5

TCF21 as a transcriptional regulator
The molecular mechanisms by which Tcf21 acts to regulate transcription remain

poorly understood in most systems. As mentioned previously, bHLH proteins must
dimerize to exert their effects, and heterodimerization between Class I and Class II bHLH
proteins is preferred. TCF21 heterodimerizes with four bHLH proteins, namely TCF3
(E12/E47) [243, 278], TCF4 (E2-2) [278], TCF12 (HEB) [242, 243, 266, 278] and ITF-2
[285]. Of note, TCF21 is unable to homodimerize [285]. TCF21 has also been shown to
associate with HDAC-1 and AR (androgen receptor) in Sertoli cells [286], as well as
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HDAC-2, Ctbp2 (C-terminal-binding protein 2) and Pbx1 (pre-B-cell leukemia
transcription factor 1) in proepicardial cells [248].
Transcriptional assays and electrophoretic mobility shift assays in a number of in
vitro systems have demonstrated that TCF21 has both activating and repressing
transcriptional activity. It exhibits repressive activities in HepG2 cells from its C-terminal
and N-terminal domains; constructs that include either of these domains retain repressive
activity, while the bHLH domain alone had no activity. Conversely, transactivation
activities in HT1080 and HeLa cells were only observed when TCF21 constructs retained
the C-terminal domain. It is suggested that this dual function of the C-terminal domain
may be cell-type dependent, and result from the presence of specific coactivators and
corepressors [285]. Importantly, there are a limited number of direct transcriptional
targets of TCF21 that have been reported and confirmed by functional assays. These
include MCK (muscle creatine kinase) [243, 254], Kiss1 (Kisspeptin-1) [278], AR [286],
p21 (cyclin-dependent kinase inhibitor) [254], Sf-1 [253, 258, 287], SHP (Small
Heterodimer Partner) [288] and Scx (Scleraxis) [267]. Bhandari et al recently identified
121 direct downstream binding targets of TCF21 using a modified ChIP-ChIP
comparative hybridization analysis [267]. All targets contained an E-Box sequence, and
10 of the 121 targets were bHLH genes. To date, only one newly identified TCF21 target
– Scx (bHLHa41), previously localized to Sertoli cells and shown to promote Sertoli cell
differentiation in rats [267] – has been investigated in subsequent functional assays. The
authors show that TCF21-induced SCX is required for the latter part of Sertoli cell
differentiation associated with pubertal development.
TCF21 is the first bHLH protein suggested to act as a general repressor of nuclear
receptors [286]. It was first identified as a repressor of the orphan nuclear receptor SF1
[253], and suppresses the promoter activity and transactivation of the AR, a nuclear
receptor important in male sexual differentiation and testicular function [286]. Hong and
colleagues propose that TCF21 acts as a repressor of several nuclear receptors, including
Estrogen Receptor β, glucocorticoid receptor and retinoic acid receptor alpha [286];
however, this has not been tested by subsequent studies and warrants further
investigation.
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1.7 Spondin 1
1.7.1

Discovery
Spondin 1 (SPON1), encoded by Spon1, was originally identified in 1992 as a

secreted ECM glycoprotein highly expressed it the floorplate of the developing rat [289].
It was originally named F-Spondin for its location in the floorplate of the neural tube (F)
and its thrombospondin repeats (spondin), and is also known as vascular smooth muscle
cell growth promoting factor (VSGP) [290]. Spondin 1 is a member of the neuronal
subgroup of the diverse thrombospondin type 1 (TSR) repeats superfamily. The tissue
expression pattern of Spon1 is highly conserved in vertebrates [291].

1.7.2

Protein structure
Spondin 1 is a molecule of 807 amino acids with a predicted molecular mass of

87 kDa [289, 291]. The protein is subdivided into three domains (Figure 1-6). The first
half of the N-terminal region (amino acids 1-200) is homologous with a domain in
Reelin, and is aptly named the “reelin domain”, while the similar domain in Reelin is
referred to as the “F-Spondin domain” [292]. The second half of the N-terminal region
(amino acids 201-440) is named the “spondin domain”, and shares similarity with a
domain in Spondin 2 (also known as Mindin), another member of the neuronal class of
TSR proteins [291, 293, 294]. The C-terminal region (amino acids 441-807) contains six
thrombospondin type 1 repeats (TSR).
Analysis of the crystal structure of the reelin domain revealed potential heparinbinding sites and weak dimerization between two reelin domains, which may be a
location for glycosaminoglycan (GAG) binding [295]. The exact function of the GAGbinding site remains unclear; however, it may be used to for anchoring Spondin 1 to the
ECM in such a way that the spondin domain and C-terminus are available for interactions
with other proteins or cells [295]. The spondin domain is not well studied; however, it
has been to shown to promote outgrowth of sensory neurons and may be involved in
axonal regeneration following nerve injury [296]. TSRs are found in several protein
families, and are involved in various functions including cell adhesion, GAG binding,
inhibition of angiogenesis and activation of TGFβ [297, 298]. Most of the post-
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translational modifications in Spondin 1 are found within the TSR repeats, as eight of ten
tryptophan residues are C-mannosylated, while several serine and threonine residues are
potential sites of O-fucosylation [299]. There are three N-glycosylation sites within the
spondin and C-terminal domains [289]. Each TSR in Spondin 1 contains a WxxW
sequence, which is known to bind TGFβ. The sixth TSR also has a KRFK motif, required
for the activation of latent TGFβ [297].
Spondin 1 contains three proteolytic cleavage sites. The first was identified
between the spondin and TSR domains [296]. Western blot analysis of conditioned
medium from HEK293 (human embryonic kidney) and primary rat Schwann cells
revealed SPON1 was cleaved into two half proteins - a 60 kDa amino-half with the reelin
and spondin domains, and a 40 kDa half that contains the TSRs [296, 300]. Spondin 1
also has two plasmin-mediated cleavage sites, one between TSR-4 and TSR-5, and the
second between TSR-5 and TSR-6. The fifth and sixth TSRs are bound to the ECM,
whereas TSRs 1- 4 are not. By cleaving the first four non-adhesive TSRs from the fifth
and sixth adhesive TSRs, plasmin generates a secreted protein [301].

1.7.3

Proteins with similar structure
In addition to the unique domains Spondin 1 shares with Spondin 2 and Reelin, it

also shares the TSR domain with members of the diverse TSR superfamily, which
contains numerous ECM and transmembrane proteins [302]. A few proteins that share
domains with Spondin 1 are briefly described below.
Thrombospondin (TSP) -1 and -2: TSP-1 and TSP-2 are matricellular ECM proteins. As
matricellular proteins they exist within the ECM but do not have a role in structural
integrity [85]. Instead, TSP-1 and TSP-2 are involved in supporting cell attachment, cell
motility and inhibiting angiogenesis [297]. Of note, TSP-1 and TSP-2 are both expressed
in the early CLs of the rat ovary, with TSP-1 also expressed in the GCs of antral follicles
[68].
Spondin 2: Spondin 1 and 2 are evolutionarily conserved, matrix-attached adhesion
proteins involved in neural development [291]. They are the only proteins to contain the
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spondin domain. Furthermore, Spondin 2 is the only protein to share two domains with
Spondin 1 – the spondin domain and a TSR. Spondin 2 is involved in the regulation of
axonal development and promotes the outgrowth and adhesion of embryonic
hippocampal neurons [293]. It is also involved in the immune response and cardiac
functions, and has been shown to bind integrins and block Akt signaling [303].
R-Spondin: The four R-Spondins (R-spondin 1-4) are relatively recent additions to the
TSR family, with R-Spondin 1 being identified in 2004 and R-Spondins 2-4 discovered
over the next four years [304]. The gene encoding R-spondin 1 (Rspo1) was first
identified in the boundary region between the roof plate and neuroepithelium in the
developing mouse, and thus was named R(oof plate specific)-spondin [305]. The four RSpondins are small secreted proteins, with a single TSR near the C-terminus, and are all
agonists of the canonical Wnt/β-catenin signaling pathway during embryogenesis [304].
R-Spondin 1 and -2 are both involved in ovarian development. Studies have
demonstrated that mice lacking R-Spondin 1 display a partial sex reversal phenotype
[306], and R-Spondin 2 is detected from the primary to antral stage in the oocyte and
promotes follicle growth [307]. Currently, R-Spondin 3 and 4 have no known role in the
ovary.
Reelin: The reelin domain is only shared by Reelin, Spondin 1 and ferric-chelate
reductase 1 (FRRS1). Reelin is a large secreted glycoprotein involved in neural
development. Its name is derived from the Reelin-deficient mouse that has a “reeling”
gait (impaired motor coordination, tremors and ataxia) [292]. In humans, loss of Reelin
expression has been linked to several neurological disorders [308]. Reelin expression has
recently been detected in the TCs of dominant bovine ovarian follicles [309], and shown
to promote proliferation of chicken GCs in culture [310].

1.7.4

Spondin 1 functions and mechanisms of action in the central
nervous system
Following its discovery by Klar and colleagues in the floorplate of the embryonic

rat [289], Spondin 1 has primarily been studied for its role as a neurological ECM
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Figure 1-6: Domain diagram of Spondin 1 and similar proteins
Schematic representations of Spondin 1 and proteins with similar domains,
thrombospondin 1 (Tsp-1), Spondin-2, R-spondin, Reelin. Reeler domain (blue), Spondin
domain (green), TSR domain (orange) and other domains are shown in grey.
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glycoprotein. In that first publication, Klar et al. demonstrated that Spondin 1 regulates
cell adhesion and neurite outgrowth. Dorsal root ganglia cells plated on recombinant
Spondin 1 grew to a greater length and were more adherent than those plated on the
control bovine serum albumin (BSA) [289]. Since then, Spondin 1 has also been shown
to promote adhesion and outgrowth of embryonic hippocampal neurons [293], and its
expression is upregulated during axonal outgrowth following nerve injury [296]. Spondin
1-mediated cell adhesion is inhibited following treatment with heparin [289] and
chondroitin sulfate [293], suggesting that binding by Spondin 1 is affected by
proteoglycans. Further studies have demonstrated that Spondin 1 has a dual role in the
accurate patterning of axons at the floorplate, because it acts as a chemoattractant that
promotes the outgrowth of commissural axons [300] and as a contact-repellent molecule
to inhibit outgrowth of motor neurons [311]. Spondin 1 also acts as an inhibitory signal
for segmentation in somites in chicken embryos, patterning the migration of neural crest
cells [312].
Neural outgrowth is mediated by the immobilization of the TSR 1-4 fragment of
the secreted Spondin 1 protein by lipoprotein receptor–related protein (LRP) receptors
expressed in the floorplate, including ApoER2 (apolipoprotein E receptor 2), also known
as LRP8 (low-density lipoprotein receptor- related protein 8) [313]. Spondin 1 also
interacts with the ApoER2 ligand, APP (β-amyloid precursor protein) via its reelin
domain [314]. Spondin 1 affects APP processing, increases its expression at the cell
surface, and appears to form an extracellular bridge between ApoER2 and APP [315].
Considering APP is a key protein in the pathogenesis of Alzheimer’s disease, Spondin 1
is an intriguing target for Alzheimer’s therapeutics [315].
In addition to affecting nerve growth and adhesion, Spondin 1 promotes nerve cell
differentiation and viability. Treatment with Spondin 1 promotes the differentiation of a
rat adult hippocampal precursor cell line, AHP, from neural precursor cells into cells with
the biochemical and morphological features of nerve cells [316]. Furthermore, Spondin 1
increases the viability of chicken ciliary ganglion (CG) cells in culture by activating
TGF-β signaling via its KRFK motif in TSR-6 [317]. Interestingly, Spondin 1 deletion
mutants that contain the TSRs but lack the reelin and spondin domains were unable to
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increase CG cell survival, suggesting that the N-terminal domains are required for
complete TGF-β signaling and survival of CG cells [317]. This increased cell survival
was also due to Spondin 1 binding to APP and inducing rapid phosphorylation of
disabled-1 (DAB-1) [317]. Reelin has previously been shown to increase the
phosphorylation of DAB-1, through APP receptor binding [308], further supporting the
idea that the reelin domain is involved in promoting neuron cell survival.

1.7.5

Spondin 1 function and mechanism of action in non-neural
tissues
The function of Spondin 1 is not restricted to the nervous system. Northern blot

analysis revealed that Spon1 is expressed in numerous tissues, including the ovary,
kidney, bone and small intestine [290], where several functions for SPON1 have been
identified.
Spondin 1 promotes cell-ECM adhesion in both neural and non-neural tissues of
C. elegans [318]. It is localized to BMs and integrin-containing regions within body
muscles of C. elegans embryos. Spondin 1 is responsible for maintaining strong
attachments between muscles and epidermis, and muscles in Spon1 mutants gradually
detach from the epidermis [318].
Spondin 1 that was isolated and purified from bovine follicular fluid promoted
growth of primary rat aortic vascular smooth muscle cells [290]. Alternatively Spondin 1
inhibits vascular endothelial growth factor (VEGF)-stimulated migration and tube
formation of HUVECs (human umbilical vein endothelial cells) as well as angiogenesis
in the rat cornea [319]. In this model system, Spondin 1 inhibits migration by blocking
integrin ανβ3-mediated adhesion of HUVECs to vitronectin as well as VEGF-induced
activation of Akt [319]
Spondin 1 has also been shown to increase cell survival of mouse Neuro-2a
neuroblastoma cells [320]. Loss of viability following knockdown of Spondin 1 was
attributed to the lower levels of IL-6, and correlated with decreases of NF-κB and p38
mitogen-activated protein kinase (MAPK). Treatment with Spondin 1 or IL-6 rescued the
cells from death [320]. Furthermore, Spondin 1 expression is higher in osteosarcoma
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specimens compared to benign osteochondroma samples. It promotes the migration and
invasion of metastatic and non-metastatic osteosarcoma cell lines through Fak and Src
dependent pathways [321].
Spondin 1 is upregulated in osteoarthritis articular chondrocytes where it is likely
involved in the activation of latent TGF-β1. TGF-β1 activation leads to increased
expression of prostaglandin E2 (PGE2) and matrix metalloproteinase 13 (MMP-13),
which reduces proteoglycan synthesis and increases collagen degradation [322]. Spondin
1 is also highly expressed in embryonic cartilage, where it enhances chondrocyte terminal
differentiation and mineralization by activating TGF-β1, which increases MMP-13 and
alkaline phosphatase (AP) expression [323]. It promotes the differentiation of a human
cementoblast-like cell line (HCEM) via bone morphogenic protein 7 (BMP7) [324].
Alternatively, Spondin1 inhibits the receptor activator of NF-κB ligand (RANKL)mediated differentiation of osteoclastic precursors via LRP8 [325].
Surprisingly, despite the broad expression of Spondin 1 and its role in neural and
non-neural tissues the SPON1-knockout mouse (Spon1-/-) is viable and has a grossly
normal phenotype [326]. The Spon1-/- mice undergo normal skeletal development without
major skeletal abnormalities, which was unexpected considering the authors’ prior
detection of elevated Spondin 1 levels in embryonic cartilage and chondrocytes of
osteoarthritic cartilage [322, 323]. At 6 months of age, the Spon1-/- mice have increased
bone mass, likely as a result of increased bone synthesis. They also exhibit reduced levels
of TGF-β1 in serum and cultured chondrocytes, and increased levels of phosphorylated
SMAD1/5, BMP-regulatory SMADs. Palmer et al. speculate that the loss of Spon1
decreases the activation of TGF-β, resulting in increased BMP signaling and bone
deposition in adult mice [326]. Our laboratory has recently determined that Spon1-/- mice
also have an ovarian phenotype. The Spon1-/- female mice are mildly subfertile, have
smaller litters, decreased ovulation capacity, and smaller ovarian weights than wildtype
mice (unpublished data).
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1.7.6

Spondin 1 and the ovary
There is limited yet compelling evidence that Spondin 1 plays a role in the ovary.

As mentioned above, Spondin 1 mRNA is abundantly expressed in the adult human
ovary, as determined by Northern blot. Spondin 1 isolated and purified from the bovine
follicular fluid has growth promoting properties towards vascular smooth muscle cells
[290]. When ovariectomized mice are treated with 17β-estradiol, Spon1 mRNA
expression increases in the uterus and mammary gland [327, 328]. Additionally, Spon1
expression is 2.5-fold in GCs of eCG-treated ERβ-null mice than in eCG-treated ERβ
heterozygous mice [156]. Our laboratory has recently demonstrated that Spon1-/- female
mice are subfertile (unpublished data). These studies collectively suggest a role for
Spondin 1 in ovarian folliculogenesis.
Furthermore, Spondin 1 mRNA is highly expressed in ovarian carcinomas
compared to normal ovarian tissues [329]. An extensive screen of 500 ovarian
carcinomas suggests Spondin 1 is a negative prognostic indicator and a promising
biomarker for ovarian cancer, particularly for high-grade serous epithelial ovarian cancer
[330].

1.8 Ovarian Cancer
1.8.1

Ovarian cancer classification
Ovarian cancers are divided into three categories – epithelial, stromal and germ

cell – of which epithelial is the most common and lethal type, comprising over 85% of
ovarian cancer cases [331, 332]. Epithelial Ovarian Cancer (EOC) is not a single disease,
but consists of four main subtypes (endometrioid, mucinous, clear cell and serous) that
are histopathologically, genetically and biologically distinct diseases [333, 334]. The four
subtypes can be further classified as benign, borderline or malignant, and low- or highgrade [335]. EOC is the focus of my research and will be the focus of this section.
Serous ovarian cancer represents approximately 80% of EOCs [336]. As the most
aggressive subtype, high-grade serous ovarian carcinoma (HGSC), accounts for 90% of
serous cancers, two-thirds of all EOC deaths, and it is the most studied subtype [337].
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HGSC often responds well to adjuvant platinum/taxane chemotherapy; however,
recurrence occurs in the majority of cases [338, 339]. Clear cell and endometrioid
carcinomas are less common, each accounting for approximately 10% of ovarian
carcinomas [336]. Endometrioid carcinomas predominantly present at low stage and low
grade therefore mortality associated with this subtype is relatively low. Clear cell
carcinomas usually present with low-stage disease; however, all are considered highgrade and do not respond well to conventional treatments, which results in poor outcome
for most patients [340, 341]. Only 3-4% of ovarian tumours are of the mucinous type, and
most are confined to the ovary at presentation. As with clear cell carcinomas, current
chemotherapeutics are ineffective for treatment of recurring mucinous carcinomas [336].
Over a decade ago, a new model for classification was proposed that separated
EOCs into two broad categories – type I and type II tumours – by taking into account
clinical and genetic findings in addition to tumour histopathology [342]. Type I tumours
include all of the histotypes (serous, endometrioid, mucinous and clear cell) that are low
grade and slow growing. These tumours have mutations rarely found in Type II tumours,
such as BRAF (v-Raf murine sarcoma viral oncogene homolog B), KRAS (V-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog), CTNNB1 (β-catenin), ARID1A (AT-rich
interactive domain-containing protein 1A), PIK3CA (phosphatidylinositol-4,5bisphosphate 3-kinase, catalytic subunit alpha) and PTEN (phosphatase and tensin
homolog) mutations [342, 343]. Type II tumours include HGSCs, carcinosarcomas and
undifferentiated carcinomas [342]. These tumours are highly aggressive, present at an
advanced, metastatic stage and are associated with poor patient outcome. Type II tumours
contain mutations in BRACA1/2 (breast cancer 1 and 2) and almost ubiquitously express
TP53 mutations (97%) [344, 345]. Unlike earlier characterizations, this model does not
consider low and high-grade tumours a spectrum of disease, but rather distinct diseases
with different origins, epidemiology and mutations [334, 342].

1.8.2

Origins of ovarian cancer
The term ‘ovarian cancer’ can be misleading. Although the unifying clinical

feature for all ovarian cancer is dissemination to the ovary and related pelvic organs, it
has been proposed that a considerable number of tumours do not originate from ovarian
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tissue [334]. The site of origin for HGSC remains strongly debated. Over the years it has
been suggested that ovarian cancers can develop from any of the following origins: the
ovarian surface epithelium (OSE), cells lining subsurface inclusion cysts, the abdominal
peritoneum or the fallopian tube epithelium [332, 346].
Early theories hypothesized that all epithelial ovarian cancers arose from the OSE
[335]. This traditional view is based on the idea that repeated ovulation during a woman’s
reproductive life increases the susceptibility of the OSE to transformation because of the
frequent damage and repair to the OSE, as a result of follicle rupture to release oocytes
[346]. Ovulation also leads to the formation of epithelial cell-lined inclusion cysts. It is
hypothesized that the cells surrounding these intraovarian cysts differentiate into a
Müllerian-like epithelium in response to the hormone-rich environment in the ovary,
become dysplastic and lead to ovarian tumours [347]. These theories are consistent with
epidemiological evidence showing that decreased ovulation, whether a result of multiple
pregnancies, prolonged lactation or use of oral contraceptives, decreases the risk of
developing ovarian cancer [346]. These models do not, however, address the fact that the
different ovarian subtypes are histologically diverse and share few molecular similarities
[348].
Recent studies indicate that the ovarian cancer subtypes arise from various sites of
origin; certain subtypes that were traditionally believed to be primary ovarian tumours
actually originate from non-ovarian tissues and involve the ovary secondarily [349].
Many studies have provided strong evidence that endometrioid and clear cell ovarian
cancers are derived from endometriosis [350-355], whereas mucinous ovarian cancers are
metastases to the ovary from gastrointestinal and appendiceal tumours [334]. The site of
origin for serous cancers remains unknown. It continues to be strongly debated whether
HGSC is derived from the surface of the ovary and/ or the distal fallopian tube [332, 335,
356-358]. The latter became a site of interest once pathologists examined fallopian tubes
from patients who underwent prophylactic salpingo-oopherectomies and found that tubal
lesions were present in women with germline BRCA1/2 mutations [357]. Therefore a new
model for the origin of HGSCs was proposed whereby cancer cells are shed from the
fimbria of the fallopian tube, implant on the surface of the ovary and produce ovarian

52

carcinomas [359, 360]. These possible precursor lesions, designated serous intraepithelial
tubal carcinomas (STICs), morphologically and molecularly resemble HGSCs [349].
Further studies supporting this mechanism have shown that 48% of women with HGSCs
have STICs, and 92% of STICs from patients with HGSC have identical mutations in
TP53 [335, 357]. Importantly, STICs have been found in patients in the absence of
ovarian carcinomas, which negates the suggestion they formed as a result of metastases
from HGSCs [335].
All of the current theories have something to offer regarding ovarian cancer
development, yet none of them successfully merges all aspects of ovarian carcinogenesis
[349]. While the data suggesting that HGSC originate from non-ovarian sites is
compelling, serous ovarian cancers involve the ovaries and the peritoneum considerably
more than the fallopian tubes. The relative importance of these two sites continues to be
debated; nevertheless, all novel findings have critical implications for screening,
prevention and treatment of this heterogeneous disease [334, 349].

1.8.3

Ovarian cancer prognosis and treatment
Ovarian carcinoma is the most lethal gynecological malignancy, and the fourth

most common cause of female cancer death in the world [343]. The prognosis is more
favourable for patients diagnosed at an early stage, before the tumour has spread beyond
the ovary (stage I); surgical resection provides a 90% cure rate. Unfortunately, most
patients present with advanced disease (stage III/IV) once the tumour has metastasized to
the peritoneal cavity. The five-year survival rate for ovarian cancer patients is a
discouraging 45% [361], and patients with HGSC have a further diminished survival rate
between 35% and 40% [362]. Although most patients initially respond well to
cytoreduction and platinum- and taxane-based chemotherapeutics, approximately 70%
will develop chemoresistance and suffer recurrences [332]. The high mortality rates are
also strongly influenced by the amount of residual tumour following cytoreductive
surgery [362]. The unusual mechanism of EOC dissemination (Section 1.8.4) is a major
contributor to the challenges associated with current treatment and the design of
improved therapeutics.
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1.8.4

Ovarian cancer metastasis
Compared to many epithelial cancers the initial dissemination of EOC is unique

because it rarely involves the vasculature, although the vasculature is often associated
with advanced stages of the disease [363]. Instead the characteristic early step of EOC
metastasis is proteinase-mediated shedding of cancer cells from the primary tumour into
the peritoneal cavity, where malignant cells are disseminated by peritoneal fluid or
ascites (an increased volume of fluid in the abdomen) [364]. Shed EOC cells exist as
single cells or multicellular spheroids within the abdominal cavity, where they attach to
and invade the mesothelial lining to establish secondary lesions [365, 366].
1.8.4.1

Peritoneal ascites fluid

The peritoneal ascites fluid is a unique and complex environment in which EOC
cells are forced to survive in suspension [363]. The typical composition of cellular
components in ascites fluid from ovarian cancer patients (often as much as 4.5 litres
accumulates) consists of 37% lymphocytes, 29% mesothelial cells, 32% macrophages,
and <0.1% adenocarcinoma cells [364, 367]. Malignant ascites also contains an assembly
of non-cellular factors that promote EOC cell survival and metastatic implantation,
including growth factors, cytokines, chemokines and ECM fragments [368]. Over onethird of ovarian cancer patients present with ascites at diagnosis, and approximately 10%
of patients with recurrent EOC are affected by malignant ascites [369]. Patients routinely
undergo paracentesis to have the fluid removed, which provides a convenient source of
tumour cells for EOC studies.
1.8.4.2

Multicellular spheroids

Appropriate cell-matrix interactions are an important aspect of cellular and tissue
homeostasis [370]. Programmed cell death occurs when adhesion between epithelial cells
and ECM components is disrupted, thereby preventing detached cells from reattaching to
a new matrix and undergoing dysplastic cell growth [371]. The apoptosis induced by the
loss of interaction between cells and the ECM is called anoikis [372]. The ability to resist
anoikis is a critical mechanism in tumour metastasis [373].
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Many tumour cells are unable to survive as single cells under anchorageindependent growth conditions; thus they form aggregates to avoid anoikis [365, 374,
375]. EOC cells that are shed from the primary tumour, and forced into suspension within
the abdominal cavity, are believed to aggregate as multicellular spheroids in order to
maintain cell-cell contact as part of their natural survival response [363]. Key cell-cell
adhesion molecules such as cadherins and integrins facilitate cell compaction and create a
tumour microenvironment that supports mechanisms of cell survival [363, 376, 377]. The
formation of ovarian cancer spheroids is greatly disrupted, for example, when cells are
treated with blocking antibodies against α5- or β1-integrin subunits [378]. Furthermore,
the formation of multicellular aggregates is likely an important intermediate mechanism
that facilitates metastasis. It has been suggested that spheroids should be considered in
the dissemination of EOC and that the adhesion of spheroids initiates the conversion of
floating cells within the ascites to an anchored metastatic lesion [364]. Of note, when
spheroids implant on the mesothelium (a cell monolayer that covers all organs in the
peritoneal cavity) they do not directly adhere to mesothelial cells, but rather to the ECM
underneath [364-366]. The Brugge laboratory has demonstrated that ovarian cancer
spheroids use myosin-generated force to displace the mesothelium, thereby gaining
access to the ECM to promote invasion [379]. Burleson and colleagues have also shown
that ovarian cancer spheroids adhere to, migrate on and invade into live human
mesothelial cell monolayers in vitro [365, 380, 381].
Both single cells and spheroids can theoretically seed metastases [363]; however,
multicellular spheroids in vitro more closely mimic the characteristics of solid tumours in
the clinical microenvironment [334]. Spheroids grown in the presence of cellular or
extracellular components normally found in the tumour microenvironment exhibit many
histologic features similar to those of cells in vivo [364]. Ovarian cancer spheroids can be
isolated from the peritoneal ascites (30-200 mm) or produced by culturing cells on nonadherent plates [382]. Of note, spheroids derived from ascites of patients with advanced
disease vary in number and size, suggesting high variability between patients [332]. Nonadherent cell culture systems are an advantageous tool for simulating aspects of the
peritoneal microenvironment and cells cultured in these conditions can provide further
insights into ovarian cancer biology. The three-dimensional system also provides a
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unique opportunity to examine the response of multicellular spheroids to many cancer
therapies [383-385]. Various studies have shown that spheroids have increased resistance
to common cytotoxic drugs and ionizing radiation compared to monolayer cultures of the
same cells [386-388]. The majority of cytotoxic drugs target rapidly dividing cells;
however, spheroids only have proliferating cells in the outer cell layers, whereas the cells
in the center of the spheroid enter a quiescent state [389, 390]. Therefore it is not
surprising that spheroids are generally more resistant to these therapeutic agents and may
present a substantial impediment to effective treatment of late stage EOC.

1.8.5

ECM and cancer progression
The cellular components within the tumour microenvironment (also referred to as

the tumour “niche”) have been explored extensively for their role in the initiation of
cancer development and its progression [391]. However, many studies have recently
emphasized the important role that noncellular components of the tumour niche play as
well, particularly the ECM [392-395]. The ECM is a complex, highly organized threedimensional structure composed of several core components, including collagens,
laminin, nidogen, fibronectin, and proteoglycans [396]. These components are produced
and secreted by cells, and the composition and organization (including isoform
expression and post-translational modifications) are specific to the particular
requirements of a tissue [397, 398]. The ECM also serves as a reservoir for cytokines,
growth factors and ECM-remodeling enzymes that work with ECM proteins to signal to
cells [399]. Although the ECM was initially viewed as simply a support system involved
in maintaining tissue morphology, it is now also recognized as a dynamic and flexible
structure that either directly or indirectly influences many essential aspects of cellular
biology [391, 399, 400]. Several mechanisms exist to closely regulate the production,
degradation and remodelling of the ECM during normal development and organ function
[401]. However, these control mechanisms can be disrupted, and when these pathways
fail the composition and assembly of the matrix becomes disorganized, which disrupts
ECM dynamics [402, 403]. Aberrant ECM dynamics are associated with various
pathologies, including skeletal diseases, fibrosis and cancers [404, 405].
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The role of tumour-associated ECM has emerged as an essential contributor to
cancer progression [403, 406, 407]. The composition of the extracellular niche is a
significant predictor of patient outcome, and classical pathology has demonstrated that
excessive deposits of ECM are a common characteristic of tumours with poor prognosis
[408]. Breast cancer tumours for instance can be divided into subcategories based only on
their ECM composition, which are predictive of clinical outcome [409]. Recently, Rafii
and colleagues analyzed data from a TCGA study where 316 serous EOC primary tumors
underwent exome sequencing [410], and discovered that 89% of tumours have at least
one mutation in cell adhesion related genes, including the ECM-receptor interaction
pathway [411]. Gene expression screens have also shown that many genes encoding
ECM components and ECM receptors are dysregulated during tumour metastasis [412414]. Interestingly, using human melanoma xenografts in mice, Naba and colleagues
have shown that the tumour matrix is produced by both tumor cells and stromal cells, and
differs with metastatic potential [408].
Metastasis is a complex process that not only requires a microenvironment to
support cancer cell growth at the primary site, but also a metastatic niche that will allow
disseminated cancer cells to invade and migrate through new tissues to form secondary
lesions [391, 415]. The ECM is an essential component of both niches. Ovarian cancer
cells remodel the normal ECM by releasing proteases to degrade the pre-existing
molecules, and by depositing new ECM with an altered composition and assembly [416].
It has been proposed, for example, that the loss of collagen IV and laminin in the ECM of
primary tumours facilitates the shedding of ovarian cancer cells into the peritoneal cavity,
and its restored expression later in tumour development promotes metastasis [417].
Deregulation of ECM dynamics facilitates cancer cell survival, migration and invasion,
disrupts tissue polarity, and dysregulates angiogenesis [394, 418-420]. Abnormal ECM
composition and dynamics have also been associated with resistance of tumour cells to
conventional therapeutics [391, 421, 422]. The interactions between cancer cells and
ECM are carefully balanced to support these pro-tumourigenic processes [407, 423].
Migration, for example, requires an intermediate level of cell-ECM adhesion because
high adhesiveness prevents cells from fracturing the cell-matrix linkage, whereas low
adhesiveness prevents cells from being able to generate enough traction to move
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efficiently [424, 425]. During invasion, the proteolytic process of degrading and
remodeling the ECM must be tightly controlled as well, so that the ECM becomes
degraded enough for cell passage, but not so degraded that cells lose traction [423].
Ovarian cancer cell adhesion to the ECM initiates signaling pathways through
specialized transmembrane ECM receptors and cell-cell adhesion molecules, such as
integrins and cadherins [402, 403]. Integrins are the most prominent and likely the best
characterized ECM receptors involved in adhesion interactions [426], and are essential in
ovarian cancer metastasis [423]. They are a diverse family of glycoproteins that form
heterodimers between covalently linked α- and β-subunits, with each pairing being
specific for a set of ligands [402]. The β1-integrin can heterodimerize with numerous αsubunits and promote the adhesion of disseminated cells to the mesothelium where
integrin α2β1-collagen type IV, α6β1-laminin and α5β1-fibronectin interactions occur [283,
332, 378]. Simultaneously, cancer-associated proteases degrade the existing ECM and
allow invasion of the mesothelium [365, 366]. The adhesion of cancer cells to the
mesothelial-lined peritoneal surfaces also triggers intracellular signaling pathways that
can regulate cell growth, differentiation, migration and invasion [391, 403]. For example,
an increase in collagen deposits or ECM stiffness increases integrin signaling, which
promotes cell proliferation and survival [391]. Therefore, as a key component of the
tumour niche, the ECM affects tumour initiation, progression and metastatic potential.

1.9 Scope of thesis
The ECM is a highly organized, dynamic three-dimensional structure with many
physiological and pathological roles. It maintains tissue integrity, regulates various
cellular and biological processes such as cell adhesion, migration, cellular differentiation,
and proliferation, and acts as a reservoir of growth factors and cytokines. The functional
diversity that allows the ECM to play an active role in developmental processes also
makes it an interesting target whose deregulation can make it a rate-limiting step in
cancer progression. Using several model systems we examined select ECM proteins that
we predicted to have a possible role in normal ovarian development or ovarian cancer
progression.

58

1.9.1

Hypothesis and Objectives
The work presented in this thesis was executed to test the hypothesis that ECM

proteins play a functional role in ovarian folliculogenesis and ovarian cancer progression.
To test this hypothesis I pursued the following objectives:
1) To characterize the expression of ECM components in the immature and adult
Estrogen Receptor β-null mouse ovary.
2) To determine whether TCF21 represses estrogen receptor-mediated transcription.
3) To characterize the ECM protein Spondin1 and its function in immortalized
epithelial ovarian cancer (EOC) cell lines and primary ascites-derived ovarian cancer
cells in order to discover a possible role for Spondin 1 in cellular processes essential
for ovarian cancer progression.

1.9.2

Rationale and Studies
Microarray and cell-clumping studies performed by Dr. Deroo indicate that ECM

composition and cell adhesion are disrupted in ERβ-null granulosa cells ([156] and
unpublished data), which may contribute to the attenuated folliculogenesis observed in
ERβ-null ovaries. Therefore, in Chapter 2, I characterize the expression and localization
of two 17β-estradiol-regulated ECM proteins, Collagen 11A1 (Col11a1) and Nidogen 2
(Nid2), in the ovaries of ERβ-null and wildtype mice, which had been identified as
differentially expressed in ERβ-null GCs in Dr. Deroo’s microarray study. I also examine
several other ECM proteins not identified as dysregulated by the original microarray, but
previously identified in the ovary. I demonstrated that the expression of several ECM
components is disrupted in the ovary of the immature and adult ERβ-null mouse. I
identify several genes of the ECM whose protein levels are significantly higher in ERβnull follicles than in wildtype follicles, suggesting that ERβ represses their expression.
The molecular mechanisms that initiate gene repression by ERβ are not well
understood, and there remains limited information in the literature regarding corepressors
specifically involved in ERβ-mediated transcription. Therefore, in Chapter 3 I investigate
a potential mechanism by which ERβ may be acting as a transcriptional repressor in GCs.
A yeast two-hybrid screen of a mouse granulosa cell cDNA library performed by Dr.
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Deroo revealed a physical interaction between ERβ and the basic helix-loop-helix
protein, Transcription factor 21 (TCF21) (unpublished data). Biochemical and genetic
analyses have previously demonstrated that TCF21 can act as a transcriptional repressor
[253, 254, 258, 285, 286]. Furthermore, it is well established that TCF21 is essential for
normal gonadogenesis and sexual differentiation. Although TCF21 transcripts have
previously been identified in ovaries of mice, the detailed mechanism of its role in
postnatal ovaries is unknown. We demonstrate that TCF21 regulates estradiol-dependent
transcriptional activity in an ER isoform-specific manner; TCF21 represses ERβ, but not
ERα transactivation. Despite our best efforts we were unable to show that TCF21 forms a
complex with ERβ in vivo. Therefore, we returned our focus to another 17β-estradiolregulated ECM protein, Spondin 1, and its potential role in ovarian cancer progression.
As a key component of the tumour microenvironment, the ECM is essential at
various stages of tumourigenesis. Spondin 1, a secreted glycoprotein, is abundantly
expressed in the normal ovary and our laboratory has (unpublished) evidence identifying
a role in folliculogenesis. Spondin 1 is highly overexpressed in ovarian cancer and has
recently been identified as a promising ovarian cancer marker, particularly for high-grade
serous epithelial ovarian cancer. Therefore, in Chapter 4 I characterize Spondin1 and its
function in immortalized EOC cell lines and primary ascites-derived ovarian cancer cells.
Spondin1 has previously been shown to have functional and mechanistic roles in various
tissues, effecting cell adhesion, migration, and survival. Since many of the same cellular
processes and behaviours that are necessary for normal development are also essential for
cancer progression, I examined the effect of Spondin 1 on these processes in EOC cells. I
demonstrate that Spondin 1 significantly reduces EOC cell adhesion, viability and
proliferation; however, it does not effect cell migration.
The studies in this thesis have uncovered novel functions of ECM proteins in normal
ovarian development and ovarian cancer progression, further demonstrating the diverse
roles of ECM in infertility and tumourigenicity.
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Chapter 2

2

Expression of Extracellular Matrix Components is
Disrupted in the Immature and Adult
Estrogen Receptor β-null Mouse Ovary

This chapter is based on a peer-reviewed journal article:
Zalewski, A., E.L. Cecchini, and B.J. Deroo, Expression of extracellular matrix
components is disrupted in the immature and adult estrogen receptor beta-null mouse
ovary. PLoS One, 2012. 7(1): p. e29937.

2.1 Introduction
It is well established that estrogens play a critical role in the ovary during
folliculogenesis. 17β-estradiol (E2) synergizes with follicle stimulating hormone (FSH)
to induce granulosa cell differentiation and the formation of a healthy preovulatory
follicle capable of ovulation in response to luteinizing hormone (LH) [1]. E2 acts directly
on granulosa cells [2, 3] via its receptor, ERβ [4, 5], which is the predominant ER form
expressed in granulosa cells of both humans and mice.
E2 and ERβ are essential for folliculogenesis in mice. Adult ERβ-null females are
sub-fertile or infertile [6-8], possess ovaries with reduced numbers of growing follicles
and corpora lutea and, due to infrequent ovulation, have litters one-third the size of
wildtype (WT) females or are completely sterile [6-8]. There is almost a complete lack of
antral follicles in the prepubertal ERβ-null ovary [7]. Furthermore, ERβ-null granulosa
cells isolated from post-natal day (PND) 23 mice have an attenuated response to FSH,
resulting in reduced cAMP accumulation [5], and poorly differentiated granulosa cells
[4]. This lack of differentiation results in attenuated follicular production of cAMP in
response to LH [9], and reduced ovulation. Therefore, an important role for E2 and ERβ
in the response to FSH in the ovaries of adult mice has been firmly established; however,
a role for ERβ in the postnatal/immature ovary has not been explored. Lack of ERβ in the
immature ovary might contribute to the impaired FSH response observed in ERβ-null
granulosa cells.
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Several lines of evidence indicate that both E2 and ERβ are not only present in
the ovaries of immature rodents, but that E2 acting through ERβ regulates
folliculogenesis at this time. E2 has been detected in neonatal circulation in the rat [10].
In addition, androstenedione (which can be converted to E2) is detectable at PND 7 in the
mouse, and increases by PND 15 [11]. ERβ protein is present [12-14] and functional [13]
in primary follicles in PND 4 mouse ovaries, consistent with earlier data indicating that
ERβ mRNA is detectable in the mouse ovary as early as PND1 [14] or PND 4 [13, 14],
and increases dramatically by PND 12 in the mouse [14] and rat [15]. Thus, both E2 and
ERβ protein are simultaneously present in mice as early as PND 4, and increase around
PND 12-15, when the ovary contains primordial and primary follicles, as well as
secondary follicles with 2-3 layers of granulosa cells [16].
Evidence also suggests that E2, acting through ERβ, may regulate development of
primordial and primary follicles. First, adult female Cyp19a1-null mice (which lack the
enzyme Cyp19a1, also known as aromatase, which converts testosterone to 17β-estradiol
in granulosa cells) have reduced numbers of primordial and primary follicles compared
with WT mice [17], suggesting that production of E2 is required for optimal primordial
and primary follicle development. Second, adult female ERβ-null mice have elevated
numbers of primordial follicles, but reduced numbers of primary follicles [18]. Third,
treatment of PND 20 mice with the ERβ-selective agonist 8β-VE2 significantly increases
the number of primary follicles, while the ERα-selective agonist, 16α-LE2 did not [19].
These data suggest that E2 acting through ERβ may regulate the formation of primordial
and/or primary follicles in young mice.
Based on these data, we hypothesized that disrupted gene expression would be
observed in the ovaries of immature ERβ-null mice. The ERβ-null ovarian phenotype has
been described almost exclusively in adult or gonadotropin-treated PND 23-29 mice;
however, few studies have examined ERβ-null immature ovaries. Therefore, we
examined the expression of a subset of genes (originally identified by microarray analysis
[5] of granulosa cells isolated from PND 23-29 ERβ-null mice) in ERβ-null ovaries as
early as PND 13. Specifically, we focussed our analysis on proteins of the extracellular
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matrix because functional analysis of the microarray data revealed the novel observation
that many ECM genes were dysregulated in ERβ-null granulosa cells, suggesting a novel
phenotype in ERβ-null ovaries not previously reported.
It is well established that dramatic changes in the ECM occur throughout
folliculogenesis to allow for the dramatic growth of the follicle from the primary to
preovulatory stage [20-27]; the ECM regulates follicular cell morphology, aggregation,
communication, differentiation, steroidogenesis, survival, and proliferation [27]. Two
main follicular ECMs are the basal lamina and the "focimatrix," a basal lamina-like
matrix located between granulosa cells, and granulosa cells are thought to produce many
of these ECM components [22, 23]. In this study, we chose to further characterize the
expression and ovarian localization of two ECM proteins whose expression was higher in
ERβ-null granulosa cells than in WT cells, suggesting that ERβ may repress their
expression: Collagen 11a1 (Col11a1) and Nidogen 2 (Nid2). We characterize Col11a1
and Nid2 localization and mRNA levels in the ovaries of immature mice at PND 13 and
PND 23-29, as well as in adult mice. We also investigate several other ECM proteins
(Col4a1, Nid1, and Laminin) which were not identified as differentially regulated in the
original microarray, but whose ovarian expression has been previously characterized in
the mouse [20, 24]. Surprisingly, many of these ECM proteins are elevated as well in the
ERβ-null ovary, suggesting a general disruption of ECM composition, and a potential
role for this disruption in the reduced fertility observed in ERβ-null mice.
Therefore, the overall aim of our study was to demonstrate that gene expression is
dysregulated in the immature ERβ-null ovary, and in particular, that extracellular matrix
(ECM) gene expression is dysregulated. We now report for the first time that the
expression of several ECM genes is dysregulated in the ERβ-null ovary as early as PND
13, and that this dysregulation is maintained within the adult ERβ-null ovary, resulting in
altered expression of ECM components compared to WT mice. Taken together, our data
identify two novel findings: a) that ERβ regulates gene expression in the mouse ovary
much earlier than previously thought, and b) that ERβ plays a role in the regulation of
ECM composition in the immature and adult mouse ovary.
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2.2 Materials and Methods
2.2.1

Mice
Experiments were performed in compliance with the guidelines set by the

Canadian Council for Animal Care, and the policies and procedures approved by the
University of Western Ontario Council on Animal Care (Protocol Number: 2007-042).
The generation of ERβ-null mice has been described previously [8]. Mice were obtained
from Taconic Farms Inc., NY. Immature ERβ-null (ERβ-/-) female mice were generated
via breeding homozygous (ERβ-/-) males with heterozygous (ERβ+/-) females. Wildtype
(WT) C57BL/6 females were generated via breeding WT males and females. WT females
were used as controls in all experiments. All females were weaned at PND 21 and
genotyped as previously described [8]. All studies were conducted with untreated animals
(ie. no gonadotropin or any other treatment).

2.2.2

Isolation of granulosa cells
Ovaries were removed from PND 23-29 mice and immediately transferred to a

100-mm cell culture dish containing 15 ml ice-cold M199 medium supplemented with 1
mg/ml BSA, 2.5 µg/ml Amphotericin B, and 50 µg/ml gentamicin (all reagents from
Invitrogen, Carlsbad, CA). Ovaries were pooled according to genotype, and the granulosa
cells from each were then expressed by manual puncture with 25-gauge needles followed
by pressure applied with a sterile spatula. Follicular debris was removed manually and
the granulosa cell suspension filtered through a 150-µm Nitex nylon membrane (Sefar
America Inc., Depew, NY) mounted in Swinnex filters (Millipore, Billerica, MA). The
granulosa cells were then pelleted by centrifugation at 250 x g for 5 min at 4°C, followed
by two washes in DMEM/F-12 medium containing 1% Penicillin/Streptomycin solution
(Invitrogen, Catalog # 15070-063). The final cell pellet was frozen at 80°C.

2.2.3

RNA isolation and quantitative qRT-PCR
Frozen pellets of granulosa cells (PND 23-29 mice) or frozen whole ovaries (PND

13 mice) were solubilized in Trizol (Invitrogen, Carlsbad, CA) and RNA was isolated
according to the manufacturer's protocol. RNA was further treated with DNaseI, then
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reverse-transcribed using Superscript II (Invitrogen). cDNA levels were detected using
quantitative PCR with the ABI PRISM 7900 Sequence Detection System (Applied
Biosystems, Foster City, CA) and Power Sybr Master Mix (Invitrogen). Primers were
designed using the Applied Biosystems Primer Express Software version 2.0 (Table 2-1).
Fold changes in gene expression were determined by quantitation of cDNA from target
(ERβ-null) samples relative to a calibrator sample (WT). The gene for ribosomal protein
L7 (Rpl7) was used as the endogenous control for normalization of initial RNA levels.
Expression ratios were calculated according to the mathematical model described by
Pfaffl [28], where ratio = (Etarget)∆Ct(target)/(Econtrol)∆Ct(control) and E=efficiency of the
primer set, calculated from the slope of a standard curve of log (ng of cDNA) vs. Ct value
for a sample that contains the target according to the formula E=10-(1/slope) and
∆Ct=Ct(vehicle)-Ct(treated sample).
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Table 2-1: Primer sequences used for quantitative RT-PCR.
Gene
Col11a1
Col4a1
Lama1
Nid1
Nid2
Rpl7

Accession #
NM_007729.2
NM_009931.2
NT_039658.1
NM_010917.2
NM_008695.2
NM_011291

Forward Primer
5’- AGTTGGTCTGCAGTGGCAATTTCG -3’
5’- CTCCAGGTCCCTACGATGTC -3’
5’- TCCGTGGATGGCGTCAA -3’
5’- CACAGGCAATGGCAGACAGT -3’
5’- GTCTGTTTGGCTGGCTCTTTGCTT -3’
5’- AGCTGGCCTTTGTCATCAGAA -3’

Reverse Primer
5’- AGATCCCAGATCCACCGTTTCGTT -3’
5’- TCCAAAGGGTCCTGTCTCTC -3’
5’- TGTAGCGGGTCAAACACTCTGT -3’
5’- CCCTTCACCTTGCCATTGA -3’
5’- TCCACGTCATGGACAAAGGTAGCA -3’
5’- GACGAAGGAGCTGCAGAACCT -3’
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2.2.4

Immunofluorescence
Ovaries were dissected from PND13, PND 23-29, or two-month old adult WT and

ERβ-null female mice and embedded in Cryomatrix (Fisher, Ottawa, ON). Using a
cryostat, tissues were cut into 6 µm sections, mounted onto slides (Fisher) and stored at 20°C until use. Sections were fixed with 4% formaldehyde for 10 minutes, rinsed three
times with phosphate-buffered saline (PBS), then permeabilized with 0.1% Triton X-100
for 15 minutes. Sections were again rinsed three times with PBS, blocked for 30 minutes
with blocking solution (5% BSA in 0.1% Triton X-100), then rinsed three times with
blocking solution. The tissue was then incubated for one hour with primary antibodies
specific to each target, including rabbit polyclonal anti-nidogen 2 raised against a mouse
epitope (1:50, Santa Cruz Inc. sc-33143), rat monoclonal anti-nidogen 1 raised against a
mouse epitope (1:400, Abcam, Cambridge, MA, ab44944), rabbit polyclonal anticollagen 11a1 raised against a human epitope (1:200, Abcam ab64883), rabbit polyclonal
anti-collagen 4a1 raised against a mouse epitope (1:500, Abcam ab19808), rabbit
polyclonal anti-laminin raised against a mouse epitope (1:200, Abcam ab11575), and
rabbit polyclonal anti-calnexin raised against a dog epitope (1:50, Enzo Life Sciences
ADI-SPA-860). Sections were then rinsed three times in blocking solution and incubated
in secondary antibody (FITC-conjugated goat anti-rabbit secondary antibody, 1:250
Sigma F9887). The tissue was then washed twice in PBS followed by a 5 minute
incubation in 4′,6-diamidino-2-phenylindole (1:1000, Sigma), and slides were mounted
with Vectashield (Vector Laboratories, Burlington, ON). Slides were stored at 4°C and
visualized the following day with an Olympus Provis AX70 upright microscope. Images
were captured using Image-Pro 6.2 Software.

2.2.5

Statistical Analysis
Differences in average mRNA levels of Nid2, Nid1, Col11a1, and Col4a1

between ERβ-null and WT granulosa cells as determined by qPCR were compared using
an unpaired two-tailed Student’s t-test. To estimate and quantify the amount of Nid2,
Nid1, Col4a1, and laminin present in the focimatrix, the number of immunoreactive
speckles per follicle in each follicle within the section was counted manually by an
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experimenter blinded to genotype. Atretric follicles were not included in the count.
Speckles were counted in 21-78 follicles per genotype for each protein of interest from a
minimum of three mice per genotype per protein. Larger aggregates of speckles were
estimated based on a pre-determined minimum speckle size. The number of
speckles/follicle was compared between ERβ-null and WT using two statistical tests.
First, averages were compared using an unpaired, two-tailed Student’s t-test. Second,
differences were investigated using the more stringent criteria of Receiver Operating
Characteristic (ROC) analysis, an analysis that tests for differences over the entirety of
both distributions.

2.2.6

Gene Ontology Analysis
The Database for Annotation, Visualization and Integrated Discovery 6.7

(DAVID 6.7) Functional Annotation tool [29, 30] was used to determine Gene Ontology
Cellular Components [31] presented in Supplementary Table 2-1 from a previously
published dataset by Deroo et al [5]. All analyses were conducted with Maximum EASE
Score/P value set to 0.05.

2.3 Results
Our previous microarray studies (Gene Expression Omnibus accession number
GSE11585) [5] comparing the gene expression profiles of granulosa cells isolated from
gonadotropin-treated immature (PND 23-29) ERβ-het (ERβ+/-) and ERβ-null (ERβ-/-)
mice indicated that the expression of numerous extracellular (ECM) proteins was
dysregulated in ERβ-null granulosa cells compared to ERβ-het cells (Supplementary
Table 2-1). From this set of ECM proteins (Supplementary Table 2-1), we chose to
further characterize the expression and ovarian localization of two proteins whose
expression was higher in ERβ-null granulosa cells than in ERβ-het cells: Collagen 11a1
(Col11a1) and Nidogen 2 (Nid2). We focussed on these two proteins because they met
the following four criteria: 1) follow-up studies confirming the microarray data indicated
that both genes were dysregulated in granulosa cells isolated from untreated ERβ-null
PND 23-29 mice, suggesting an earlier role for ERβ in ovarian development than
previously thought, 2) the higher levels of expression in ERβ-null granulosa cells
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compared to ERβ-het cells suggested a novel inhibitory role for ERβ in the regulation of
their expression (rather than an activational role), 3) there is previously-reported evidence
for regulation of Col11a1 (Gene Expression Omnibus dataset GDS884) and Nid2
expression by 17β-estradiol [32, 33], and 4) the fold difference between ERβ-het and
ERβ-null granulosa cells was greater than two, our predetermined cut-off value for
further analysis. In addition, to our knowledge, expression of Collagen 11a1 had not been
previously reported in the ovary, suggesting that its aberrantly high expression in ERβnull granulosa cells may contribute to the disrupted folliculogenesis observed in ERβ-null
mice. Note that untreated mice were used for all studies, ie. mice were not primed with
gonadotropins or estradiol.
Therefore, we wanted to investigate Col11a1 and Nid2 expression and
localization at PND 13 and PND 23-29 to determine when dysregulated gene expression
could first be detected in the ERβ-null ovary. We also investigated these genes in adult
ovaries to determine if the dysregulation observed in immature mice was maintained in
the adult ovary.

2.3.1

Collagen 11A1
At PND 13, Col11a1 mRNA levels were approximately two-fold higher in ERβ-

null whole ovaries than in WT ovaries, as determined by quantitative RT-PCR (qPCR)
(Figure 2-1A). Similarly, Col11a1 mRNA levels were 2.5-fold higher in granulosa cells
isolated from PND 23-29 ERβ-null mice than in WT granulosa cells isolated from agematched mice (Figure 2-1A). We then wanted to determine, using immunofluorescence:
a) if these increases in Col11a1 mRNA levels correlated with increases in protein
expression, and b) the localization of Col11a1 within the immature and adult ovaries of
WT and ERβ-null mice. At PND 13, when the mouse ovary contains many preantral
follicles with 2-3 rows of granulosa cells surrounded by a basal lamina, in addition to
primary and primordial follicles [16], ERβ-null ovaries expressed higher levels of
Col11a1 than WT mice of the same age (Figure 2-1B), and Col11a1 appeared to be
localized to the cytoplasm and extracellular region of granulosa cells. AT PND 23-29
(Figure 2-1C) Col11a1 was almost undetectable in WT PND 23-29 ovaries. However,
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Col11a1 was dramatically elevated in the follicles of ERβ-null mice (Figure 2-1C).
Col11a1 protein was localized primarily to the cytoplasm of granulosa cells (Figure 2-1C,
panel f). Similar localization in the follicle was observed for calnexin, which localizes to
the endoplasmic reticulum and is frequently used as a cytoplasmic marker (Figure S2-1).
Col11a1 expression was primarily observed in preantral follicles (both small and large),
which predominate in the immature ERβ-null ovary. Only very weak Col11a1 staining
was observed in the thecal layer or ovarian interstitium. In adult mice, as observed in the
immature mice, Col11a1 expression was again higher in the granulosa cell cytoplasm in
ERβ-null ovaries than in WT ovaries (Figure 2-1D).

2.3.2

Nidogen 2
At PND 13, Nid2 mRNA levels were approximately 1.5-fold higher in ERβ-null

whole ovaries than in WT ovaries, as determined by qPCR (Figure 2-2A). Similarly, Nid2
mRNA levels were approximately 2.3-fold higher in granulosa cells isolated from PND
23-29 ERβ-null mice than in WT granulosa cells isolated from age-matched mice (Figure
2-2A). With respect to localization of Nid2 within the ovary as determined by
immunofluorescence, while Col11a1 localized almost exclusively to the cytoplasm of
granulosa cells (Figure 2-1C), Nid2 was localized to the follicular basal lamina, thecal
matrix, sub-endothelial basal lamina of stromal blood vessels, and in a punctate pattern as
“speckles” or “plaques” between granulosa cells (known as focimatrix) (Figure 2-2C) of
PND 23-29 WT mice, as previously reported [24]. The focimatrix (focal intra-epithelial
matrix; a term coined by Irving-Rodgers et al. [34]), is a specialized ECM composed of
basal-lamina like material that exists as plaques or aggregated deposits between
granulosa cells, but does not surround the cells as a true basal lamina. Focimatrix is found
in the ovaries of many species. In the mouse, primary focimatrix components include
collagen, type IV α1 and α2, laminin α1, β1 and γ1, nidogens 1 and 2, perlecan, and
collagen type XVIII [24]. Granulosa cells express mRNA encoding many focimatrix
proteins [23, 35], and granulosa cells are thought to be the source of focimatrix protein
production [25]. In our study, Nid2 localization was similar in both WT and ERβ-null
ovaries (Figure 2-2B and 2-2C) at PND 13 and PND 23-29. However, as predicted by the
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mRNA levels (Figure 2-2A), Nid2 expression was higher in the follicles of ERβ-null
mice (Figures 2-2B and 2-2C) than in WT mice at both ages. However, this increase was
only observed in the focimatrix of ERβ-null ovaries; Nid2 levels in the follicular basal
lamina, thecal matrix, and sub-endothelial basal lamina of stromal blood vessels were
similar in both genotypes. These differences in focimatrix Nid2 expression between WT
and ERβ-null follicles were quantified in PND 23-29 ovaries by counting the number of
focimatrix speckles per follicle, and the difference tested for statistical significance
(Figure 2-2E). A statistically significant difference in the number of focimatrix speckles
per follicle was observed between WT and ERβ-null follicles (Figure 2-2E) on average,
as determined by Student’s t-test (Figure 2-2E, left panel). In addition, a statistically
significant difference was also detected using the more stringent criteria of Receiver
Operating Characteristic (ROC) analysis (Figure 2-2E, right panel), an analysis that tests
for differences over the entirety of both distributions. At PND 13, ERβ-null ovaries again
expressed higher levels of Nid2 protein than WT mice of the same age (Figure 2-2B).
Interestingly, Nid2 expression appeared higher throughout the ovary of ERβ-null mice at
this stage: in the focimatrix, in the follicular basal lamina and in thecal matrix.
(Focimatrix speckles were not counted due to difficulty of accurate counts resulting from
the irregularity of follicle shapes and sizes at this stage). Expression of Nid2 was
strikingly and significantly higher (Figure 2-2D and 2-2F) in adult ERβ-null focimatrix
than in WT focimatrix, while expression of Nid2 in other follicular compartments was
similar in both genotypes, as observed in younger mice (Figures 2-2B and 2-2C).
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Figure 2-1: Collagen 11a1 mRNA and protein levels are higher in granulosa cells
and ovaries of ERβ-null mice than in wildtype mice.
(A) Granulosa cells were isolated and pooled from ovaries of untreated PND 13 or PND
23-29 wildtype (+/+) or ERβ-null (-/-) mice, and the levels of Col11a1 mRNA were
determined by quantitative RT-PCR compared to an Rpl7 control (± SEM of three
independent experiments). Wildtype and ERβ-null average mRNA levels were compared
using an unpaired two-tailed Student’s t-test. a: p < 0.05. B-D. Immunofluorescence with
an anti- Col11a1 antibody was used to detect Col11a1 localization and expression in
ovaries isolated from wildtype (+/+) and ERβ-null (-/-) mice at (B) PND 13 (a-d), (C)
PND 23-29 (a-f; negative controls with secondary antibody only are shown in g and h),
and (D) PND 60 (adult). Various magnifications are shown. (B) Scale bar = 100 µM for
a-b, and 50 µM for c-d. (C) Scale bar = 200 µM for a-b and g-h, 100 µM for c-d, and
50 µM for e-f; (D) Scale bar = 200 µM for a-b, 100 µM for c-d.
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Figure 2-2: Nidogen 2 mRNA and protein levels are higher in granulosa cells and
ovaries of ERβ-null mice than in wildtype mice.
(A) Granulosa cells were isolated and pooled from ovaries of untreated PND13 or PND
23-29 wildtype (+/+) or ERβ-null (-/-) mice, and the levels of Nid2 mRNA were
determined by quantitative RT-PCR compared to an Rpl7 control (± SEM of three
independent experiments). Wildtype and ERβ-null average mRNA levels were compared
using an unpaired two-tailed Student’s t-test. a: p < 0.05; b: p < 0.01. B-D.
Immunofluorescence with an anti-Nid2 antibody was used to detect NID2 localization
and expression in ovaries isolated from wildtype (+/+) and ERβ-null mice (-/-) at (B)
PND 13 (a-d), (C) PND 23-29 (a-d; negative controls with secondary antibody only are
shown in e and f), and (D) PND 60 (adult). Various magnifications are shown at each
age. (B) Scale bar = 100 µM for a-b, and 50 µM for c-d. (C) Two different sections from
each genotype are shown (same magnification for both sections). Scale bar = 100 µM for
a-f; (D) Scale bar = 200 µM for a-b, 100 µM for c-d. Nid2 is localized to the follicular
basal lamina (white filled arrowhead), focimatrix (open arrowhead), thecal matrix
(asterix), and endothelial basal lamina of stromal blood vessels (square). (E, F)
Focimatrix speckles in the PND 23-29 and adult sections were counted per follicle, and
the difference between genotypes analyzed by a two-tailed, un-paired Student’s t-test (±
SEM, left panel) and by Receiver Operating Characteristic analysis (right panel). Each
dot in the scatter plot (right panel) represents one follicle. b: p < 0.01; d: p < 0.0001.
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To show that this difference in expression between ERβ-null and WT granulosa
cells was specific to Nid2 and Col11a1, but not to all ECM genes, we also investigated
the expression of Nidogen 1 (Nid1), Collagen, type IV (Col4a1), and Laminin (Lama1).
We chose the Nid1, Col4a1, and Lama1 genes because their expression and localization
has been previously characterized in the mouse ovary [20, 24, 36], and because neither
gene had been detected as differentially expressed between WT and ERβ-null granulosa
cells by our previously-conducted microarray (Supplemental Table 1). Nidogen 1 is
structurally similar to Nidogen 2 and shares overlapping expression patterns during
development and in many adult tissues [37, 38], and both Collagen, type IV and Laminin
are ubiquitous ECM proteins found in many tissues, including the ovary.

2.3.3

Nidogen 1
Nid1 mRNA levels were similar in both ERβ-null and WT granulosa cells at PND

23-29 (Figure 2-3A). Similar to Nid2, Nid1 localized to the follicular basal lamina, thecal
matrix, focimatrix, and basal lamina of stromal blood vessels (Figure 2-3B) of PND 2329 WT mice as previously reported [24]. No differences in Nid1 expression levels were
observed between genotypes in the follicular basal lamina, thecal matrix, or basal lamina
of stromal blood vessels. Unexpectedly, Nid1 expression in the focimatrix was slightly
higher in ERβ-null follicles than in WT follicles (Figure 2-3B), and this increase was
statistically significant (Figure 2-3C). No significant differences were observed in Nid1
expression (Figures 2-3D and E) between adult wildtype and ERβ-null mice in the
focimatrix, although the overall signal in the basal lamina and stroma appeared higher in
ERβ-null ovaries than in WT ovaries.
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Figure 2-3: Nidogen 1 expression and localization in immature and adult ERβ-null
and wildtype mouse ovaries.
(A) Granulosa cells were isolated and pooled from ovaries of untreated PND 23-29
wildtype (+/+) or ERβ-null (-/-) mice, and the levels of Nid1 mRNA were determined by
quantitative RT-PCR compared to an Rpl7 control (± SEM of three independent
experiments). (B) Immunofluorescence with anti-Nid1 antibodies was used to detect
Nid1 localization and expression in ovaries isolated from wildtype (+/+) and ERβ-null
(-/-) mice at PND 23-29 (a-d; negative controls with secondary antibody only are shown
in e and f). Nid1 was localized to the follicular basal lamina (white filled arrowhead),
focimatrix (open arrowhead), thecal matrix (asterix), and endothelial basal lamina of
stromal blood vessels (square). Nid1 focimatrix expression is slightly higher in ERβ-null
ovaries than in wildtype ovaries at PND 23-29. Scale bar = 200 µM for a-b and e-f,
100 µM for c-d. (C) A significant increase in Nid1 expression within the focimatrix of
ERβ-null ovaries compared to wildtype ovaries was observed at PND 23-29, as
determined by the number of focimatrix “speckles” counted per follicle. Differences in
the number of speckles/follicle between genotypes were analyzed by Receiver Operating
Characteristic analysis (top panel) and a two-tailed, un-paired Student’s t-test (± SEM,
bottom panel). Each dot in the scatter plot (top panel) represents one follicle. a: p < 0.05.
(D) Nid1 expression in adult ERβ-null and wildtype mouse ovaries. Immunofluorescence
with anti-Nid1 antibodies was used to detect Nid1 localization and expression in ovaries
isolated from adult wildtype (+/+) and ERβ-null (-/-) mice. Two magnifications are
shown. Scale bar = 200 µM for a-b, 100 µM for c-d. (E) Expression of Nid1 in the adult
focimatrix was quantified by counting the number of focimatrix speckles/follicle, and
these values were compared between genotypes by Receiver Operating Characteristic
analysis (E, top panel) and a two-tailed, un-paired Student’s t-test (± SEM, E bottom
panel) in each case. Each dot in the scatter plot (E, top panel) represents one follicle. No
statistically significant difference in NID1 focimatrix was observed between genotypes in
the adult ovary.
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2.3.4

Collagen 4a1
Col4a1 mRNA levels were similar in both ERβ-null and WT granulosa cells at

PND 23-29 (Figure 2-4A). Similarly, Col4a1 protein levels were the same in WT and
ERβ-null mice (Figure 2-4B). Interestingly, the localization of Col4a1 and Col11a1 was
not the same within the WT or ERβ-null ovary. While Col11a1 localized almost
exclusively to the cytoplasm of granulosa cells (Figure 2-1C), Col4a1 staining was
observed in the follicular basal lamina, the focimatrix, the thecal matrix, and in the
stromal sub-endothelial basal lamina of blood vessels (Figure 2-4B), as previously
reported for WT mice [20, 24, 36]. Similar Col4a1 localization and staining intensity was
observed in WT and ERβ-null PND 23-29 ovaries (Figure 2-4A). Focimatrix Col4a1
expression was quantified by counting the number of focimatrix speckles per follicle
(Figure 2-4C). As predicted by the mRNA levels (Figure 2-4A), no statistically
significant differences in the number of focimatrix speckles per follicle were observed
between WT and ERβ-null follicles (Figure 2-4C). Expression of Col4a1 (Figure 2-4D)
was strikingly and significantly higher (Figure 2-4E) in adult ERβ-null focimatrix than in
WT focimatrix, while expression of Col4a1 in other follicular compartments was similar
in both genotypes, as observed in younger mice (Figure 2-4D).

2.3.5

Laminin
Lama1 mRNA levels were similar in both ERβ-null and WT granulosa cells at

PND 23-29 (Figure 2-5A). As previously reported [24], laminin was localized to the
follicular basal lamina, the basal lamina of stromal blood vessels, the thecal matrix,
focimatrix, and corpora lutea in both immature and adult mice (Figures 2-5B and 2-5D).
At PND 23-29, ERβ-null follicles consistently possessed significantly higher numbers of
focimatrix speckles per follicle than WT follicles (Figures 2-5B and 2-5C). Interestingly,
laminin expression in the focimatrix of adult ERβ-null ovaries (Figure 2-5D) was again
significantly higher than in WT focimatrix (Figure 2-5E).
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Figure 2-4: Collagen 4a1 expression and localization in immature and adult ERβnull and wildtype mouse ovaries.
(A) Granulosa cells were isolated and pooled from ovaries of untreated PND 23-29
wildtype (+/+) or ERβ-null (-/-) mice, and the levels of Col4 mRNA were determined by
quantitative RT-PCR compared to an Rpl7 control (± SEM of three independent
experiments). (B) Immunofluorescence with an anti-Col4a1 antibody was used to detect
Col4a1 localization and expression in ovaries isolated from wildtype (+/+) and ERβ-null

(-/-) mice at PND 23-29 (a-d; negative controls with secondary antibody only are shown
in e and f). Col4a1 was localized to the follicular basal lamina (white filled arrowhead),
focimatrix (open arrowhead), thecal matrix (asterix), and endothelial basal lamina of
stromal blood vessels (square). Scale bar = 200 µM for a-b and e-f, 100 µM for c-d. (C)
No significant differences in Col4a1 expression within the focimatrix were observed, as
determined by the number of focimatrix “speckles” counted per follicle analyzed by
Receiver Operating Characteristic analysis (top panel) and a two-tailed, un-paired
Student’s t-test (± SEM, bottom panel). Each dot in the scatter plot (top panel) represents
one follicle. (D) Col4a1 expression in adult ERβ-null and wildtype mouse ovaries.
Immunofluorescence with anti-Col4a1 antibodies was used to detect Col4a1 localization
and expression in ovaries isolated from adult wildtype (+/+) and ERβ-null (-/-) mice.
Two magnifications are shown. Scale bar = 200 µM for a-b, 100 µM for c-d. (E)
Expression of Col4a1 in the focimatrix was quantified by counting the number of
focimatrix speckles/follicle, and these values were compared between genotypes by
Receiver Operating Characteristic analysis (top panel) and a two-tailed, un-paired
Student’s t-test (± SEM, bottom panel). Each dot in the scatter plot (bottom panel)
represents one follicle. d: p < 0.0001
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Figure 2-5: Laminin expression and localization in immature and adult ERβ-null
and wildtype mouse ovaries.
(A) Granulosa cells were isolated and pooled from ovaries of untreated PND 23-29
wildtype (+/+) or ERβ-null (-/-) mice, and the levels of Lama1 mRNA were determined
by quantitative RT-PCR compared to an Rpl7 control (± SEM of three independent
experiments). (B) Immunofluorescence with an anti-laminin antibody was used to detect
laminin localization and expression in ovaries isolated from wildtype (+/+) and ERβ-null
(-/-) mice at PND 23-29 (a-d; negative controls with secondary antibody only are shown
in e and f) wildtype (+/+) and ERβ-null (-/-) mice. Two magnifications are shown. Scale
bar = 200 µM for a-b, 100 µM for c-d. (C) Focimatrix levels of laminin were quantified
by counting the number of focimatrix speckles/follicle, and these values compared
between genotypes by Receiver Operating Characteristic analysis (top panel) and a twotailed, un-paired Student’s t-test (± SEM, bottom panel). Each dot in the scatter plot (top
panel) represents one follicle. f: p < 0.005. (D) Laminin expression in adult ERβ-null and
wildtype mouse ovaries. Immunofluorescence with anti-laminin antibodies was used to
detect laminin localization and expression in ovaries isolated from adult wildtype (+/+)
and ERβ-null (-/-) mice. Two magnifications are shown. Scale bar = 200 µM for a-b,
100 µM for c-d. (E) Expression of laminin in the focimatrix was quantified by counting
the number of focimatrix speckles/follicle, and these values were compared between
genotypes by Receiver Operating Characteristic analysis (top panel) and a two-tailed, unpaired Student’s t-test (± SEM, bottom panel). Each dot in the scatter plot (bottom panel)
represents one follicle. e: p < 0.0005.
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2.4 Discussion
In this study, we show that disrupted gene expression is observed in the ovaries of
immature ERβ-null mice as early as PND 13, resulting in abnormal expression of ECM
components in the ERβ-null ovary. We found that the mRNA levels of the ECM genes,
Col11a1 and Nid2 were higher in granulosa cells isolated from ERβ-null PND 23-29
mice, or in whole ovaries isolated from PND 13 mice, than in age-matched WT controls.
These elevated mRNA levels correlated with higher Col11a1 in the cytoplasm of
granulosa cells and higher Nid2 expression in the focimatrix of the immature ERβ-null
ovary, at both PND 23-29 and PND 13. Interestingly, the elevated expression of Col11a1
and Nid2 in ERβ-null follicles continued into adulthood. Finally, levels of the ubiquitous
ECM proteins, collagen IV and laminin, were also higher in the adult ERβ-null ovary
than in the WT ovary.

2.4.1

An early role for ERβ in ovarian development
Our results showing that gene expression is dysregulated in ovaries of ERβ-null

mice at PND 13 are consistent with studies suggesting that both the levels of ovarian ERβ
and its ligand, E2, increase during a similar time-frame in post-natal ovarian
development, and that E2 may act through ERβ at this time to regulate gene expression,
and possibly follicle development. The presence of circulating E2 or its precursors has
been established in neonatal rats [10] and mice [39], and androstenedione is detectable at
PND 7 and increases dramatically at PND 15 [11]. ERβ protein is present and functional
in the ovaries of PND 4-5 mice, but not in younger mice [13, 14], and ovarian ERβ
protein levels increase with age [14], with the most abundant expression in granulosa
cells. ERβ mRNA is detectable at PND 1 [14] or PND 4 [13] in the mouse ovary, with a
dramatic increase occurring between PND 1 and PND 12 [14]. Evidence supporting a
role for both E2 and ERβ in regulating primary and primordial follicle development in
the mouse ovary has been suggested using various model systems [17, 19, 40], and our
results showing disrupted gene expression in ERβ-null mice at PND 13 support a role in
ovarian development in the immature mouse. Interestingly, during the period of human
gestation when primordial follicles are formed, the fetal ovary expresses both the
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steroidogenic enzymes necessary for E2 production, and ERβ protein, suggesting that
estrogen signaling may also regulate human primordial follicle formation [41]. While it
may be possible that ERβ plays a role during prenatal ovarian development in the mouse,
this is unlikely because ERβ mRNA is undetectable in the mouse ovary 26 days postcoitum [14] and only becomes detectable between PND 1 to PND 4 [13, 14].
Interestingly, although detectable at PND 8, we do not observe differences in gene
expression by qPCR or protein levels by immunofluorescence in Col11a1 or Nid2
between ERβ-null and WT ovaries (data not shown) as we do at PND 13. One possible
explanation for this lack of differential Col11a1/Nid2 gene expression at PND 8 may be
that ovarian ERβ levels are not high enough at PND 8 to detectably alter Col11a1/Nid2
gene expression in WT mice, since there is a dramatic increase in ERβ mRNA between
PND 1 and PND 12 in the mouse [14]. Thus it may not be until PND 13 that the lack of
ERβ would result in significant differences in Col11a1/Nid2 gene expression. On the
other hand, there may be transcriptional coregulators required for ERβ-mediated
transcription that are not present at PND 8 but are expressed at PND 13. Further
experiments in WT and ERβ-null ovaries isolated from mice between PND 8 and
PND 13 will be required to determine at which point during ovarian development ERβ
activity is required for Col11a1/Nid2 gene expression.
We have previously shown that ERβ-null granulosa cells isolated from PND 2329 mice demonstrate an attenuated response to FSH, resulting in impaired Lhcgr and
Cyp19a1 expression, despite similar expression of FSH receptors [4, 5]. At least part of
this attenuated response is due to reduced cAMP levels in response to FSH stimulation
compared to WT granulosa cells [5]. Another important finding resulting from this
previous study was that granulosa cells freshly-isolated from PND 23-29 ERβ-null
ovaries produced significantly less cAMP than WT cells, even prior to stimulation by
FSH. This reduced cAMP correlated with the elevated expression of phosphodiesterase
1c (PDE1C) in ERβ-null granulosa cells compared to WT cells (both isolated from
untreated PND 23-29 mice) [5]. These results suggested that prior to PND 23, differences
in granulosa cell gene expression between ERβ-null and WT mice are observed. Our
current study supports and expands this observation, and provides strong evidence that
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the impaired ERβ-null granulosa cell response to FSH at PND 23-29 is also due to the
dysregulation of perhaps numerous ERβ-dependent genes prior to PND 23 that are
required to prepare a granulosa cell to fully respond to FSH at the onset of puberty.
Thus, we propose that ERβ, acting either through E2 or in a ligand-independent
manner, regulates granulosa cell gene expression in follicles at various stages of growth:
in the primordial, primary, or preantral follicle, and in response to FSH during the
formation of a preovulatory follicle, as has previously been shown. While it is well
established that E2 acting through ERβ is required to augment the granulosa cell response
to FSH for the formation of a preovulatory follicle [4, 5, 42-46], fewer studies exist
establishing a role for E2 in folliculogenesis, prior to the gonadotropin surge at puberty.
Several reports indicate that E2 enhances or is required for the production of primary
follicles [17, 19], although others suggest that E2 inhibits primordial follicle assembly
[12, 40]. It has been reported that the number of primordial and primary follicles are
similar in immature (PND 23) ERβ-null and WT mice, suggesting that ERβ is not
required for the formation of primordial or primary follicles [18]. In contrast, adult
female ERβ-null mice have elevated numbers of primordial follicles, and reduced
numbers of primary follicles [18], suggesting that ERβ may participate in primordial
follicle recruitment and/or maintenance. Further experiments will be required to
determine the function of ERβ in the PND 13 ovary, and whether ERβ’s loss at earlier
stages truly impacts primary follicle formation and/or granulosa cell function.

2.4.2

Disrupted Expression of ECM components in ERβ-null
ovaries
This work is also novel in that we have characterized a significant elevation in

multiple ECM proteins in immature and adult ERβ-null ovaries: a phenotype that has not
previously been reported at either age. Col11a1 is expressed at very low levels in the WT
immature ovary (Figure 2-1), but is robustly expressed in the cytoplasm of granulosa
cells in the ERβ-null ovary at these ages. The localization of Col11a1 in the ovary of any
species has, to our knowledge, not previously been reported, and in the mouse, Col11a1
mRNA levels are highest in bone and cartilage [47]. In rat cartilage, Col11a1 is localized
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in the ECM between chondrocytes [48]; however, in human colon tissue, Col11a1 is
localized to the cytoplasm (specifically, the Golgi apparatus) of goblet cells [49]. We also
observed Col11a1 in the cytoplasm of granulosa cells, and the function of Col11a1 in
granulosa cell cytoplasm certainly merits further study, as does the possibility that
granulosa cells may secrete Col11a1 and contribute to granulosa cell-cell adhesion or
migration. We also observe Nid2 overexpression in the focimatrix in ERβ-null ovaries as
early as PND 13 (Figure 2-2B), and Nid2 remains elevated in the adult (Figure 2-2D).
Similarly, laminin expression (Figure 2-5) was higher in the focimatrix of both PND 2329 and adult ERβ-null ovaries compared to their WT counterparts, while Col4a1 was
elevated in ERβ-null adult but not PND 23-29 ovaries (Figure 2-4). Our results are
consistent with two previous reports in which global collagen levels were higher in adult
ERβ-null ovaries than in WT ovaries, in either: a) both stromal and thecal layers [50], or
b) in the stroma only [6]. Our work supports and expands these observations, indicating
that not just collagen, but a number of other ECM proteins are aberrantly highly
expressed in the adult ERβ-null follicle, and in addition, these elevated levels are
observed in immature mice. The fact that Nid2, laminin and Col4a1 expression was
higher specifically in the focimatrix of ERβ-null ovaries, and not, for example, in the
stroma, suggests that it is likely ERβ within granulosa cells regulating the expression of
these genes (or other upstream genes required for their expression), since granulosa cells
are the primary location of ERβ within the ovary, resulting in their secretion from the cell
and localization to the extracellular region of granulosa cells. Further studies using in situ
hybridization are needed determine which cells within the ovary produce these common
ECM components.

2.4.3

Regulation of Nid2 and Col11a1 by Estradiol and ERβ
There is evidence that E2 regulates ECM composition in the ovary and other

tissues. For example, E2 regulates collagen turnover and ECM maintenance in the uterus
and vagina of ovariectomized rats [51], and neonatal estrogen treatment disrupts the
ECM composition of the rat prostate [52]. Abnormal ECM composition and structure is
also observed in lungs of ERβ-null mice [53]. Within the context of our study, several
hypotheses can be put forward to explain how the lack of ERβ results in increased
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expression of Nid2 and Col11a1 in the ERβ-null immature ovary. First, ERβ may directly
repress the transcription of these genes either by binding EREs located proximal to or
distant from the transcriptional start site, or by binding to other transcription factors,
which themselves are bound to DNA (tethering). There is evidence that Col11a1 and
Nid2 expression is regulated by E2 in other model systems. Col11a1 mRNA is increased
by E2 treatment of osteosarcoma cells expressing ERβ, but not ERα, indicating that not
only is Col11a1 regulated by E2 but that ERβ is selectively required for its regulation
(Gene Expression Omnibus dataset GDS884) [33], although in this case E2 increases
rather than decreases Col11a1 expression, as would be predicted by the elevated Col11a1
levels we observe in the absence of ERβ. Treatment of ovariectomized adult mice with
E2 decreases uterine Nid2 mRNA levels within six hours of treatment, consistent with a
role for ERβ in repressing Nid2 gene expression in the ovary [32]. It is also possible that
ERβ indirectly decreases the transcription of Nid2 and Col11a1 by regulating the
expression of other protein(s), such as transcription factors or transcriptional
coregulators, or signaling molecules known to regulate folliculogenesis. In fact, in a
whole ovary culture model in which PND 4 rat ovaries (which contain almost exclusively
primordial follicles) were treated with Kit ligand [54], Col11a1 expression was reduced,
suggesting that Kitl signaling may be disrupted in ERβ-null neonatal ovaries. Lack of
ERβ may also stabilize Nid2 and Col11a1 mRNA through regulation of a protein
involved in RNA stability. Finally, it is possible that, ERβ may upregulate expression of
a proteinase that degrades ECM proteins, resulting in the accumulation of Nid2 and
Col11a1, and perhaps laminin and Col4a1 as well, in the absence of ERβ. Further
experiments are required to determine which of these potential mechanisms is responsible
for the elevated expression of Col11a1 and Nid2, and the other ECM proteins we
observed elevated in ERβ-null ovaries.

2.4.4

Potential impact of altered expression of ECM components
on ERβ-null ovaries
What impact the elevated levels of ECM protein in the cytoplasm (Col11a1) or in

focimatrix (Nid2, Col4a1, laminin) of granulosa cells might have on folliculogenesis or
function of the ERβ-null ovary is not clear. It is well established that dramatic changes in

121

the ECM occur throughout folliculogenesis [24, 25, 27], and that the ECM carries out
many functions within the ovary. Within the ovary and follicle, the ECM provides
structural support, organizes and connects cells, and serves as a reservoir for signaling
molecules that regulate follicle growth. The ECM also regulates establishment of the
basement membrane, oocyte maturation, follicle atresia, steroidogenesis, and cell lineage
[21, 26]. Further studies testing these specific functional endpoints in ERβ-null ovaries
will help determine the potential impact of these overexpressed ECM proteins on ERβnull ovary and granulosa cell function. The role of the focimatrix in granulosa cell and
follicular function is less clear than that of the ECM, and very little is known regarding
focimatrix function, although recent studies are beginning to address this question.
Irving-Rodgers et al. have demonstrated that cholesterol side-chain cleavage cytochrome
P450 (Cyp11a1) mRNA levels are highly and positively correlated with the expression of
a number of focimatrix proteins in bovine ovaries, suggesting that the focimatrix
participates in the selection of a dominant follicle [23, 35]. The same authors have also
suggested that focimatrix may trigger the transition of an epithelial granulosa cell to a
mesenchymal luteal cell by reducing the polarizing “cue” provided by the follicular basal
lamina [34]. Thus, it is possible that the increased Nid2, Col4a1, and laminin expression
we observe in the focimatrix of ERβ-null ovaries may impact the steroidogenic capacity
of ERβ-null granulosa cells, and indeed, reduced E2 levels have been observed in
cultured ERβ-null follicles [18]. Altered focimatrix composition may also affect ERβnull granulosa cell luteinization, and this effect would be consistent with the dramatically
reduced luteinization of ERβ-null granulosa cells in response to LH [4, 5, 41]. Also,
given that focimatrix Nid2 levels are lower in bovine partially dominant follicles than in
fully dominant follicles or subordinate follicles, it is also possible that increased Nid2 in
focimatrix of ERβ-null ovaries may interfere with or alter follicle selection. Further
experiments will be required to test these hypotheses.
A surprising finding was that Nid1 mRNA is not elevated in immature ERβ-null
granulosa cells, but that its protein expression is significantly higher in the focimatrix of
immature ERβ-null follicles than WT follicles. Given this elevated Nid1 expression
observed in immature ERβ-null follicles, it was also surprising that Nid1 focimatrix
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levels are similar in both genotypes in the adult mouse. One possible explanation for
these findings is that ERβ may regulate export or secretion of focimatrix proteins such as
Nid1, and that attenuation of this activity might occur with age, resulting in similar Nid1
protein levels in the adult ovaries of both genotypes. The ERβ-dependent regulation of
focimatrix protein secretion may also explain the elevated focimatrix levels of Col4a1
and laminin observed in adult ERβ-null ovaries (and for laminin, also in immature
ovaries), although Col4a1 and Lama1 mRNA levels were similar in both genotypes in
both immature (Figures 2-4 and 2-5) and adult (data not shown) ovaries. A final
possibility to explain Col4a1 accumulation in the adult but not the immature focimatrix is
that Col4a1 protein may begin to accumulate in the ERβ-null immature focimatrix, but
differences between WT and ERβ-null may not be detectable until sufficient Col4a1 has
accumulated in the adult to detect these differences. In total, these results suggest that not
all focimatrix genes are regulated via the same transcriptional mechanisms, and that ERβ
may differentially regulate focimatrix protein export, as differential mechanisms of
export have previously been observed for individual ECM proteins [55-57]. Although coregulated expression of Nid1, Nid2, and Col4a1 mRNA has been previously observed in
bovine follicles [23], species differences may also account for the lack of coordinated
regulation we observe in the ERβ-null ovary.

2.4.5

Conclusions
In summary, we have shown for the first time that disrupted gene expression is

observed in the ovaries of immature ERβ-null mice as early as PND 13, resulting in
elevated expression of ECM proteins in the extracellular regions within the focimatrix or
surrounding granulosa cells within the ERβ-null ovary. This increased expression is also
observed in the adult ERβ-null ovary. These findings suggest that ERβ regulates gene
expression in the ovary prior to puberty, and we speculate that dysregulation of ERβmediated gene expression in early postnatal life may disrupt folliculogenesis and/or
contribute to the impaired response of immature ERβ-null granulosa cells to FSH [4, 5].
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Figure S2-1: Calnexin and Col11A1 localize to the cytoplasm of granulosa cells in
ovaries of immature PND 23-29 mice
Immunofluorescence with anti-calnexin (A) and anti-Col11A1 (B) antibodies were used
to confirm the cytoplasmic localization of (A) calnexin in PND 23-29 wildtype mice, and
(B) Col11A1 in PND 23-29 ERβ-null (-/-) mice (identical image to that in Figure 2-1C,
section f). (A): Scale bar = 100 µM; (B) Scale bar = 50 µM.

129

Table S2-1: Dysregulated extracellular matrix genes in ERβ-null granulosa cells
compared to ERβ-het cells.
Genbank ID
NM_008695
NM_178929

Gene Symbol
Nid2
Kazald1

NM_007729
NM_175506

Col11a1
Adamts19

NM_016762
NM_008606
NM_011775
NM_009369
AK078108

Matn2
Mmp11
Zp2
Tgfbi
Ptprz1

NM_008482
NM_009368
NM_026439
NM_009929
NM_007833
NM_175148
NM_016696
AK003211
NM_011261
NM_012050
NM_010681
NM_028266
NM_145584

Lamb1
Tgfb3
Ccdc80
Col18a1
Dcn
N/A
Gpc1
N/A
Reln
Omd
Lama4
Col14a1
Spon1

NM_019919

Ltgp1

NM_016685

Comp

Gene Name
nidogen 2
Kazal-type serine peptidase inhibitor
domain 1
collagen, type XI, alpha 1
a disintegrin-like and metallopeptidase
(reprolysin type) with thrombospondin
type 1 motif, 19
matrilin 2
matrix metallopeptidase 11
zona pellucida glycoprotein 2
transforming growth factor, beta induced
protein tyrosine phosphatase, receptor type
Z, polypeptide 1
laminin B1 subunit 1
transforming growth factor, beta 3
coiled-coil domain containing 80
collagen, type XVIII, alpha 1
decorin
RIKEN cDNA 2300002M23 gene
glypican 1
RIKEN cDNA 1110001D15 gene
reelin
osteomodulin
laminin, alpha 4
collagen, type XVI, alpha 1
spondin 1, (f-spondin) extracellular matrix
protein
latent transforming growth factor beta
binding protein 1
cartilage oligomeric matrix protein

Fold
3.9
3.7

P-value
6.5E-42
1.2E-40

2.3
2.3

1.4E-16
1.6E-07

1.7
1.6
1.6
1.6
1.5

9.3E-10
0.00002
9.5E-10
0.00083
0.00001

1.4
1.4
1.4
1.4
1.4
1.3
-1.2
-1.3
-1.4
-1.5
-1.9
-1.9
-2.5

4.2E-11
3.1E-06
0.00004
9.5E-10
0.00002
0.00002
0.00007
0.00093
0.00041
5.6E-09
0.00007
0.00001
6.1E-19

-2.7

6.8E-20

-15.7

7.2E-33
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Chapter 3

3

The Basic Helix-Loop-Helix Transcription Factor TCF21
Represses Estrogen Receptor β-Mediated Transcription

3.1 Introduction
Estrogens are a class of steroid hormones that regulate cell differentiation,
proliferation and function in many tissues. The biological effects of estrogens are
facilitated by estrogen receptors (ERs), which are transcription factors that bind both
natural and synthetic estrogens to regulate transcription of target genes [1]. The ER
belongs to the nuclear receptor family of ligand-inducible transcription factors. Its classic
mechanism of action is similar to that of other receptors in this superfamily. In the
absence of ligand, the ERs are present in an inactive state within the nuclei. Ligand
binding induces a conformational change within the ER, which allows the receptors to
dimerize and bind with high affinity to specific sequences, called estrogen response
elements (ERE), located within the regulatory regions of target genes and many other
regions within the genome [2-4]. The receptors then interact with the general
transcription machinery either directly or indirectly via cofactor proteins [3, 5]. The cell
and promoter involved will determine whether the ER will exert a positive or negative
effect on the expression of the downstream target gene [5].
Two isoforms of ER have been identified, ERα and ERβ. Although both are
widely distributed throughout the body, they have distinct levels and expression patterns
in different tissues and cell types [6, 7]. ERβ is expressed in fewer tissues than ERα, and
is most highly expressed in the ovary [6]. Within the ovary ERβ is restricted to the
granulosa cells, which nourish the oocyte and are essential for its growth [8]. Mice
lacking ERβ ovulate less frequently and have smaller litters than wildtype mice due to an
impaired response to follicle stimulating hormone, resulting in poor granulosa cell
differentiation[9].
We have previously shown that the levels of expression of ECM components is
disrupted in the ovary of the immature and adult ERβ-null mouse [10]. We have
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identified a number of genes of the ECM whose protein levels are significantly higher in
ERβ-null follicles than in wildtype follicles. This results in abnormally high expression of
ECM components in the ERβ-null ovary, suggesting that these ECM genes are repressed,
either directly or indirectly by ERβ. The molecular processes that initiate gene repression
by ERβ in vivo are not well understood, and there remains limited information in the
literature regarding corepressors specifically involved in ERβ-mediated transcription or
transactivation in vivo [11-14]. Herein we look at the mechanism by which ERβ may be
acting as a transcriptional repressor in granulosa cells.
Transcription factor 21 (TCF21) is a basic helix-loop-helix (bHLH) protein
identified for its role in embryonic development [15-17]. Class II bHLH proteins, to
which TCF21 belongs, have a tissue-specific pattern of expression. While Class I proteins
are widely expressed and capable of binding to DNA as homodimers, a Class II bHLH
factor typically requires heterodimerization with a Class I factor to bind at the target
gene. TCF21 often binds to the E Box, a consensus CANNTG sequence, as a heterodimer
with the ubiquitously expressed E12 protein [15, 16]. A phenotypic analysis of
homozygous TCF21 mouse mutants demonstrates that TCF21 plays an important role in
the formation of the spleen [18], kidney and lung [19], and is critical for sexual
differentiation [20]. Mice lacking TCF21 die in the perinatal period and show male-tofemale sex reversal [18-20]. TCF21 is one of the earliest genes expressed in the
mesodermal cells that later develop into the gonads [21]. TCF21 transcripts have been
identified in fetal and postnatal ovaries of mice, with the levels of TCF21 expression
increasing from 13.5 dpc to PND28 [21]. Although it has become clear that TCF21 is
essential for normal gonadogenesis, the detailed mechanism of its role in postnatal
ovaries remains unclear.
Biochemical and genetic analyses have demonstrated that TCF21 can act as a
transcriptional repressor [20-24]. It is the first bHLH protein suggested to act as a general
repressor of nuclear receptors [24]. A detailed analysis of its effect on the Androgen
Receptor (AR), another member of the nuclear receptor family, has suggested that TCF21
controls AR transcription and function [24]. A yeast two-hybrid screen of a mouse
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granulosa cell cDNA library performed by Dr. Deroo revealed a physical interaction
between ERβ (amino acids 1-254) and TCF21 (amino acids 23-149) (unpublished data).
To test the hypothesis that TCF21 represses ERβ-mediated transcription we
utilized transient transfection of immortalized cell lines in combination with reporter
assays. We also aimed to identify which regions of ERβ and TCF21 interact for this
repression to occur. In the present study we demonstrate that TCF21 represses ERβmediated transcription, which is, to the best of our knowledge the first evidence of a
bHLH transcription factor repressing the function of ERβ.

3.2 Materials and Methods
3.2.1

Cell Culture
HuH7 human hepatoma cells were maintained in Dulbecco’s Modified Eagle’s

Medium (DMEM; Wisent) supplemented with 5% (v/v) fetal bovine serum (FBS;
Wisent) and 1% (v/v) penicillin/streptomycin (P/S; Wisent). The HuH7 cells were a gift
from Dr. J. Matthews (University of Toronto). MCF7 human breast cancer cells (a gift
from Dr. J. Torchia, University of Western Ontario) and COS-7 African green monkey
kidney cells (a gift from Dr. J. Mymryk, University of Western Ontario) were both
cultured in DMEM supplemented with 10% FBS and 1% P/S. HEC1 cells derived from a
human endometrial adenocarcinoma were grown in McCoy’s 5a medium supplemented
with 10% FBS and 1% P/S. The HEC1 cells were a gift from Dr. B. Katzenellenbogen
(University of Illinois) The HEK293 human embryonic kidney cell line (a gift from
Dr. A. Babwah, Univerity of Western Ontario) was cultured in Minimal Essential
Medium (MEM; Wisent) with 10% FBS and 1% P/S. The KGN cells derived from a
human granulosa cell tumour were cultured in Dulbecco modified Eagle medium/F-12
(DMEM/F12; Wisent) supplemented with 10% FBS and 1% P/S. The KGN cells were
obtained from the RIKEN BioResource Center. The GFSHR-17 rat granulosa cell line
(obtained from Dr. A. Amsterdam, Weizmann Institute of Science) was grown in
DMEM/F12 with 5% FBS +1% P/S. All cell lines were maintained at 37°C in 5% CO2
and subcultured every 2–3 days or when cells reached 80% confluency.
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3.2.2

Transient transfection and reporter assays
HuH7 cells were seeded 24 h before transfection in 12-well plates at a density of

1.5x105 cells/well in phenol red-free DMEM supplemented with 5% charcoal-stripped
FBS (CS-FBS) and 1% P/S. Complete culture medium was freshly added 1 h before
transfection. HuH7 cells were transfected with “GenJet Reagent for HuH7 Cells”
(SignaGen) according to the manufacturer’s protocol; 0.8 µg plasmid DNA was added to
each well. Cells were transfected with 200 ng of receptor (pcDNA-hERβ), 500 ng of
reporter (3x-ERE-luc, pS2-Luc, C3-luc or Lf-Luc), 5 ng of the pRL-SV40 renilla
luciferase normalization vector, and either 200 ng bHLH expression plasmid (pCMVSPORT-TCF21 (hTCF21), pcDNA-Mist1 (Mist1) or E12-pCLBabe (E12)) or the empty
vector pcDNA3.1 to maintain the total amount of DNA constant per well. The pS2 and
Lf-luc were generous gifts from Dr. T. Teng and Dr. K. Korach, respectively
(NIH/NIEHS). The C3-ERE-luc reporter, TCF21 and E12 expression plasmids were
purchased from Addgene.org. The Mist1 expression plasmid was a kind gift from Dr.
C. L. Pin (University of Western Ontario). Transfections were performed in triplicate.
Twenty-four hours after transfection cells were treated with 10 nM (10-9 M) of 17βestradiol (estradiol) for 24 h. This dose was selected based on published studies in which
HepG2 liver hepatocellular carcinoma cells were treated with estradiol (ranging from 1011

to 10-4 M) and ERβ-specific induction of several promoters was investigated [2, 3].

Cells were then rinsed twice with PBS and 1X Passive Lysis Buffer (Promega) was added
directly to the culture plates. The plates were gently rocked for 15 min at room
temperature (RT) to ensure complete coverage of the cell monolayer. Luciferase assays
were performed using the Dual-Luciferase Reporter Assay System (Promega) according
to the manufacturer’s standard protocol, and each value was normalized to its Renilla
luciferase control. Fluorescence was measured using a Synergy H4 Microplate Reader
(Biotek).
HEC1, HEK293 and KGN cells were seeded 24 h before transfection in 24-well
plates at a density of 8 x 104 cells/well in phenol red-free culture medium (McCoy’s 5a,
MEM and DMEM/F12 respectively) supplemented with 10% CS-FBS. Transfections
were performed using FuGENE HD (Promega); 0.7 µg DNA was added to each well. A
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reagent:complex ratio (µl FuGENE HD:µg DNA) of 7:2 was used to transfect HEC1 and
HEK293 cells, and 5:2 to transfect KGNs. Cells were transfected with 90 ng hERβ, 500
ng reporter plasmid, 10 ng pRL-SV40 and 100 ng hTCF21 or pcDNA plasmid.
Treatments with estradiol and luciferase assays were performed as described above for
HuH7 cells.
MCF7 and COS7 cells were seeded 24 h before transfection in 6-well plates at a
density of 2.5x105 in phenol red-free DMEM with 10% CS-FBS. Both cell lines were
transfected using FuGENE 6 (Promega) according to the manufacturer’s protocol; a
complex of reagent and plasmid was prepared at a ratio of 3:1 (µl FuGENE 6:µg DNA)
with 1 µg DNA added per well. The amount of receptor plasmid, reporter plasmid and
TCF21/pcDNA plasmid transfected was consistent with the HuH7 protocol described
above. The lacZ expression plasmid pCMVβ (200 ng) was used as an internal
transfection control in these reporter assays. Twenty-four hours after transfection cells
were treated with 10 nM of estradiol for 24 h. Luciferase activity was assayed using the
Luciferase Assay System (Promega) and normalized to β-galactosidase activity
determined by X-gal staining.
All experiments were repeated a minimum of three times, and reproducible results
were obtained in independent experiments.

3.2.3

Cell extracts and Western blotting
Protein lysates from adult mouse tissues were generated by homogenizing tissues

in ice-cold radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl [pH 8.0],
150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 0.1% SDS) with a
protease inhibitor cocktail (1:100; Sigma) until the resulting lysate was completely
homogeneous. Lysates were incubated on ice for 20 min then clarified by centrifugation
(15 000 × g for 20 min at 4°C). Total cellular protein from adherent cells was isolated
using Pierce IP Lysis Buffer (Thermo Scientific) with 1X Halt Protease Inhibitor Cocktail
(Thermo Scientific), clarified by centrifugation (13 000 × g for 10 min at 4°C) and
quantified by DC Protein Assay (Bio-Rad).
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Protein extract was boiled in Laemmli Buffer for 5 min and separated by SDSPAGE (40 µg/lane) using a 12% gel. The separated proteins were then transferred to a
polyvinylidene difluoride membrane (PVDF; Roche) at 100V for 1 h at 4°C, and blocked
for 1 h at RT with 5% skim milk in Tris-buffered saline with Tween-20 (TBST).
Following washes with TBST, the membrane was incubated with anti-TCF21 antibody
(1:200 in 5% skim milk/TBST; Santa Cruz Inc. sc-15007) overnight at 4°C, then with a
peroxidase-conjugated anti-goat (1:10 000 in 5% skim milk/TBST; Santa Cruz) for 1 h at
RT. Immunoreactive bands were visualized using enhanced chemiluminescence reagent
(ECL Plus; Amersham Biosciences) and Hyperfilm (Amersham).

3.2.4

Coimmunoprecipitation
Optimization of coimmunoprecipitation assays was performed with HuH7, HEC1,

HEK293 and MCF7 cell lines. Cells were seeded 24 hours before transfection in 100 mm
dishes and transfected with 10 µg of DNA (hERβ, FLAG-ERβ, hTCF21, hERβ +
hTCF21, FLAG-ERβ + TCF21, hAR, hAR + hTCF21 or pcDNA3.1). The appropriate
transfection reagent for each cell line was used as described above. Transfected cells
were treated 24 and 48 hours later with 10 nM ligand (ERβ transfected cells with
estradiol, AR transfected cells with testosterone) for 24 and 48 hours.
We tested four lysis buffers to isolate cellular proteins: Radioimmunoprecipitation
assay (RIPA) buffer A (50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% Triton X-100,
0.5% sodium deoxycholate, and 0.1% SDS) supplemented with a protease inhibitor
cocktail (1:100; P8340; Sigma), RIPA buffer B (50 mM Tris-HCl [pH 7.5], 50 mM NaCl,
2.5 mM EGTA, 1% Triton X-100, 50 mM NaF, 10 mM Na4P2O7, 10 mM Na3VO4)
supplemented with a protease inhibitor cocktail (1:100; Sigma), Pierce IP Lysis Buffer
(Thermo Scientific) with 1X Halt Protease Inhibitor Cocktail (Thermo Scientific) and
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific). Cells
harvested with RIPA A or RIPA B Buffer were incubated for 20 (or 40 min) at 4°C with
gentle rocking, then scraped and transferred to a 1.5-mL microcentrifuge tube. Lysates
were then clarified by centrifugation (RIPA A: 15 000 × g for 20 min at 4°C; RIPA B: 23
000 × g for 20 min at 4°C). Pierce IP Lysis Buffer and NE-PER reagents were used
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according to the manufacturer’s protocol to isolate total cellular protein. Total protein
was quantified using the DC Protein Assay (Bio-Rad).
Whole cell lysate (500 µg) was incubated with 50 µl of 50% protein G Sepharose
Fast Flow (Sigma) slurry and one of the following antibodies [TCF21 (Abcam; ab32981);
TCF21 (Santa Cruz; sc-15007); ERβ (Abcam; ab16813); ERβ (Abcam; ab92306); ERβ
(Santa Cruz; sc-8974); AR (Santa Cruz; sc-815); FLAG (Sigma; F7425)] overnight,
rotating at 4°C. The following day, the beads were washed four to six times with lysis
buffer at 4°C, boiled in Laemmli Buffer for 5 min and separated by SDS-PAGE (50
µg/lane) using a 12% gel. The separated proteins were then transferred to a PVDF
membrane (Roche) and probed for coimmunprecipitated proteins. Because we were
attempting to optimize this protocol, we ran samples in duplicate whenever possible
which allowed us to also probe for the immunoprecipitated protein with its own antibody.
When this was not possible the single membrane was stripped and reprobed for the
immunoprecipitated protein. The protein bands were detected with an enhanced
chemiluminescence reagent (ECL Plus; Amersham Biosciences) and Hyperfilm
(Amersham).

3.2.5

Statistical analysis
Statistical analysis was performed using GraphPad Prism software. Data were

expressed as mean ± SEM. Statistical analysis was performed using one-way ANOVA
and Tukey’s post-hoc test with significances set at *p < 0.05, ** p < 0.01, *** p < 0.001
and **** p < 0.0001 as indicated.

3.3 Results
It has been reported that TCF21 is critical for sexual differentiation[20] and its
expression increases in the murine whole ovary from the embryonic to postnatal
stages[21]. Because ERβ is predominantly expressed in granulosa cells of the ovary we
sought to determine whether granulosa cells also express TCF21. I have confirmed by
Western blot that TCF21 is expressed in both primary mouse granulosa cells and in
several granulosa cell lines, as well as various cell lines of other tissue origin, and mouse
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tissues (Fig 3.1). HEK293 cells were transfected with hTCF21 expression plasmid to
serve as a positive control in Western blot analysis.

3.3.1

TCF21 is a novel transcriptional repressor of ERβ-mediated
transcription
The malignant liver cell lines HuH7[25] and HepG2[2, 3] are commonly used in

the literature to study ER transcriptional activity because they do not have functional
endogenous ER and therefore require exogenous ER to activate ERE-mediated
transcription. Therefore, we elected to use HuH7 cells for each of our assays. Taking into
account that different cell types will have different endogenous cofactors, we also used
other cell lines to determine whether the effect of TCF21 on ERβ transcriptional activity
is cell-line or cell type-specific.
To examine the possibility that TCF21 may modulate ERβ transcriptional activity
we performed transient transfections and luciferase assays. We utilized both ER negative
(HuH7 [25], HEC1 [26], COS7 [27], HEK293 [27]) and ER positive (MCF7 [high
endogenous ERα, lower levels of ERβ] [28], KGN [ERβ positive, ERα negative] [29])
cell lines for these assays. Cells were co-transfected with an ERβ expression plasmid, a
synthetic estrogen-responsive 3x-ERE (three copies of the vitellogenin estrogen response
element) firefly luciferase reporter vector, a renilla luciferase or LacZ normalization
vector and either hTCF21 or an empty vector. Because ERβ is a ligand-inducible
transcription factor the cells were then treated with 10 nM estradiol (E2) for 24 hours.
Luciferase assays were performed to determine the effect of TCF21 on ERβ-mediated
transcriptional activity.
HuH7 cells were initially transfected with an increasing hTCF21:ERβ ratio (1:1,
2:1, and 3:1) to optimize transfection efficiency. Surprisingly, increasing the amount of
TCF21 had no significant effect on ERβ-mediated transcription of the 3x-ERE luciferase
reporter, which contains three copies of the canonical estrogen response element (Fig
3.2). Therefore, the 1:1 ratio was used for subsequent experiments.
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Figure 3-1: TCF21 expression in cell lines and mouse tissues.
Whole cell extracts from adult mouse tissues (granulosa cells, testis, kidney and spleen)
as well as immortalized cell lines (HEK293, HEK293 transfected with a hTCF21
expression vector, KGN, KK1, GFSHR17, HEC1, MCF7 and HuH7) were analyzed by
Western blot to detect TCF21 protein expression.
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Figure 3-2: Effect of TCF21 on ERβ-mediated transcription.
HuH7 cells were transiently transfected with a 3x-ERE-luc reporter (200 ng), pRL-SV40
(5 ng) and increasing amounts of TCF21 expression plasmid (+, 200 ng; ++, 400 ng; +++,
600 ng). They were then treated with 10 nM estradiol (E2) (24 hours). Dual luciferase
assays were performed. Data are expressed as means ±SEM of three independent
experiments performed in triplicate. ****, p <0.0001; ns = not significant (one-way
ANOVA and Tukey’s post-hoc test). RLU, relative light unit.
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We have demonstrated that TCF21 represses ERβ transactivation of the 3x-EREluc reporter in six mammalian cell lines (Fig 3.3). The level to which E2 activates and
TCF21 inhibits ERβ-mediated transcription is cell-line dependent. The lowest level of
E2-induced activation was observed in the KGN cell line (Fig 3.3D), which is not
surprising because ERE-luc is poorly activated by E2 when either ER form is transfected
in KGN cells[29]. The relative level of repression by TCF21 is also low (33%), yet
significant. In all remaining cell lines we studied TCF21 represses ERβ-mediated
activation of the 3x-ERE-luc by at least 50%. TCF21 had no significant affect on ERα
transactivation (Fig S3.1).

3.3.2

TCF21 inhibits ERβ transactivation of naturally occurring
estrogen response elements
Estradiol does not activate transcription from all estrogen-responsive promoters in

an equivalent manner and studies have shown that the transcriptional activity of ER is
significantly affected by the nature of the target promoter [2]. Most naturally occurring
EREs are imperfect, non-canonical EREs; therefore we used three well-known naturallyoccurring estrogen-responsive promoters to determine if TCF21 would repress their
estrogenic activity. Specifically, we studied the lactoferrin (Lf), pS2 and complement 3
(C3) promoters. We tested these promoters in two ER negative cell lines – HuH7 and
HEC1; we elected to use these cell lines because the former is TCF21 positive, while the
latter does not express endogenous TCF21 (Fig 3.1). We have demonstrated that TCF21
represses ERβ-mediated transcriptional activity of all three natural estrogen-responsive
promoters; the extent to which TCF21 inhibits ERβ transactivation depended on the
nature of the response element as well as being cell-type dependent (Fig 3.4). TCF21 has
a significantly greater repressive effect on pS2 activation compared to the C3-ERE in
HuH7 cells. Lactofferin is neither activated upon E2 treatment, nor repressed when
TCF21 expression plasmid is co-transfected in HuH7 cells (Fig 3.4A). In HEC1 cells, the
relative level of repression by TCF21 is C3>pS2>Lf. Surprisingly, pS2 was not activated
by E2 treatment yet we still observed significant repression of the promoter by TCF21
(Fig 3.4B).
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Figure 3-3: TCF21 represses ERβ-mediated transcription of a 3x-ERE reporter.
Various cell lines were transiently co-transfected with an ERβ expression plasmid, a 3xERE firefly luciferase reporter vector, a renilla luciferase (A-D) or lacZ (E-F)
normalization vector, and either the TCF21 expression plasmid or empty vector
(pcDNA). The cells were then treated with 10 nM estradiol (E2) for 24 hours. Dual
luciferase assays were performed to determine ERβ-mediated transcriptional activity. All
values represent mean ±SEM of three separate experiments. *p<0.01; **p<0.01;
***p<0.001; ****p<0.0001 as determined by one-way ANOVA and Tukey’s post-hoc
test. RLU, relative light unit.
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Figure 3-4: TCF21 represses ERβ transactivation of natural estrogen-responsive
promoters.
HuH7 (A) and HEC1 (B) cell lines were transfected with ERβ expression plasmid, a
native estrogen-responsive promoter (C3, pS2 or Lf), a renilla luciferase normalization
vector, and either TCF21 or empty vector (pcDNA). The cells were then treated with 10
nM estradiol (E2) for 24 hours. Dual luciferase assays were performed to determine ERβmediated transcriptional activity. All values represent mean ±SEM of three separate
experiments. *p<0.01; ***p<0.001; ****p<0.0001 as determined by one-way ANOVA
and Tukey’s post-hoc test. RLU, relative light unit.
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3.3.3

ERβ transactivation is not inhibited by co-transfection with
Mist1, another Class II bHLH protein
To confirm that the repression of ERβ transactivation by TCF21 is specific, rather

than a broad response to co-transfection of ERβ with a Class II bHLH protein, we tested
the effect of another Class II bHLH transcription factor on ERβ-mediated transcription.
Mist1 is a bHLH transcription factor expressed in pancreatic acinar cells and other serous
exocrine cells. It represses myogenic differentiation by targeting the MyoD gene[30]. We
showed that Mist1 had no effect on ERβ-mediated transcription of the 3x-ERE reporter
(Fig 3.5), demonstrating that the repression we have observed by TCF21 is specific and
cannot be achieved by all Class II bHLH transcription factors.

3.3.4

Repression of ERβ transactivation by TCF21 does not
require E12
E12 is a Class I bHLH transcription factor that often heterodimerizes with Class II

bHLH transcription factors. TCF21 has previously been shown to transactivate promoters
alone or in combination with E12[15, 16, 24, 31]; therefore we tested whether E12 was
required for optimal TCF21-mediated repression of ERβ activity. We found that ERβmediated transactivation does not require TCF21 heterodimerization with E12 in this
model (Fig 3.6). Unlike TCF21, E12 alone enhanced the effect of E2 treatment on 3xERE-luc promoter activity. Interestingly, co-expression of E12 with TCF21 appeared to
antagonize the ability of TCF21 to repress ERβ-mediated estrogenic activity.

3.3.5

ERβ and TCF21 interaction
After successfully demonstrating that TCF21 represses ERβ-mediated

transcription in vitro, we next determined whether ERβ and TCF21 interact to form a
complex in vivo. Both proteins are localized in the nucleus [23, 32] and Dr. Deroo’s
previous yeast two-hybrid screen suggested that the repressive effect of TCF21 on ERβ
involved their physical association. Our objective was to assess their direct physical
interaction using both GST-pull-down analyses and co-immunoprecipitation (Co-IP)
experiments in TCF21 and ERβ-containing granulosa cell lines, with the ultimate goal of
testing their interaction in primary granulosa cells.
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Figure 3-5: Mist1 does not repress ERβ-mediated transcription of a 3x-ERE
reporter.
HuH7 cells were transfected with an ERβ expression plasmid, 3x-ERE firefly luciferase
reporter vector, a renilla luciferase normalization vector, and either an empty vector
(pcDNA), TCF21 or Mist1. The cells were then treated with 10 nM estradiol (E2) for 24
hours. Dual luciferase assays were performed to determine ERβ-mediated transcriptional
activity. All values represent mean ±SEM of three separate experiments. **p<0.011 as
determined by one-way ANOVA and Tukey’s post-hoc test. RLU, relative light unit.
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Figure 3-6: E12 is not required for TCF21 to repress transactivation of ERβ.
HuH7 cells were transfected with ERβ expression plasmid, 3x-ERE firefly luciferase
reporter vector, a renilla luciferase normalization vector, and either an empty vector
(pcDNA), TCF21 and/or E12. The cells were then treated with 10 nM estradiol (E2) for
24 hours. Dual luciferase assays were performed to determine ERβ-mediated
transcriptional activity. All values represent mean ±SEM of three separate experiments.
**p<0.01; ***p<0.001; ns, not significant, as determined by one-way ANOVA and
Tukey’s post-hoc test. RLU, relative light unit.
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Initial experiments focused on GST pull-down assays. However, we were unable
to successfully purify ERβ or its deletion mutants (data not shown). We next turned our
attention to Co-IP experiments. Our first objective was to optimize our protocol using the
previously described protocol that demonstrated the interaction between TCF21 and the
Androgen Receptor (AR) (Hong et al); however, we were unable to reproduce these data
primarily due to non-specific binding by the AR antibody (data not shown). Therefore we
proceeded to determine whether our proteins of interest, ERβ and TCF21, interact.
Despite our best efforts we were unable to produce evidence of TCF21-ERβ interactions
(data not shown). For over a year we tested a large variety of conditions including: four
cell lines, four lysis buffers, duration of cell lysis, duration of transfection and ligand
treatment, as well as numerous antibodies from different commercial sources. We were
unable to show interaction, regardless of which protein we used for the IP. The most
significant obstacle was the lack of a trusted ERβ antibody; all antibodies tested produced
inconsistent results, significant background and non-specific bands in Western blot
analyses [33]. We also attempted co-transfecting and detecting FLAG-ERβ without
success. Therefore, although we were able to successfully demonstrate TCF21 repression
of ERβ activity at the transcriptional level, we were unable to show they form a complex
in vivo.

3.4 Discussion
Nuclear receptors (NR) and basic helix-loop-helix (bHLH) proteins are two
superfamilies of transcription factors. The NRs regulate vital processes such as
reproduction, development and metabolism, while the bHLH factors are involved in
regulation of the cell cycle as well as many developmental processes. The interactions
between members of the NR and bHLH families allow for accurate expression of
downstream target genes.
Estrogens regulate many important physiological processes, including tissuespecific gene regulation in the reproductive tract. The biological responses to estrogens
are mediated by estrogen binding to one of two specific estrogen receptors, ERα or ERβ.
Both ERs are expressed in the body, yet there are considerable differences in their tissue
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distribution [34]. Within the ovary ERβ is restricted to the granulosa cells, whereas ERα
is expressed in the thecal cells [8]. Granulosa cells are responsible for estradiol synthesis,
nourish the oocyte throughout folliculogenesis and are essential for its growth. Therefore,
the function of ERβ in granulosa cells during follicle development has to be tightly
regulated for proper ovarian function. As a member of the NR superfamily, ERβ
regulates gene expression by binding to an estrogen response element and/ or by forming
protein-protein complexes with other transcription factors.

3.4.1

TCF21 is a repressor of ERβ-mediated transcription
In this study, we investigated the role of the bHLH transcription factor TCF21 in

regulating transcription of estradiol target genes. Our promoter assays in numerous
mammalian cell lines demonstrated that TCF21 has an ER isoform-specific affect in
regulating estradiol-dependent transcriptional activity. We observed significant
repression of ERβ transactivation of the synthetic 3x-ERE promoter as well as three ER
target genes that contain imperfect EREs (C3, pS2 and Lf), however, we saw no impact
on ERα-mediated transcription. To our knowledge, this is the first bHLH transcription
factor identified to act as a specific co-repressor of ERβ.
TCF21 has previously been reported to exert inhibitory effects on gene
expression[20-24] and shown to associate with repressor complex proteins [35]. The
transactivation property of TCF21 was first analyzed using the Gal4 fusion system, which
found that TCF21 exhibits repressive activities in HepG2 cells from its C-terminal and Nterminal domains; constructs that include either of these domains retained repression
activity, while the bHLH domain alone had no activity [22]. Conversely, transactivation
activities in HT1080 and HeLa cells were only observed when constructs retained the Cterminal domain. It is suggested that this dual function of the C-terminal domain may be
cell-type dependent, likely a result of specific coactivators and corepressors [22].
Interestingly, we found that the repression by TCF21 on ERβ-mediated transcriptional
activity is not cell-type dependent.
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3.4.2

TCF21 does not dimerize with E12 to repress ERβ-mediated
transcription
TCF21 has previously been shown to interact with other bHLH transcription

factors – E12 (TCF3), HEB (TCF12) and E2-2 (TCF4) [36]; E12 is the most likely Class
I bHLH to heterodimerize with TCF21. We found that E12 does not improve the ability
of TCF21 to repress ERβ transactivation; rather E12 acts as a coactivator and interferes
with TCF21 repression. In this system E12 may be inhibiting the ability of TCF21 to bind
an E box or preventing its interaction with ERβ. We cannot exclude the possibility that
TCF21 heterodimerizes with another Class I bHLH to repress the activation of estradiol
target genes.

3.4.3

Future studies
Many studies have focused on the molecular mechanisms that regulate the

transcription of the ERα gene [37-39]; however, the mechanisms that regulate the ERβ
gene remain largely unclear. Fujimoto et al. identified good homology between the
human, mouse and rat ERβ promoters (80% identity between positions −1 and −550
between the rat and mouse, and 69% identity between −30 and −110, as well as −300 and
−400 between the rat and the corresponding section of the human promoter) [40], and an
evolutionarily conserved E box in the 5’ promoter region of ERβ exists which has
previously been shown to bind the bHLH-zip factor USF [40, 41]. The presence of an EBox does not imply that it will be active for all bHLH proteins. However, considering
TCF21 has previously been shown to act as a transcriptional repressor, including a
repressor of the nuclear receptor AR, it may also function as a negative transcriptional
regulator of the ERβ gene by binding to the E-Box within the ERβ promoter. In future
studies it may be of interest to perform chromatin immunoprecipitation (ChIP) assays and
determine whether TCF21 is recruited to the E-Box found in the ERβ promoter. If TCF21
and ERβ form a complex in vivo, further ChIP and GST-pulldown assays could be used
to investigate the potential involvement of histone deacetylases (HDACs), well
understood downstream recruits of corepressors that are often found within a repressor
complex [11].
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3.4.4

Limitations of study
The yeast two-hybrid screen suggests that the functional interaction we have

observed between TCF21 and ERβ involves their physical association. Our objective was
to identify what regions of ERβ and TCF21 interact using GST-pulldown assays;
however, our attempts to purify GST-tagged ERβ and ERβ deletion mutants did not yield
a detectable product. We also attempted to utilize Co-IP analysis to determine whether
these proteins form a complex in vivo. In spite of our best efforts, testing numerous
conditions and variables, we were unable to optimize the Co-IP protocol and confirm an
ERβ/TCF21 complex. The most significant obstacle was the lack of a reliable ERβ
antibody, an appreciated issue in the ERβ field [33, 42]. We also tried transfecting a
FLAG-tagged ERβ into HuH7 and HEK293 cells to circumvent the need for an ERβ
antibody. Unfortunately, we were unable to produce reliable results with a FLAG
antibody as well. Despite our best efforts, we were disappointed with inconsistent results.

3.4.5

Potential mechanisms by which TCF21 inhibits ERβ
transactivation
Since we were unable to obtain results from our Co-IP experiments due to the

lack of a reliable ERβ antibody, we were also unable to conclusively determine whether it
is by a passive or active mechanism that TCF21 inhibits ERβ transactivation. Therefore,
we are proposing two potential mechanisms by which TCF21 may be acting as a
corepressor. The first is a classic mechanism of transcriptional repression whereby a
repression complex is formed and recruited to a target gene promoter. The second is
based on a mechanism recently proposed for repression of ERα transcriptional activity
[43]. 1) In the absence of TCF21, ERβ is recruited to the ER-target gene promoter upon
ligand binding and target gene transcription is initiated. When TCF21 is expressed, it is
recruited together with ERβ once ligand is introduced. Upon ligand binding, a
TCF21/ERβ complex is formed and ERβ activity is inhibited. 2) Alternatively, TCF21
and ERβ could both be present on the ER-target gene promoter in the absence of ligand.
Once ligand is introduced and ERβ is activated, TCF21 gradually is released from the
promoter as more ERβ is recruited, and target gene transcription begins. Consequently,
when we over-express TCF21 in promoter assays, more TCF21 remains bound to the ER-
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target gene promoter, out-competing ERβ, and repression of ERβ transcriptional activity
is observed.

3.4.6

Conclusions
We have demonstrated that TCF21 regulates estradiol-dependent transcriptional

activity in an ER isoform-specific manner; TCF21 represses ERβ, but not ERα
transactivation. Further studies with cell type-specific knockout of TCF21 in granulosa
cells would allow for analysis of its role and its mechanism in the development and
function of the granulosa cells and the ovary. Once a trusted antibody for ERβ is
identified, it would be greatly beneficial to not only determine the interaction between
TCF21 and ERβ in cell lines, but also in primary granulosa cells.
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Figure S3-1: TCF21 does not repress ERα transactivation.
HuH7 and MCF7 cell lines were transfected with ERβ expression plasmid, 3x-ERE
firefly luciferase reporter vector, a renilla luciferase normalization vector, and either
TCF21 or empty vector (pcDNA). The cells were then treated with 10 nM estradiol (E2)
for 24 hours. Dual luciferase assays were performed to determine ERβ-mediated
transcriptional activity. All values represent mean ±SEM of three separate experiments.
No significance was found by one-way ANOVA and Tukey’s post-hoc test. RLU,
relative light unit.
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Chapter 4

4

Characterization of the extracellular matrix protein
Spondin 1 and its function in immortalized ovarian
cancer cell lines and primary ascites-derived cancer
cells

4.1 Introduction
Ovarian carcinoma is the most lethal gynaecological malignancy, and the fourth
most common cause of female cancer death, in the world [1]. Despite modern
management the prognosis remains poor, with a five-year survival rate of 45% after
initial diagnosis [2]. The prognosis is more favourable for patients with stage I/II
tumours; however, most patients present with advanced disease (III/IV) [1].
Ovarian cancer is a heterogeneous disease [3]. Epithelial ovarian tumours are
classified as serous, clear cell, endometrioid, and mucinous subtypes. Each subtype is
correlated with different genetic risk factors and molecular events during oncogenesis [4],
and each has a characteristic mRNA profile [5, 6]. Serous ovarian cancer represents
approximately 70% of epithelial ovarian cancers (EOC) [7]. The most aggressive
subtype, high-grade serous ovarian carcinoma, accounts for 90% of serous cancers, twothirds of all EOC deaths, and it is the most studied subtype [8].
Metastasis of EOC is unique because unlike most solid tumours, ovarian cancer
rarely disseminates through the vasculature; rather malignant cells spread from the
primary tumour into the peritoneal cavity [9]. The peritoneal cavity accumulates ascites
fluid containing malignant single EOC cells or EOC aggregates called spheroids [10].
The successful adhesion of these cells to the surfaces of abdominal organs is a key step
controlling ovarian cancer metastasis and the formation of secondary tumours [9].
Many of the same cellular processes and behaviours that are necessary for normal
tissue development are also essential for cancer progression. An example of such a
process is remodelling of the extracellular matrix (ECM), which is closely regulated
during normal development. When these remodelling pathways fail, cells can grow
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uncontrollably, such that changes to the ECM composition can occur and tumours
develop [11]. Another important aspect of cancer progression is the tumour
microenvironment, which is composed of ECM proteins, fibroblasts and endothelial cells
[12]. The tumour microenvironment can have a direct effect on cell proliferation,
migration and differentiation through secreted proteins, cell–cell interactions and ECM
remodelling [12].
Ovarian cancer cells are able to adjust the type and amount of ECM proteins they
produce and secrete into their microenvironment, which can result in both stimulatory
and inhibitory affects on tumour development [13]. The ECM is in direct contact with the
tumour cells, thereby providing factors involved in growth, survival, motility, and
angiogenesis, which affect the progression of the tumour [11, 14]. Furthermore, cell
adhesion to the ECM through integrins and other cell surface receptors initiates signalling
pathways, that are involved in regulating migration and differentiation [14]. ECM
components can also contribute to tumour dormancy and enhance chemotherapy
resistance [11, 15]. Therefore, as a key component of the tumour niche, the ECM is
essential at various stages of tumourigenesis, and it may serve as a rate-limiting step in
cancer progression and provide a potential target for therapeutics.
Spondin 1 (SPON1), also referred to as F-Spondin and vascular smooth muscle
cell growth-promoting factor (VSGP), is a secreted ECM protein that was originally
identified in the mouse embryonic floorplate [16]. SPON1 is a member of the diverse
thrombospondin type 1 repeat superfamily, and possesses six C-terminal thrombospondin
repeats (TSRs), an N-terminal reeler domain, and a spondin domain [16, 17]. The reeler
domain is homologous with a domain in Reelin, a protein involved in neuronal migration
[16, 18]. The spondin domain is homologous with regions in Mindin, a secreted protein
and member of the thrombosondin type 1 family that binds to the ECM [16, 18, 19].
SPON1 has been primarily studied for its role in the central nervous system
(CNS), where it regulates migration of neurons during embryonic development and cell
adhesion in many cell types of the CNS [17, 19-22]. Apart from neuronal tissues, SPON1
has been shown to affect differentiation, proliferation and migratory functions in other
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tissues. SPON1 localizes to integrin-containing tissues and basement membranes in C.
elegans, coupling with integrins to maintain ECM adhesion [23]. SPON1 promotes
growth of vascular smooth muscle cells [24] and increases cell survival of murine
neuroblastoma [25]. It promotes the differentiation of chondrocytes [26], a human
cementoblast-like cell line (HCEM) [27], and inhibits differentiation of osteoclastic
precursors [28]. It has also been shown to promote the migration and invasion of
osteosarcoma cells in vitro [29], and to inhibit the migration of HUVECs [30] and
HCEMs [27].
SPON1 isolated from bovine follicular fluid has growth promoting properties
[24], and our laboratory has recently demonstrated that SPON1 regulates steroidogenesis
and increases proliferation of ovarian granulosa cell lines in vitro (unpublished data).
Interestingly, Spondin 1 mRNA expression is higher in ovarian tumours than in normal
ovarian tissues [31]. Furthermore, a recent study involving an extensive screen of ovarian
carcinomas from 500 patients has suggested SPON1 is a promising biomarker for ovarian
cancer, particularly high grade serous EOC, and a potential target for cancer
immunotherapy [32]. However, the functional role of SPON1 in ovarian cancer cells has
yet to be examined.
We hypothesized that SPON1 regulates properties essential for the progression
and metastasis of epithelial ovarian cancer cells. Herein, we used EOC cell lines and
primary ascites-derived ovarian cancer cells to examine the effect of exogenous
recombinant human SPON1 on the adhesion, migration, viability and proliferation of
ovarian cancer cells.

4.2 Materials and Methods
4.2.1

Culture of cell lines and ascites-derived cells
All experiments described below were performed in three established ovarian

cancer cell lines: OVCAR3, OVCAR8 and HEY. OVCAR3 and OVCAR8 cells were
originally established from the ascites fluid of patients with progressive adenocarcinoma
that had prior chemotherapy treatment30. The HEY cell line is derived from a human
ovarian cancer xenograft originally grown from a peritoneal deposit of a patient
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diagnosed with moderately differentiated cystadenocarcinoma of the ovary31. Our
preliminary studies also included the OVCAR5 and OVCA429 EOC cell lines.
OVCA429 cells were cultured in Alpha Modified Eagle Medium (Wisent) supplemented
with 5% (v/v) fetal bovine serum (FBS; Wisent), 1% (v/v) penicillin/streptomycin (P/S;
Wisent) and 1x non-essential amino acids (Invitrogen). The remaining four cell lines
were cultured in RPMI-1640 supplemented with 5% FBS and 1% P/S. All cell lines were
a generous gift from Dr. T. Shepherd and Dr. G. DiMattia (University of Western
Ontario).
Work with patient materials was approved by The University of Western Ontario
Health Sciences Research Ethics Board and coordinated with Dr. Trevor Shepherd of the
Translational Ovarian Cancer Research Group. Dr. Shepherd and Dr. Gabriel DiMattia
generously provided all primary ascites cell cultures, collected from patients with
advanced stage (III or IV) high-grade serous epithelial ovarian cancer. Patient cultures
were generated from ascites fluid collected from patients at the time of paracentesis or
debulking surgery. Patient EOC samples were cultured in Dulbecco Modified Eagle
Medium/F12 (Wisent) supplemented with 10% FBS and 1% P/S. Fresh media was
replaced every other day. All experiments with primary EOC cells were performed
between passages 3 and 5. All cells were maintained at 37°C in 5% CO2 and subcultured
when cells reached 80% confluency.

4.2.2

Cell extracts and secreted protein concentration
Total cellular protein from adherent cells was isolated using Pierce IP Lysis

Buffer (Thermo Scientific) with 1X Halt Protease Inhibitor Cocktail (Thermo Scientific).
Lysates were clarified by centrifugation (13 000 × g for 10 min at 4°C) and quantified by
DC Protein Assay (Bio-Rad).
Protein isolation from media: Conditioned media from cell lines and patient
samples was concentrated using ultrafiltration columns (30K Amicon Ultra-0.5 mL
Centrifugal Filters; Millipore). Prior to concentration of medium, cells were cultured as
follows. Cells were plated in T25 flasks in complete medium and grown to 80%
confluency. The cells were then rinsed twice with serum- and antibiotic-free medium to
ensure that excess albumin from high serum was eliminated. Otherwise, the high albumin
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levels during media concentration result in the formation of a gel and clogging of the
Amicon columns. Fresh media with lower (0.1% FBS) or no serum was then added.
Conditioned medium from cell lines was collected 24 and 48 h after the media change
(1 ml at each time point). Conditioned medium from primary EOC samples was collected
after 48 h only. Samples were centrifuged at 10 000 x g for 5 min at room temperature
(RT) to remove cell debris prior to concentration. Amicon columns were used according
to the manufacturer’s protocol. Briefly, media was centrifuged twice at 14 000 x g for 10
min to concentrate the conditioned media (500 µl loaded onto the same column twice),
followed by a final spin of 1000 x g for 10 min to recover the concentrated sample into a
fresh microcentrifuge tube.

4.2.3

Western blotting
Protein extracts and concentrated media samples were boiled in Laemmli Buffer

for 5 min and separated by SDS-PAGE (40 µg/lane and 20 µl/lane, respectively) using a
8% gel. The separated proteins were then transferred to a polyvinylidene difluoride
membrane (PVDF; Roche) at 100V for 2 h at 4°C, and blocked for 1 h at RT with 5%
skim milk in Tris-buffered saline with Tween-20 (TBST). Following washes with TBST
the membrane was incubated with anti-SPON1 antibody (1 µg/ml in 5% skim
milk/TBST; Abcam ab40797) overnight at 4°C, then with a peroxidase-conjugated antirabbit (1:10 000 in 5% skim milk/TBST; Santa Cruz) for 1 h at RT. Immunoreactive
bands were visualized using enhanced chemiluminescence reagent (ECL Plus; Amersham
Biosciences) and Hyperfilm (Amersham). The membrane was re-probed with anti-actin
antibody (1:5000; Sigma A2668) overnight at 4°C, followed by incubation with
peroxidase-conjugated anti-rabbit, and visualized as described for SPON1.
Additional antibodies used: anti-WNK-1 (1:1000; Abcam ab53151), anti-phospho-WNK1 (1:500; Cell Signalling Technology 4946S) and anti-p53 (1:1000; Cell Signalling
Technology 9282).

4.2.4

Cell viability assay
Cell viability was assessed using the MTS CellTiter 96®AQueous One Solution

assay (Promega), which detects the activity of NAD(P)H-dependent cellular

161

oxidoreductase enzymes, and serves as a measure of the relative number of viable cells.
Each of the five ovarian cancer cell lines was seeded at 1.0 x 103 cells/well in 1% FBScontaining medium onto 96-well plates. Two hours (h) later the cells were treated with
5 µg/ml human recombinant SPON1 (R&D Systems 3135-SP) or 250 µg/ml BSA
(BioShop) vehicle control. At a series of time points (24, 48 and 72 h after treatment),
20 µl of MTS reagent was added to each well, and the cells were incubated at 37°C for
2 h. Following incubation, the plate was shaken and the absorbance was measured at 490
nm using a microplate reader (Synergy H4 Microplate Reader; Biotek).
Cell viability was similarly assessed in patient samples using the MTS assay, with
minor changes: 2.5 x 103 cells/well were seeded in 10% FBS-containing medium, and the
MTS assays were performed on Days 2, 4 and 6 after recombinant SPON1 treatment.

4.2.5

Cell proliferation assay
Cell proliferation assays were performed in parallel with the Cell Viability

Assays. The five established cell lines were seeded in triplicate (6.0 x 103 cells/well) in
1% FBS-containing medium in 24-well dishes and treated 2 h after seeding with human
recombinant SPON1 (5 µg/ml) or a BSA (250 µg/ml) control. Cell counts were
performed using the Coulter counter (Beckman Coulter) 24, 48 and 72 h after treatment;
each cell suspension was counted in triplicate. Cell growth assays for patient samples
were performed in parallel with the MTS assays; however, 6.0 x 103 cells were seeded in
96-well dishes in 10% FBS-containing medium (rather than 1% FBS for the cell lines).

4.2.6

Cell detachment assay
OVCAR3, OVCAR5 and OVCAR8 (3 x 104/well), HEY and OVCA429

(2 x 104/well) cells were seeded into 96-well plates and treated with carrier-free
recombinant SPON1 (R&D Systems 3135-SP/CF) (1 µg/ml, 5 µg/ml or 10 µg/ml) or
vehicle. After 48 h cells were detached first using weak trypsin (0.06% trypsin/EDTA)
and counted using the Coulter counter [33]. Because we found that each cell line adhered
with different strengths to the tissue culture surface, we optimized the length of time that
each cell line was incubated in 0.06% trypsin so that 10-50% of cells detach yet no more
than half of the total cells on the plate. The remaining cells were completely detached
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from the culture dishes using full trypsin (0.25% Trypsin/EDTA) and counted using a
Coulter counter. Cell adhesion was scored as the percentage of cells detached with 0.06%
trypsin. Each experiment was conducted using three technical replicates; each experiment
was carried out three times.
The cell detachment assay was performed in patient EOC samples as described
above, except that 1 x 104 cells were seeded per well in 10% FBS-containing medium.
All primary EOC cells were incubated with 0.06% trypsin/EDTA for 1 min.

4.2.7

Cell adhesion assay
96-well plates were incubated with increasing amounts (250 ng, 500ng or 1µg) of

the following protein solutions for 12 h at 4°C: carrier-free recombinant SPON1, laminin
or poly-L-lysine (positive control) or PBS (no coating control), to coat the wells with the
specified proteins. After 12 h of incubation, the protein solution was aspirated and the
plate air-dried at RT in the tissue-culture hood overnight. The following day, cells that
had been serum starved for 12 h were seeded (2 x 104 cells/well) in serum-free media on
the immobilized protein substrate and incubated at 37°C. After one hour, non-adherent
cells were removed using gentle washes with a multi-channel pipettor, and full media
replaced to allow adhered cells to recover from the serum starvation. After 4 h of
recovery, 20 µl of the MTS CellTiter 96®AQueous One Solution assay substrate (Promega)
was added and the absorbance determined 2 h later (490 nm) using a microplate reader
(Synergy H4 Microplate Reader; Biotek), which provided a relative measure of the
number of adherent cells on the different protein substrates.

4.2.8

Spheroid formation and reattachment assays
Spheroid formation assays: Ultra Low-Attachment (ULA) plates (Corning) are

commercially-purchased tissue culture plates that are coated with a hydrophilic, neutrally
charged hydrogel to prevent cell attachment. Single-cell suspensions of HEY, OVCAR8
and OVCAR3 cells (5 x 104 cells/ml) were seeded onto ULA plates, and spheroids
formed over time [34]. To determine whether SPON1 affects the formation of spheroids,
cells were treated with recombinant SPON1 (10 µg/ml) or vehicle control (in triplicate) at
the time of seeding. Spheroid formation was visualized after 24, 48 and 72 h and images
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captured at the centre of each well. After 3 days in culture the spheroids were collected
and re-plated onto 6-well tissue culture dishes with fresh growth medium, and allowed to
reattach. Once re-attached the cells were fixed and stained using the HEMA-3 stain kit
(Fisher). Phase contrast images of re-attached spheroids were captured using an Olympus
IX70 inverted microscope and ImagePro software.
Spheroid reattachment assays: To determine whether SPON1 affects spheroid
reattachment, spheroids were first formed on ULA plates for 3 days as described above,
with the notable exception that cells were not treated with recombinant SPON1 at the
time of seeding. HEY, OVCAR8 and one primary EOC sample (EOC 272) were used.
Individual spheroids were collected, transferred onto 48-well dishes and treated with
10 µg/ml recombinant SPON1 (or vehicle control) at the time of spheroid re-plating.
Phase contrast images of reattaching spheroids were taken prior to dispersion (3 h after
re-plating) as well as 24 h (HEY and primary sample EOC 272) and 48 h (OVCAR8)
following re-plating. Reattached spheroids were fixed and stained using the HEMA-3
stain kit (Fisher). Phase contrast images were captured using an Olympus IX70 inverted
microscope and ImagePro software. Spheroid dispersion was quantified using the area
measurement tool in ImageJ (NIH). Dispersion area at 24 h/48 h was calculated as a
percentage of the original spheroid size at 3 h.

4.2.9

Cell migration assay
We utilized Transwell filters (8 µm pore size) (Corning) placed in 24-well plates

to determine whether SPON1 affects cell motility. Cells were seeded in the upper
chamber of a transwell dish in 0.5% FBS-containing medium, ± 5 µg/ml of SPON1. The
bottom chamber was filled with 0.5% FBS-containing medium, 10% FBS-containing
medium (positive control) or 5µg/ml SPON1 in 0.5% FBS-containing medium. After
24 h, cells that had not migrated through the membrane were gently removed from the
membrane using a cotton swab. The remaining cells were fixed with 4%
paraformaldehyde, and the nuceli of migrated cells stained using 4',6-diamidino-2phenylindole (DAPI). Six random fields of view per membrane were imaged with an
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Olympus IX70 inverted microscope and ImagePro software, and the nuclei counted. Each
experiment was performed in triplicate.

4.2.10 Chemotaxis assay
We used the ibidi µ-Slide Chemotaxis2D system to determine whether SPON1
may act as a chemoattractant or a chemorepellant. HEY cells were seeded according to
the manufacturer’s protocol. Briefly, cells were diluted to a concentration of 3 x 106/ml.
6 µl of cell suspension was applied to one filling port of the µ-Slide, after which 6 µl of
air was aspirated from the opposite filling port. This procedure flushed the cell
suspension through the observation channel. The slides were maintained at 37°C in 5%
CO2 in a moist chamber (a 10 cm dish lined with damp Kimwipes [Kimtech]) until the
cells attached. To conduct the chemotaxis experiment each chamber was first filled with
80 µl medium supplemented with 0.5% FBS (without test reagent) or 10% FBS (positive
control). One chamber previously filled with 0.5%-containing medium was then filled
with 18 µl of 50 ng/µl SPON1 solution. The cells were tracked over time by capturing
images at a series of time points using an Olympus IX70 inverted microscope and
ImagePro software.

4.2.11 siRNA transfections
All siRNA transfections were performed in 6-well tissue culture dishes. The day
before transfection, cells were plated at a density of 1 x 105 cells per well (OVCAR8 and
HEY) or 2 x 105 cells per well (OVCAR3) in antibiotic-free media. The following day,
Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) was used to
transfect cells according to the manufacturer’s protocol. A set of three predesigned
SPON1 Stealth Select RNAi™ siRNA oligos was tested (siRNA 1: HSS115946,
siRNA 2: HSS173622, siRNA 3: HSS115945) (Invitrogen). Briefly, for each well we
diluted 4 µl of RNAiMAX in 196 µl Opti-MEM (Thermo Fisher Scientific) and 2 µl
siRNA in 198 µl Opti-MEM. The diluted siRNA was added to diluted RNAiMAX and
incubated for 5 min at RT. The siRNA-lipid complexes were then added directly to each
well. Media was replaced 24 h after transection with fresh growth media. The cells were
harvested 48 h and 72 h post transfection, and lysates prepared for Western blot analysis
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as described above using Pierce IP Lysis Buffer (Thermo Scientific) with 1X Halt
Protease Inhibitor Cocktail (Thermo Scientific). Densitometric quantification was carried
out using ImageJ software. SPON1 expression was calculated relative to a β-actin
control.

4.2.12 Functional blocking with antibody
To identify potential function blocking antibodies against SPON1, we utilized the
Detachment Assay and Viability Assay protocols described above. For these assays, we
used four antibodies that we had previously found to detect SPON1 by Western blot
analysis (C-16, N-19, S17 from Santa Cruz and ab40797 from Abcam) were tested.
Detachment assay: Briefly, HEY cells were seeded as for the Detachment Assays
described (Methods – 4.2.6), and diluted antibodies (1µg/ml), vehicle control or SPON1
(5µg/ml) were added at the time of seeding. Each of the three Santa Cruz antibodies
detects a different fragment of SPON1 therefore they were combined together and the
treatment referred to as the Santa Cruz cocktail (SCC). After 48 h cells were detached
with weak trypsin (0.06%), then full trypsin (0.25%) and counted as described above.
Viability assay: Functional blocking of SPON1 was also attempted with the
Viability Assay protocol. HEY cells were plated as before (Methods – 4.2.4), and diluted
antibodies (1 µg/ml and 10 µg /ml), vehicle (250 µg/ml BSA) or SPON1 (5 µg/ml) were
added 2 h after seeding. MTS assays were performed as described above: 24, 48 and 72 h
following treatments.
The effects of SPON1-antibodies on detachment and viability were determined by
using wells with no added antibodies as reference.

4.2.13 Phospho-kinase array
To screen for potential downstream targets of SPON1 in EOC cell lines we used
the Human Phospho-Kinase antibody array (R&D Systems), which simultaneously
detects the relative levels of phosphorylation of 43 kinases or their targets. OVCAR3 and
HEY cells were cultured as described above (see Culture of cell lines section) in 10 cm
dishes. Upon reaching 80% confluency the cells were serum starved for 12 h, then treated
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with 5 µg/ml SPON1 or 250 µg/ml BSA (vehicle) for 15 min. This time point was
selected based on published studies [25, 35] in which cultured cells were treated with
recombinant SPON1 and SPON1-induced kinase activation was observed 10-30 minutes
after treatment. Cell lysates (100 µg OVCAR3 and 350 µg HEY protein lysate) were
applied to the phospho-kinase array and the blots developed according the manufacturer’s
instructions. Spot intensities were quantified using ImageJ software (National Institutes
of Health).

4.2.14 Statistical analysis
Graphs were generated and statistical analysis was performed using GraphPad
Prism software. Data were expressed as the mean ± SD. Statistical analysis was
performed using Student’s t-test or Analysis of Variance (ANOVA) and Tukey’s
Multiple Comparison Test with significances set at *p < 0.05, ** p < 0.01, *** p < 0.001
and **** p < 0.0001 as indicated.

4.3 Results
SPON1 is abundantly expressed in the ovary relative to other tissues in both
human and mouse (Figure 4-1). Furthermore SPON1 is highly overexpressed in ovarian
cancer and has been identified as a promising ovarian cancer biomarker [31, 32].
Therefore, herein, we investigated the functional role of SPON1 in ovarian cancer cells.
Ovarian cancer is a heterogeneous disease and many ovarian cancer cell lines are
used as in vitro models in cancer research. Some of the most commonly used cell line
models for high grade serous ovarian carcinoma (HGSC), particularly SKOV3 and
A2780, are poor models for the disease as they do not accurately represent the molecular
profiles of HGSC tumour samples[36]. The five epithelial ovarian cancer (EOC) cell
lines we used in this study – OVCAR3, OVCAR5, OVCAR8, HEY and OVCA429 –
more closely resemble tumour profiles [36]. We also utilized eight primary human EOC
samples (EOC181, EOC183, EOC193, EOC196, EOC 200, EOC208, EOC25 and
EOC272) generously provided by Dr. Shepherd and Dr. DiMattia. Carcinoma cell lines
remain a fundamental tool in pre-clinical research; however the ascites-derived primary
EOC cells provide greater clinical relevance. The ascites-derived EOC cells can only be
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cultured for approximately three weeks and are relatively slow growing [37]. Therefore,
due to the limited source material, we selected a few key functional assays to determine
the effect of SPON1 on the primary EOC cells.

4.3.1

EOC cell lines and primary human EOC cells express and
secrete SPON1
Spon1 mRNA expression is elevated in ovarian tumour tissues compared to the

healthy ovary[31]. We first investigated whether our cell lines of interest and primary
human EOC cells endogenously express SPON1 protein. Two granulosa cell lines, the
human granulosa cell-like cell line, KGN[38] and the KK-1 cell line, an immortalized
mouse ovarian granulosa cell line [39] were used as positive controls with the EOC
samples because our laboratory has previously demonstrated that both cell lines express
SPON1 protein as determined by Western blot. I found that, as expected, both KGN and
KK-1 cell lines expressed SPON1 (Figure 4-2A-i) as determined by Western blot.
Similarly, SPON1 was robustly expressed in all EOC cell lines (Figure 4-2A-i) and
primary EOC samples (Figure 4-2B-i).
SPON1 is a secreted ECM glycoprotein[16]; therefore we next investigated
whether the cell lines and primary EOC samples secreted SPON1 into the culture
medium. SPON1 was recovered from the conditioned medium of cell cultures using
centrifugal concentrators. The concentration of albumin in cell culture medium is
typically high because of the presence of FBS; concentration of supernatant with a high
albumin concentration will result in the formation of a gel and clogging of the
concentration columns. To avoid this technical difficulty, cells were incubated in serumfree medium and reduced serum (0.1% FBS).
SPON1 was detected in conditioned medium from all five EOC cell lines after
24h. The level of secreted SPON1 increased over time, as higher SPON1 expression was
observed after 48 h (Figure 4-2A-ii). Consistent with the cell line data, we found that
primary EOC cells also secreted SPON1 into the medium (Figure 4-2B-ii). Due to the
slower proliferation of primary cells, we only incubated them in reduced-serum and
collected medium after 48 h.
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Figure 4-1: SPON1 expression in human and mouse tissues.
A) A human tissue INSTA-Blot™ was incubated with an anti-Spondin 1 antibody to
detect SPON1. Lanes: 1) Brain; 2) Heart; 3) Small Intestine; 4) Kidney; 5) Liver; 6)
Lung; 7) Muscle; 8) Stomach; 9) Spleen; 10) Ovary; 11) Testis. Amido black staining as
a control (bottom). B) A mouse tissue INSTA-Blot™ was incubated with an anti-SPON1
antibody to detect SPON1. Lanes: 1) Brain; 2) Heart; 3) Small Intestine; 4) Kidney; 5)
Liver; 6) Lung; 7) Muscle; 8) Stomach; 9) Spleen; 10) Ovary; 11) Testis. Amido black
staining as a control (bottom).
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Figure 4-2: SPON1 is expressed and secreted by EOC cell lines and primary human
EOC cells.
A) (i) Western blot analysis of SPON1 expression in five EOC cell lines: OVCAR3,
OVCAR5, OVCAR8, HEY and OVCA429. KGN, human granulosa cell tumour cell line,
and KK1 mouse granulosa cell line were used as positive controls. β-actin was used as a
loading control.
(ii) Western blot analysis of SPON1 in conditioned media of EOC cell lines (HEY,
OVCAR8, OVCAR3, OVCAR5, OVCA429). Conditioned media was collected after
cells were in culture for 24 h and 48 h, in media supplemented with 0% FBS or 0.5%
FBS. OVCAR3 cell lysate was a positive control.
B) (i) Western blot analysis of SPON1 in primary EOC cells (β-actin was used as a
loading control) and (ii) conditioned media of primary EOC cells.
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4.3.2

SPON1 reduces adhesion of EOC cell lines and primary
human EOC cells to tissue culture surfaces
Changes in cell-cell and cell-matrix adhesion play important roles in tumour

development and metastasis, contributing to angiogenesis, cell migration and
proliferation [40]. Given that Spondin 1 has previously been shown to affect adhesion
properties in vivo, by promoting muscle-epidermal adhesion in C. elegans [23], we
postulated that it also alters the adhesion properties of EOC cells in vitro. We tested this
in monolayer adherent cell cultures by utilizing two adhesion assays – the Detachment
Assay (Methods 4.2.6) and Adhesion Assay (Methods 4.2.7). We used the Detachment
Assay to first measure the effect that carrier-free recombinant SPON1 treatment has on
cell adhesion to cell culture plastic. BSA is a non-adhesive protein that has the ability to
‘trigger’ or ‘activate’ the attachment of cells to low levels of adhesion protein [41];
therefore, to avoid interference with BSA we used carrier-free recombinant SPON1
(BSA-free) for all adhesion studies. The Adhesion Assay was then used to examine
whether coating of tissue culture plastic with carrier-free recombinant SPON1 affects cell
adhesion.
Ovarian and/or circulating concentrations of SPON1 in humans or mice are
currently unknown. Therefore, initially during Detachment Assay optimization, cell lines
were treated with 1 µg/ml and 5 µg/ml of recombinant human SPON1. Treatment with
1µg/ml SPON1 did not have a significant effect on cell adhesion (Figure S4-1); cell
detachment was comparable between untreated and 1µg/ml SPON1-treated cells when
incubated with weak trypsin. Cells treated with 5 µg/ml SPON1 released more readily
from the cell culture surface than untreated cells when incubated with weak trypsin.
Therefore 5 µg/ml and 10 µg/ml SPON1 were used for subsequent Detachment Assays.
These doses are comparable to those used in other studies in which cell lines were treated
with recombinant SPON1, which ranged from 0.5 µg/ml [26, 28] to 10 µg/ml [25]. The
cell detachment assays showed that SPON1-treated HEY, OVCAR8 and OVCAR3 cells
had increased sensitivity to trypsinization compared to vehicle-treated cells (Figure 4-3).
Indeed both SPON1 treatments initiate significantly higher cell detachment with weak
trypsin incubation compared to vehicle-treated cells. A dose-response relationship exists
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because significantly greater cell detachment occurred when these three cell lines were
treated with 10 µg/ml SPON1 compared to 5 µg/ml SPON1. Interestingly, neither
treatment with 5 µg/ml nor 10 µg/ml SPON1 changed the adhesion of OVCAR5 or
OVCA429 cells (Figure S4-2).
To determine if the effect of SPON1 on cell adhesion in cell lines would also
occur in a more clinically-relevant model, we conducted the Detachment Assay with
primary EOC cells. All eight patient samples assayed demonstrated a significant increase
in cell detachment with weak trypsin incubation following treatment with 10 µg/ml
SPON1 compared to vehicle treated cells. The lower SPON1 dose significantly decreased
the adhesion of one of the patient samples (EOC183, Figure 4-4B).
To further examine the effect of SPON1 on adhesion we used another model
system and conducted Adhesion Assays with HEY, OVCAR8 and OVCAR3 cells; we
excluded OVCAR5 and OCVA429 because they did not respond to SPON1 in the
Detachment Assays. Plates were coated with serial dilutions of carrier-free recombinant
human SPON1, Laminin, Poly-L-lysine (PLL) or PBS (no coating control). Based on our
earlier results demonstrating that treatment of EOC cells with recombinant SPON1
decreases their adhesion, we wanted to compare the adhesion of EOC cells to another
protein substrate previously shown to decrease EOC cell adhesion in vitro. Therefore we
used laminin as a negative control to coat the plates because SKOV3 ovarian cancer cells
do not adhere well when plated on a laminin-coated surface [42]. PLL was used as a
positive control because it is a well-known promoter of cell adhesion [42, 43]. An MTS
assay, a colorimetric method for determining the relative number of viable cells, was
used as a read-out of the relative number of adherent cells on the different protein
substrates, and therefore as a measure of adhesion. As in the Detachment Assay, we
noticed a dramatic reduction in cells adhering to the SPON1-coated surface compared to
uncoated wells or those coated with PLL (Figure 4-5). Interestingly, cells were also less
likely to adhere to SPON1-coated wells compared to laminin-coated wells.

173

Figure 4-3: SPON1 reduces adhesion of ovarian cancer cell lines in a dosedependent manner.
HEY (A), OVCAR8 (B) and OVCAR3 (C) cells were treated with vehicle, 5 µg/ml
carrier-free recombinant human SPON1 or 10 µg/ml carrier-free recombinant human
SPON1 at the time of seeding. After 48 h the cells were detached with 0.06% trypsin.
Any adherent cells remaining were then detached with 0.25% trypsin and cells from each
pool were counted. The proportion of cells detached by 0.06% trypsin is shown. SPON1
reduced adhesion in a dose-dependent manner because higher percentages of cells detach
following weak trypsinization when treated with a higher SPON1 dose. The data
represent the mean ± SD of triplicate measurements from at least two independent
experiments. One-way ANOVA with Tukey’s test was performed (*p<0.05; **p<0.01;
***p<0.001).
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Figure 4-4: SPON1 reduces the adhesion of primary epithelial ovarian cancer cells.
Eight primary EOC samples were treated with vehicle, 5 µg/ml carrier-free recombinant
human SPON1 or 10 µg/ml carrier-free recombinant human SPON1 at the time of
seeding. After 48 h the cells were detached with 0.06% trypsin. Any adherent cells
remaining were then detached with 0.25% trypsin. Cells from each pool were then
counted. The proportion of cells detached by 0.06% trypsin is shown. SPON1 decreased
cell detachment in seven out of the eight EOC patient samples tested. All values represent
the mean ± SD of triplicate measurements from at least two independent experiments.
One-way ANOVA with Tukey’s test was performed (*p<0.05; **p<0.01; ***p<0.001;
****p<0.0001).
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Figure 4-5: SPON1 inhibits adhesion of EOC cell lines to cell culture surfaces.
Tissue culture surfaces were pre-coated with several dilutions of carrier-free recombinant
human SPON1, Laminin, Poly-L-lysine (PLL) or left uncoated (horizontal dashed line).
The MTS assay provides a relative measure of the number of cells attached to each
protein substrate following 1 h incubation and 4 h recovery. HEY (A), OVCAR8 (B) and
OVCAR3 (C) cells attach best to PLL and least to SPON1. Data represents mean ± SD of
triplicate wells. Each assay is representative of three independent experiments. Two-way
ANOVA with Tukey’s test was performed (*p<0.05; ** p<0.001).
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4.3.3

SPON1 affects reattachment of EOC spheroids but not
spheroid formation
Within peritoneal ascites, shed EOC cells can be present as single cells and/or

multi-cellular spheroids, and both populations of cells are capable of seeding secondary
metastases [10]. EOC dissemination is significantly impacted by the formation of
multicellular spheroids and their ability for reattachment and growth at secondary sites
[10]. Given our results in monolayer cultures of EOC cells thus far, we postulated that
treatment of EOC spheroids with SPON1 would decrease spheroid formation,
reattachment and dispersion.
To determine whether SPON1 affected spheroid formation, at the time of seeding
onto Ultra Low-Attachment (ULA) plates, we treated HEY, OVCAR8 and OVCAR3
cells with 10 µg/ml recombinant SPON1. Spheroid formation was visualized, as well as
spheroid size and number, after 24, 48 and 72 h. No differences in spheroid size or
number following SPON1 treatment were observed at these time points, and the
spheroids did not appear more loosely aggregated, which suggested SPON1 does not
affect cell-cell adhesion (Figure 4-6).
Since SPON1 treatment consistently reduced cell attachment in monolayer EOC
cell cultures, we next sought to determine whether SPON1 treatment would affect the
ability of EOC spheroids to reattach to standard tissue culture plastic. To test this, we
again utilized ULA plates to form EOC spheroids; however we did not treat cells at the
time of seeding; rather, cells were treated with 10 µg/ml recombinant SPON1 once the
spheroids were re-plated onto standard tissue culture plastic. HEY, OVCAR8 and EOC
272 spheroids were formed on ULA dishes. OVCAR3 cells were excluded from these
experiments because they form smaller, more delicate spheroids than the other cell lines,
and are too difficult to transfer for a reliable experimental model. Spheroids were plated
for reattachment by directly transferring them from ULA dishes onto standard tissue
culture plastic with fresh culture medium.
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Figure 4-6: SPON1 treatment does not effect the formation of spheroids by EOC cell
lines.
HEY (A), OVCAR8 (B) and OVCAR3 (C) cells were cultured with vehicle or 10 µg/ml
recombinant SPON1 on ULA plates for three days (each treatment performed in
triplicate/ cell line). Phase contrast images were captured daily at the centre of each well
and representative images are shown. SPON1 does not affect the ability of EOC cell lines
to form multicellular spheroids, as the size and number of spheroids formed were
comparable to vehicle-treated controls. After 72 h on ULA dishes in the presence of
SPON1, spheroids were re-plated in fresh medium onto standard tissue culture plastic and
allowed to re-attach. Once re-attached the cells were fixed and stained using the HEMA-3
stain kit (Fisher). Scale bar = 50 µm.
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Interestingly, we observed increased cell dispersion areas for HEY and EOC 272
SPON1-treated spheroids within the first 24 h of re-plating compared to controls; cell
dispersion was increased by 59% and 51% for HEY and EOC 272 cells, respectively
(Figure 4-7A and C). OVCAR8 cells form irregular spheroids and reattach more slowly
than HEY or EOC 272 cells; therefore, dispersion areas of OVCAR8 cells were measured
after 48 h, rather than 24 h. Consistent with the other cell lines, we found that SPON1treated OVCAR8 spheroids also produced a greater dispersion area than control
spheroids (68% increase) (Figure 4-7B). These results suggested that SPON1 reduced
cell-cell adhesion upon spheroid reattachment to standard tissue culture plastic, as more
cells were released from the SPON1-treated multicellular aggregates than controls. Taken
together, these results suggest a functional role for SPON1 in reducing adhesion of
adherent monolayer and spheroid EOC cells.

4.3.4

SPON1 does not affect EOC cell migration
Cell migration is an essential factor in tumour progression and metastasis.

Although cells can move randomly, dissemination, invasion and migration are most
efficient when cells are involved in directed migration in response to a chemical stimulus
(chemotaxis) [44]. Adhesion of cancer cells to the ECM is a prerequisite for cells to
develop the traction necessary for movement [45, 46]. Therefore, we sought to determine
whether the decreased adhesion following SPON1 treatment impacts EOC cell migration.
Furthermore, we wanted to investigate whether the increased dispersion area generated
by SPON1-treated spheroids might be due in part to increased cell motility. Spondin1 has
previously been shown to promote and inhibit the cell migration of other cell types.
Spondin1 increases migration of osteosarcoma cells [29], and inhibits vascular
endothelial growth factor (VEGF)-stimulated migration and tube formation of human
umbilical vein endothelial cells (HUVECs) [30]. It has also been proposed that Spondin1
may act as a chemoattractant and/or chemorepellant, guiding commissural axons at the
floor plate [18].
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Figure 4-7: SPON1 enhances the dispersion area generated by reattached EOC
spheroids.
HEY (A), OVCAR 8 (B) and EOC272 (C) spheroids were treated with 10 µg/ml SPON1
or vehicle at the time of re-plating onto standard tissue culture plastic. SPON1 increases
the dispersion area generated by reattached EOC spheroids as quantified using ImageJ
software. Dispersion area was calculated 24 h (A and C) or 48 h (B) after spheroids were
re-plated, and the dispersion area normalized to the size of the original spheroid (3 h after
re-plating). Representative images are shown of EOC cells at each time point. Each data
point represents one spheroid. **p<0.01; ***p<0.001 as determined by Student’s t-test.
Scale bar = 50 µm.
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To test this hypothesis, we initially used Transwell filters (Corning) to evaluate
the effect of SPON1 on EOC cell migration. HEY, OVCAR8 and OVCAR3 cells were
seeded in the upper chamber of a transwell insert in low serum (0.5% FBS), ±
recombinant SPON1. The cells were allowed to migrate for 24 h towards recombinant
SPON1, low serum (0.5% FBS) or a high serum positive control (10% FBS) in the
bottom chamber of the transwell insert. We found that the presence of SPON1 did not
affect the migration of EOC cells across the transwell membrane (Figure S4-3).
We also utilized the ibidi µ-Slide Chemotaxis2D system to determine whether
SPON1 affects cell motility. The slides are designed for analysis of migrating adherent
cells on a 2D surface. The small chambers of the ibidi system allowed us to use higher
concentrations of recombinant SPON1 (10 µg/ml) than we used with the transwell model.
HEY cells were used for the optimization of the ibidi system protocol because they are
the fastest growing of the EOC cell lines we studied and their epithelial-like, slightly
elongated morphology makes them the easiest to track over time (compared to the
cobblestone-like morphology of the OVCAR3 and OVCAR8). The preliminary
experiments demonstrated that SPON1 had no effect on chemotaxis; rather we observed
HEY cells migrating randomly within the ibidi observation chamber (Figure S4-4). Based
on these results and the transwell migration data we did not pursue SPON1’s potential
impact on migration further, with other EOC cell lines or with primary EOC cells.

4.3.5

SPON1 reduces cell viability and proliferation of EOC cells
To determine whether SPON1 affects EOC cell viability we treated EOC cell

lines with recombinant human SPON1 or bovine serum albumin (BSA) vehicle as a
negative control for 24, 48 and 72 h. We assessed viability using an MTS assay, which
measures the conversion of a tetrazolium compound into formazan by a mitochondrial
dehydrogenase enzyme in live cells. The amount of formazan is measured
spectrophotometrically and provides a measure for the relative number of viable cells.
We found that SPON1 reduced the viability of HEY cells modestly by 8% after 24 h,
with a significant decrease in viability of 21% and 22% after 48 and 72 h, respectively
(Figure 4-8A-i). Surprisingly, SPON1 did not significantly effect the viability of the other
ovarian cancer cell lines (Figure 4-8B-i, 4-8C-i and Figure S4-5), even when a higher
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SPON1 concentration (10 µg/ml) was used (Figure S4-6), or when SPON1 was
replenished daily (Figure S4-7). Interestingly, we also did not observe a dose-response
relationship between SPON1 and cell viability because the decrease in viability following
treatment with 10 µg/ml SPON1 was not significantly different than the reduction
observed with 5 µg/ml SPON1 (Figure S4-6). Therefore the lower SPON1 dose was used
for subsequent experiments.
The effect of SPON1 on primary EOC cell viability was also assessed. Due to the
slower proliferation of these cells the treatment times were extended to 2, 4 and 6 days
rather than 24, 48 and 72 h, as used for the cell lines. Although the results are variable,
SPON1 significantly decreased cell viability of each primary EOC sample (Figure 4-9).
Of note, EOC 196 cell viability was significantly decreased after 2, 4 and 6 days of
SPON1 treatment, compared to BSA-treated cells, by 21%, 11% and 10%, respectively
(Figure 4-9D). We found that half of the primary EOC samples demonstrated a
significant reduction in cell viability after 4 days of SPON1 treatment and this continued
into day 6 (Figure 4-9A, E, F, H). On day 6, EOC 193 cell viability decreased
dramatically with SPON1 treatment (Figure 4-9C), and in parallel, a subtle, yet
significant decrease in EOC 183 viability (Figure 4-9B). The effect of SPON1 treatment
on EOC 259 cells followed a different trend from the other samples; viability decreased
early on day 2, however, there was no difference in viability at later time points (Figure
4-9G).
To determine whether the changes in cell viability might be due at least in part to
decreased cell proliferation, we determined cell number under corresponding conditions
to the viability assay treatments and time points. We found that the number of HEY cells
decreased significantly compared to controls following SPON1 treatment at 48 and 72 h
by 11% and 20%, respectively (Figure 4-8A-ii). SPON1 treatment had no effect on the
proliferation of OVCAR8 (Figure 4-8B-ii) and OVCAR3 (Figure 4-8C-ii) cells.
We also found that SPON1 treatment decreased proliferation of primary human
EOC cells (Figure 4-10). Generally in the EOC samples, a decrease in viability coincided
with decreased cell numbers. Of the eight EOC samples assessed, EOC 193 was the only
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sample that did not show a decrease in cell number following SPON1 treatment at any
time point (Figure 4-10C), whereas SPON1 treatment decreased EOC 193 cell viability
on Day 6 (Figure 4-9C).

4.3.6

Challenges with silencing SPON1 expression
Given that we observed significant effects of exogenous SPON1 treatment (gain-

of-function assays) on adhesion, viability and proliferation of EOC cells, we wanted to
complement these functional assays after blocking endogenous Spondin1 expression
using “knockdown assays” to serve as loss-of-function experiments. We hypothesized
that inhibiting endogenous SPON1 expression would increase EOC cell adhesion,
viability and proliferation.
Knockdown of SPON1 was attempted using small interfering RNA (siRNA)
contructs. A variety of conditions and protocols was tested; however, a successful
knockdown was not achieved. The protocol that was the most successful was described
earlier (4.3.11 – siRNA transfections). Densitometric quantification was carried out using
ImageJ software, measuring SPON1 expression relative to β-actin control. The “no
treatment” controls (Lane 1 and Lane 5) were considered as 100% SPON1 expression
and all values were normalized to them. The greatest success we had with this approach
was a 45% and 40% reduction of SPON1 protein in HEY and (Figure S4-8A) and
OVCAR8 (Figure S4-8B) cells, respectively, that lasted only 24 h before SPON1 levels
began to increase or were nearly restored to pre-knockdown levels. Knockdown of
SPON1 in OVCAR3 cells (Figure S4-8C) was not achieved under any conditions tested.
Function-blocking antibodies can be an attractive experimental alternative to
siRNA for clarifying the function of proteins [47]; therefore we next tried blocking
SPON1 function in HEY cells using antibodies against SPON1. Four antibodies we
previously found to detect SPON1 by Western blot analysis (C-16, N-19, S17 from Santa
Cruz and ab40797 from Abcam) were tested within the Detachment Assay and Viability
Assay protocols.
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Figure 4-8: SPON1 has a cell line-dependent effect on the viability and proliferation
of EOC cells.
Cell viability (i) was assessed in EOC cell lines by MTS assay in the presence or absence
of SPON1. Cells were cultured in BSA vehicle (black bars) or human recombinant
SPON1 (5 µg/mL) (grey bars). Cell proliferation (ii) was determined by measuring cell
counts under corresponding conditions to the viability assay treatments and time points.
Each bar represents the mean ± SD of triplicate measurements. Each assay is
representative of a minimum of three independent experiments. SPON1 significantly
decreased the viability and proliferation of HEY (A) EOC cells, but has no significant
affect on the viability and proliferation of OVCAR8 (B) or OVCAR3 (C) cells. Two-way
ANOVA with Tukey’s test was performed (*p<0.05; **p<0.01; ****p<0.0001).
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Figure 4-9: SPON1 decreases viability of primary human EOC cells.
Cell viability was assessed in ascites-derived primary EOC cells by MTS assay in the
presence or absence of SPON1. Cells were cultured in BSA vehicle (black bars) or
human recombinant SPON1 (5 µg/mL) (grey bars). Each bar represents the mean ± SD of
six measurements. Each assay is representative of a minimum of three independent
experiments. SPON1 significantly decreased the viability of each primary EOC sample.
Two-way ANOVA with Tukey’s test was performed (*p<0.05; **p<0.01; ***p<0.001;
****p<0.0001).
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Figure 4-10: SPON1 decreases proliferation of primary human EOC cells
Cell proliferation of ascites-derived primary EOC cells was determined by measuring cell
counts under corresponding conditions to the viability assay treatments [BSA (black
bars), SPON1 (grey bars)] and time points. Each bar represents the mean ± SD of six
measurements. Each assay is representative of a minimum of three independent
experiments. SPON1 significantly decreased the proliferation of each primary EOC
sample. Two-way ANOVA with Tukey’s test was performed (*p<0.05; **p<0.01;
***p<0.001; ****p<0.0001).
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Using the Viability Assay as a read out we attempted to block SPON1 function by
adding each antibody independently to the EOC cells 2 h after seeding. Two
concentrations of antibodies were used, 1 µg/ml and 10 µg /ml, which are comparable to
doses previously used to block integrin function [47]. We postulated that one of the
antibodies would successfully block endogenous SPON1 function, and EOC cell viability
would increase. Surprisingly, this did not occur with any of the antibodies, at either
concentration (Figure S4-9A). Of note, treatment with the higher dose of C-16, N-19 and
S17 antibodies killed most of the cells after 48 h and 72 h.
We then tried blocking SPON1 function using the Detachment Assay as a read
out. Since each of the Santa Cruz antibodies detects a different amino acid sequence of
SPON1 we used a combination of the three (referred to as Santa Cruz Cocktail, SCC),
which spanned the entire length of the protein. Each anti-SPON1 antibody was used at a
concentration of 1 µg/ml. The morphology of HEY cells was affected by the Santa Cruz
Cocktail in the Detachment Assay. Specifically, cells were rounded, and detached from
the tissue culture plastic in multicellular clusters following weak trypsinization, which
may have produced inaccurate cell counts despite sample triteration. The 1 µg/ml
ab40797 treatment slightly reduced the percentage of cells that detached following weak
trypsin incubation compared to vehicle-treated cells. However, neither antibody resulted
in a significant effect on cell attachment. Therefore, we did not pursue this method of
SPON1 function blocking in other assays. Although there are multiple SPON1 specific
antibodies commercially available it appears that none of them block SPON1 function
under the conditions we tested (Figure S4-9B).

4.3.7

Screening for downstream targets of SPON1-induced
signaling in EOC cells
To screen for potential intracellular targets of SPON1 in EOC cells that could be

responsible for decreased adhesion, viability and/or proliferation, we used the Proteome
Profiler Human Phospho-kinase Array Kit, which simultaneously detects the relative
levels of phosphorylation of 43 phosphorylation sites on 43 proteins and 2 kinase-related
(nonphosphorylated) total proteins, and/or their targets. HEY and OVCAR3 cells were
serum starved for 12 h to reduce background kinase activity, then treated with vehicle or
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SPON1 for 15 minutes, after which cell lysates were prepared. The lysates were then
applied to the Human Phospho-Kinase array, and the blots processed and spot intensities
quantified according to the manufacturer’s directions. Overall there were very subtle
differences between the pixel densities of vehicle and SPON1-treated cells (Figure S410). The phosphorylation of WNK-1 (T60) decreased by 40% in HEY cells and by 35%
in OVCAR3 cells after SPON1 treatment compared to control. SPON1 treatment of
OVCAR3 cells also decreased the phosphorylation of p53 at three sites (S392, S46 and
S15); however, this was not reproduced in HEY cells.
To validate the SPON1-mediated decreases in WNK-1 and p53 phosphorylation
that we observed in the array, we conducted Western blot analysis with lysates from HEY
and OVCAR3 cells serum starved for 12 h and treated with vehicle or SPON1 for 15
minutes. Despite multiple attempts, we were unable to confirm these results by Western
blot because of high background and non-specific binding of the phospho-WNK-1
antibody, and inconsistent results with the total p53 antibody (data not shown).

4.4 Discussion
Epithelial ovarian cancer, a leading cause of death in women around the world, is
a disease of dysregulated and aberrant protein expression and activation [1]. The
extracellular matrix (ECM) is a complex, dynamic and essential component of the
microenvironment of cells, particularly for providing mechanical support. The role of
ECM in tumourigenesis has been intensively studied because ECM composition and
organization undergo major changes in cancer that can affect properties of both tumor
and stromal cells [48]. Although many details of the relationship between the ECM and
cancer cells remain unknown, growing evidence suggests that the interactions of cells
with ECM components can have either positive or inhibitory effects on cancer cell
behaviour depending on the context [12, 13]. An extensive screen of 500 ovarian
carcinomas suggests the ECM glycoprotein SPON1 is a promising biomarker for ovarian
cancer, particularly high grade serous EOC [32]. Its use in combination with other
markers could improve both specificity and sensitivity of monitoring and diagnosing the
disease, yet its role in ovarian cancer had not previously been investigated. In this study
we utilized established EOC cell lines to determine the affect of SPON1 on various
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ovarian cancer cell phenotypes, and repeated select experiments in primary human
ascites-derived EOC cells.

4.4.1

SPON1 is involved in changes of the adhesive, proliferative
and viability phenotype of human ovarian cancer cells.
Firstly, we have shown that recombinant SPON1 treatment decreases adhesion of

EOC cell lines and primary ovarian cancer cells. Dissemination of cells from the primary
tumour to other organs is often the cause of patient morbidity and mortality [49].
Shedding of cells into the peritoneal cavity and subsequent adhesion to the serosal and
organ surfaces is the initial step in further metastasis [50]. This progression of ovarian
cancer relies on different forms of cell adhesion to maintain the signals necessary for
sustaining and advancing tumour development [13]. We have demonstrated that either
treating cells with exogenous SPON1 (Figure 4-3, 4-4) or plating cells on SPON1precoated tissue culture plastic (Figure 4-5) reduces cell adhesion, as compared to control
cells.
Interestingly, there is a dose-dependent relationship between SPON1 and the
extent to which adhesion is affected in most EOC cell lines and primary EOCs. Patient
EOC 259 cells were the only patient sample not significantly affected by recombinant
SPON1 treatment. However, EOC 259 primary cells were prone to forming cellular
aggregates upon trypsinization, despite sample triteration, which likely impacted cellsurface availability and cell counts and consequently led to SPON1-treated cells failing to
reach significance.
Malignant cells survive in the peritoneum as single cells or multicellular
spheroids until they are able to reattach to a hospitable substratum [10]. Adhesion of
spheroids initiates a transition from a floating cell population to a metastatic lesion
anchored in the peritoneal cavity. Given that malignant cells are capable of altering cellsubstratum as well as cell-cell interactions, and the clinical relevance of multicellular
spheroids has been documented [10, 51, 52], we also investigated the effect of SPON1 on
spheroid formation and reattachment. Surprisingly, we did not observe a difference in
spheroid size or density following SPON1 treatment of EOC cell lines in suspension
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(Figure 4-6). If cell-cell adhesion was reduced during spheroid formation we would
expect to see smaller, less dense-appearing spheroids [53]. Interestingly, treatment with
exogenous SPON1 at the time of spheroid transfer from ULA plates did affect spheroid
reattachment (Figure 4-7). The cell dispersion area was significantly higher in HEY,
OVCAR8 and primary EOC 272 cells, which may suggest that cells detach from the
spheroid more readily when treated with SPON1. The treated cells were more loosely
dispersed than controls, which suggested that the increased cell dispersion area was
unlikely due to an increase in cell proliferation. In fact, in this study we showed that
SPON1-treated EOC cells had significantly decreased proliferation (Figure 4-8, 4-10) and
viability (Figure 4-8, 4-9) than vehicle-treated controls. The development of secondary
metastases is dependent on both successful cell proliferation and motility of reattached
EOC cells from the peritoneum [10]. Unexpectedly, despite affecting migration in other
tissues [18, 29, 30], the increase in cell dispersion was also unlikely due to an increase in
cell motility because SPON1 did not affect migration of EOC cell lines (Figure S4-2 and
S4-3).
Although we failed to observe an effect of SPON1 on the migration of EOC cell
lines using trans-well dishes and the ibidi chemotaxis system, the effect of SPON1 on
spheroid reattachment merits further attention, as larger studies may reveal a role for
SPON1 in EOC cell motility. In this study, we were only able to test one primary human
sample and with few replicates on ULA dishes due to limited sample availability. In the
future, it would be beneficial to further examine the effect of SPON1 on primary EOC
spheroid formation and reattachment with a greater number of samples and replicates.

4.4.2

Mechanisms by which SPON1 regulates cellular function in
other model systems
A small number of studies in various model systems have examined the

mechanisms and signaling pathways by which SPON1 regulates cellular functions, yet no
common mechanism has been identified. Some studies have found that SPON1 acts
either via integrin-mediated adhesion. In C. elegans, SPON1 localizes to integrincontaining structures on body muscles and to other basement membranes, and may be
required for integrin-mediated muscle-epidermal adhesion [23]. SPON1 inhibits the
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spreading of human umbilical vein endothelial cells (HUVECs) on vitronectin by
specifically blocking integrin αvβ3 [30].
Integrins are known to associate with kinases to initiate cascades of signaling
events [54]; therefore it is not surprising that SPON1 has also been shown to regulate
kinase activity. SPON1 inhibits the VEGF-stimulated activation of Protein Kinase B
(Akt) and phosphorylation of focal adhesion kinase (FAK) in HUVECs plated on
vitronectin-coated dishes [30]. Conversely, SPON1 increases the phosphorylation of p38
mitogen-activated protein kinase (MAPK) in murine neuroblastoma cells [25], the
phosphorylation of the intracellular adaptor protein, disabled-1 (DAB-1) and Akt in chick
ciliary ganglion [35], as well as phosphorylation of FAK and SRC in osteosarcoma cells,
which promotes cell migration and invasiveness [29]. SPON1 also interacts with LRP8
(low-density lipoprotein receptor-related protein 8) which leads to inhibition of the
TRAF6 and c-Fos signaling pathways in clastic cells [55], and acts as an adaptor protein
and bridge between APP (amyloid precursor protein) and several apoE receptors
(apoER2, LRP2 and LRP4) [56, 57]. Considering the diverse mechanisms and signaling
pathways by which SPON1 exerts its effects, it is clear that much remains to be
discovered regarding its actions in various tissues and model systems, including ovarian
cancer progression.

4.4.3

Searching for mechanisms by which SPON1 may reduce
adhesion and growth of epithelial ovarian cancer cells
Certain cell-ECM interactions in the tumour microenvironment induce cell

adhesion, proliferation, migration and invasion by activating well-studied signaling
pathways that include kinases such as MAPK and Akt [58]. To identify potential
signaling pathways induced or repressed by SPON1 in ovarian cancer cells, quiescent
HEY and OVCAR3 cell lines were treated with recombinant SPON1 and downstream
signaling targets evaluated using the human phospho-kinase array. We quantified the spot
intensities of targets that have previously been shown to influence tumourigenesis and
appeared even slightly dysregulated by SPON1 treatment in either cell line. These studies
identified p53, Chk2, ERK, GSK3, and WNK1 as potential SPON1 targets.
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The p53 tumour suppressor protein has well-established functions in monitoring
various stress signals and controlling cell cycle arrest and apoptosis. Many
phosphorylation sites span the p53 protein, with the majority of these sites rapidly
phosphorylated in response to cellular stress [59]. The phospho-kinase array targets three
of these sites. One of the more widely studied N-terminal phosphorylation sites is S15. Its
phosphorylation reduces p53 affinity for its negative regulator Hdm2 and encourages the
recruitment of transcriptional co-activators. Phosphorylation of S46 is essential for p53mediated induction of pro-apoptotic genes but is not necessary for the activation of cell
cycle arrest targets. C-terminal S392 is phosphorylated in response to ultra-violet light.
S392 phosphorylation stabilizes the p53 tetramer and activates specific DNA binding [59,
60]. SPON1 decreased p53 phosphorylation at all three sites in OVCAR3 cells (by 2035%), which was not reproduced in HEY cells. We were unable to confirm this by
Western blotting because of inconsistent detection of total p53 levels (data not shown).
Elements upstream or downstream of p53 can also be dysregulated in cancer, and
Checkpoint kinase 2 (Chk2) is such a target. Chk2, a key regulator within the complex
network of DNA damage checkpoints, is phosphorylated and recruited to DNA strand
breaks to recruit several members involved in mediating cell cycle arrest, thereby
delaying cell cycle arrest and allowing for DNA repair [61]. Chk2 is a direct regulator of
p53 and mediates p53-mediated cell cycle arrest and apoptosis after DNA damage. For
example, following activation by ionizing radiation Chk2 stabilizes p53 [62]. We
observed only a subtle increase in phosphorylation of Chk2 following SPON1 treatment.
Disruptions of the ERK and PI3K/Akt/mTOR pathways are common in many
types of cancer, including ovarian carcinomas. Specifically, genetic alterations are
common in a high percentage of high-grade serous ovarian cancers, and therefore ideal
targets for inhibitors in clinical development [50]. A 15 min treatment with recombinant
SPON1 induced a slight increase in ERK1/2 phosphorylation and Akt S473
phosphorylation in HEY and OVCAR3 cells. SPON1 treatment did not affect Akt T308
phosphorylation.
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SPON1 slightly increased the phosphorylation of GSK3 in both EOC cell lines,
with more pronounced phosphorylation in HEY cells. GSK-3 has various roles in cancer,
which even after years of study remain complex and controversial. GSK-3 is
overexpressed in various tumour types including ovarian, in which it is believed to exert
pro-proliferative effects [63].
In both EOC cell lines the most obvious change in phosphorylation levels
following SPON1 treatment was a decrease of WNK1 T60 phosphorylation (39%
reduction in HEY cells and 33% in OVCAR3 cells). The serine/threonine protein kinase
WNK1 [with no lysine (K)] is ubiquitously expressed in tissues; however its biological
functions and regulation are not well understood. The only known activators of WNK are
changes in ionic strength, which is consistent with its role in regulating ion transport [64].
The down regulation of WNK1 in a mouse neural progenitor cell line greatly reduced cell
growth and migration [65]. Despite our best efforts we were unable to confirm the
phospho-kinase array results by Western blotting due to high background and nonspecific antibody binding (data not shown).
Lastly, we analyzed the phosphorylation of Proline Rich AKT1 Substrate of 40
kDa (PRAS40) because our laboratory recently identified it to be a target of SPON1 in
the KGN granulosa cell tumour cell line using the same phospho-kinase array. PRAS40 is
a member of the mTORC1 complex, and when PRAS40 is not phosphorylated it is bound
to mTORC1 and inhibits its activity. Phosphorylation of PRAS40 activates the mTORC1
complex and promotes ovarian cancer cell proliferation [66]. SPON1 does not
significantly affect PRAS40 phosphorylation in either OVCAR3 or HEY cell lines
(Figure S4-10).
The phospho-kinase array did not clarify which pathways SPON1 is using to
affect biological events in ovarian carcinomas; consequently we will have to utilize other
techniques when pursuing this question in the future, such as global gene expression
analysis. We could also use a targeted approach and examine whether SPON1 interacts
with integrins in this system. Not only are integrins one of the few known interacting
partners of SPON1 (as discussed above), but they play an essential role in tumour
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progression by providing a dynamic interface for the ECM to “integrate” with the cell
interior [58, 67]. High levels of integrin expression increase tumourigenesis and impact
cell shape, proliferation, and migration [68]. Integrin αvβ3 would be an interesting target
to pursue considering it is expressed in most ovarian cancer cells [54] and SPON1
specifically blocks integrin αvβ3 in HUVECs [30]. Furthermore, it has been reported that
interaction of αvβ3 with its ligand vitronectin promotes adhesion, proliferation, and
motility of ovarian cancer cells [54]; blocking αvβ3 integrin function inhibits vitronectininduced migration of ovarian cancer cells [69]. Although the precise mechanism of tumor
progression promoted by αvβ3 remains inconclusive, various studies support a role for
αvβ3 in ECM-induced phenotypic changes of ovarian cancer cells [54]. Therefore, it is
reasonable to postulate that SPON1 may be acting through integrin αvβ3 to exert its
effects on EOC cells, specifically, binding of SPON1 to αvβ3 integrin may decrease
integrin αvβ3/vitronectin-mediated ovarian cancer cell adhesion and growth.

4.4.4

Examples of molecules known to inhibit biological properties
of EOC cells
Many ECM components enhance adhesion, proliferation, migration and invasion

of ovarian cancer cells. For example, collagen, laminin and fibronectin have previously
been shown to enhance all of these biological properties in both HEY and OVCAR3 cell
lines [58]. There are relatively far fewer examples in the literature of proteins that inhibit
these functions in ovarian carcinomas, which make our observations of SPON1’s
function in EOC cells all the more intriguing. Some examples from the literature include
TSP-1, SPARC, ADAM15 and S1P.
Thrompbospondin-1 (TSP-1), like SPON1, is also a member of the
thrombospondin superfamily, and is an adhesive glycoprotein and a potent inhibitor of
tumour growth, migration, invasion and angiogenesis [70]. The therapeutic use of TSP-1
has been a topic of research for many years because studies have shown that TSP-1 and
its mimetic molecules can inhibit the growth of tumours of melanoma, pancreatic, lung
and ovarian origin [71-73].

197

Secreted protein acidic and rich in cysteine (SPARC) is a secreted glycoprotein
that interacts with various ECM macromolecules. SPARC is involved in the regulation of
cell adhesion, proliferation, and migration, as well as in processes requiring ECM
turnover such as tumor progression. The mechanism through which SPARC modulates
cancer progression is complex and depends on tumor cell type and the surrounding
microenvironment. SPARC has anti-proliferative and pro-apoptotic functions in ovarian
cancer, and has also been shown to abolish ovarian carcinoma cell adhesion by inhibiting
integrin-mediated cell adhesion to extracellular matrix proteins. [74]
ADAM15 is known to inhibit various biological functions in ovarian cancer. The
ADAM proteins, a family of transmembrane and secreted glycoproteins, have diverse
functions that include cell adhesion, cell fate determination, migration and intracellular
signalling [75]. Double immunostaining has shown that ADAM15 and αvβ3 have a similar
distribution pattern on the surface of ovarian cancer cells [75]. When ADAM15 is
overexpressed in ovarian cancer cells it binds to integrin αvβ3 thereby decreasing integrin
αvβ3/vitronectin-mediated ovarian cancer cell growth, adhesion and motility [75].
Sphingosine-1-phosphate (S1P) is a bioactive lipid molecule that inhibits the
growth and survival of ovarian cancer cells. S1P has an inhibitory effect on cell
attachment and cell adhesion; S1P inhibits cell attachment to the surface of uncoated
culture dishes as well as dishes pre-coated with laminin, collagens I and IV and
fibronectin [76]. Interestingly, Hong et al. suggest that the inhibitory effect of S1P on cell
growth is preceded by its inhibitory effect on cell attachment or cell adhesion.

4.4.5

Does SPON1 have an oncogenic or tumour suppressive role
in ovarian cancer progression?
Further in vitro and in vivo studies are required to determine whether SPON1 has

an oncogenic or tumour suppressive role in ovarian cancer tumour progression. Survival
analyses have suggested that SPON1 is a negative prognostic indicator [32]; therefore the
SPON1-induced decrease in cell adhesion we observe may increase cell detachment at
the primary tumour and thereby promote dissemination and tumour progression.
However, we have also shown that SPON1 decreases EOC cell viability and
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proliferation, suggesting it may be suppressing tumour growth. Therefore the reduced cell
adhesion may inhibit cell attachment at secondary sites in the peritoneal cavity and
reduce tumour progression.
The SPON1-induced decrease in adhesion, viability and proliferation I have
observed in vitro can be explored further in vivo using the SPON1-/- mouse, which is
viable and develops normally to adulthood [26]. Following implantation of ovarian
cancer cells in the SPON1-/- mouse, tumour burden can be assessed by comparing tumour
weight, ascites volume, and number of metastases to tissues within the peritoneal cavity.

4.4.6

Future Directions
Beyond the future experiments we have already proposed, further investigations

into the acellular fraction of ascites and the potential role of SPON1 in tumour
angiogenesis will help create a more comprehensive picture of SPON1’s role in ovarian
cancer.
Over one-third of ovarian cancer patients present with large amounts of ascites at
the time of diagnosis [77]. Ascites accumulates when fluid production in the peritoneal
cavity exceeds fluid reabsorption [78]. Ascites is composed of a cellular fraction
containing ovarian cancer cells, lymphocytes, and mesothelial cells and an acellular
fraction consisting of angiogenic and growth factors, bioactive lipids, cytokines and ECM
components [77]. All of these factors have been shown to promote cell growth, survival
and/or invasion. Clinical observations have revealed that the presence of ascites
correlates with more extensive tumour spread [78]. In vitro studies have shown that the
acellular fraction of ascites can affect proliferation, apoptosis, migration and invasion of
EOC cell lines; both positive and inhibitory regulators of tumour progression can be
present in the acellular fraction [77, 79]. In our study, we detected endogenous SPON1 in
lysates generated from five EOC cell lines and eight primary ascites-derived samples, as
well as conditioned medium from all EOC cells (Figure 4-2). Future studies could focus
on examining the acellular fraction of ascites to confirm that EOC cells are secreting
SPON1 in vivo.
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It would also be beneficial to determine whether SPON1 regulates angiogenesis
during ovarian cancer progression. Angiogenesis is the development of new blood vessels
from the preexisting vasculature. This process is a key factor in the progression of cancer
and has been shown to strongly correlate with risk of invasion and metastasis. A balance
of pro- and anti-angiogenic factors controls angiogenesis. During tumour progression and
metastasis there is a disruption in this balance that favours angiogenesis [80]. The unique
method of ovarian cancer metastasis, by shedding of EOC single cells or small clusters
from the primary tumour into the peritoneal cavity where they establish secondary lesions
on abdominal organs, is one of the reasons ovarian cancer is difficult to treat. Unlike
many epithelial cancers the initial dissemination of EOC rarely involves the vasculature;
however, the vasculature is often involved in advanced stages of ovarian carcinomas [10].
Though SPON1 may either have a pro- or anti-angiogenic effect, there is evidence in the
literature to support an inhibitory role for angiogenesis in ovarian cancer [30]. Future
investigations could utilize established in vitro angiogenesis models, such as growing
HUVEC cells in supernatant from EOC cells and establishing whether the presence of
SPON1 impacts the formation of complex tube network, a hallmark of angiogenesis [81].

4.4.7

Limitations of study
We were unable to use a loss-of-function approach to establish a requirement of

SPON1 for the phenotypic changes to EOC cells we have demonstrated by a gain-offunction approach. This was not due to omission or lack of effort. Firstly, we attempted to
reduce SPON1 levels using an siRNA approach. Another member of our laboratory also
had previously attempted to optimize the knockdown of SPON1 in granulosa cell lines
using a number of different protocols, culturing conditions, primer sets and transfection
reagents, without success. Nevertheless, due to the variability between cell types and cell
lines, we attempted to optimize the conditions for knockdown of SPON1 in OVCAR3,
OVCAR8 and HEY cell lines. The most success we had with this approach was a 45%
and 40% reduction of SPON1 protein in HEY and OVCAR8 cells, respectively, that
lasted only 24 h before SPON1 levels began to increase, and eventually were nearly
restored to pre-knockdown levels.
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We also attempted to block SPON1 function using anti-SPON1 antibodies,
without success. The four antibodies we tested successfully detect SPON1 using Western
blot analysis; therefore it is possible that either these antibodies are only able to bind to
the denatured SPON1 protein following SDS-PAGE or are simply unable to act as
functional blocking antibodies. Interestingly, the lower dose of the Abcam antibody (1
µg/ml) showed promise because we observed a slight decrease in cell adhesion with weak
trypsinization compared to control cells; however the reduction in adhesion failed to
reach statistical significance. Higher doses of this antibody caused the cells to take on a
rounded morphology and detach in clusters following weak trypsinization. Therefore, we
were unable to use a loss-of-function approach to further support the results and
conclusions of our study.

4.4.8

Conclusions
This is the first study to determine cellular functions of SPON1 in ovarian

carcinomas. We have shown for the first time that SPON1 decreases the adhesion,
viability and proliferation of ovarian cancer cells. We have also demonstrated that
SPON1 is endogenously expressed in, and secreted by, established ovarian cancer cell
lines and primary human epithelial ovarian cancer cells. Further investigations are
necessary to determine whether SPON1 plays an oncogenic, tumour suppressive or
dichotomous role in ovarian cancer development and metastasis, and whether it may
serve as a potential treatment target for the progression of ovarian cancer.

201

4.5 Bibliography
1.

Jayson, G.C., et al., Ovarian cancer. The Lancet, 2014. 384(9951): p. 13761388.

2.

Siegel, R., et al., Cancer statistics, 2011: the impact of eliminating
socioeconomic and racial disparities on premature cancer deaths. CA Cancer J
Clin, 2011. 61(4): p. 212-36.

3.

Vaughan, S., et al., Rethinking ovarian cancer: recommendations for improving
outcomes. Nat Rev Cancer, 2011. 11(10): p. 719-25.

4.

Shih Ie, M. and R.J. Kurman, Ovarian tumorigenesis: a proposed model based
on morphological and molecular genetic analysis. Am J Pathol, 2004. 164(5):
p. 1511-8.

5.

Schwartz, D.R., et al., Gene expression in ovarian cancer reflects both
morphology and biological behavior, distinguishing clear cell from other poorprognosis ovarian carcinomas. Cancer Res, 2002. 62(16): p. 4722-9.

6.

Zorn, K.K., et al., Gene expression profiles of serous, endometrioid, and clear cell
subtypes of ovarian and endometrial cancer. Clin Cancer Res, 2005. 11(18): p.
6422-30.

7.

Gilks, C.B., Molecular abnormalities in ovarian cancer subtypes other than
high-grade serous carcinoma. J Oncol, 2010. 2010: p. 740968.

8.

Bowtell, D.D., The genesis and evolution of high-grade serous ovarian cancer.
Nat Rev Cancer, 2010. 10(11): p. 803-8.

9.

Naora, H. and D.J. Montell, Ovarian cancer metastasis: integrating insights
from disparate model organisms. Nat Rev Cancer, 2005. 5(5): p. 355-66.

10.

Shield, K., et al., Multicellular spheroids in ovarian cancer metastases: Biology
and pathology. Gynecol Oncol, 2009. 113(1): p. 143-8.

11.

Lu, P., V.M. Weaver, and Z. Werb, The extracellular matrix: a dynamic niche in
cancer progression. J Cell Biol, 2012. 196(4): p. 395-406.

12.

Barbolina, M.V., et al., Microenvironmental regulation of ovarian cancer
metastasis. Cancer Treat Res, 2009. 149: p. 319-34.

13.

ElMasri, W., et al., Cell Adhesion in Ovarian Cancer, in Ovarian Cancer, M.S.
Stack and D.A. Fishman, Editors. 2010, Springer US. p. 297-318.

202

14.

Barkan, D., J.E. Green, and A.F. Chambers, Extracellular matrix: a gatekeeper
in the transition from dormancy to metastatic growth. Eur J Cancer, 2010.
46(7): p. 1181-8.

15.

Chien, J., et al., Platinum-sensitive recurrence in ovarian cancer: the role of
tumor microenvironment. Front Oncol, 2013. 3: p. 251.

16.

Klar, A., M. Baldassare, and T.M. Jessell, F-spondin: a gene expressed at high
levels in the floor plate encodes a secreted protein that promotes neural cell
adhesion and neurite extension. Cell, 1992. 69(1): p. 95-110.

17.

Burstyn-Cohen, T., et al., Accumulation of F-spondin in injured peripheral
nerve promotes the outgrowth of sensory axons. J Neurosci, 1998. 18(21): p.
8875-85.

18.

Burstyn-Cohen, T., et al., F-Spondin is required for accurate pathfinding of
commissural axons at the floor plate. Neuron, 1999. 23(2): p. 233-46.

19.

Feinstein, Y., et al., F-spondin and mindin: two structurally and functionally
related genes expressed in the hippocampus that promote outgrowth of
embryonic hippocampal neurons. Development, 1999. 126(16): p. 3637-48.

20.

Tzarfati-Majar, V., T. Burstyn-Cohen, and A. Klar, F-spondin is a contactrepellent molecule for embryonic motor neurons. Proc Natl Acad Sci U S A,
2001. 98(8): p. 4722-7.

21.

Debby-Brafman, A., et al., F-Spondin, expressed in somite regions avoided by
neural crest cells, mediates inhibition of distinct somite domains to neural crest
migration. Neuron, 1999. 22(3): p. 475-88.

22.

Schubert, D., et al., F-spondin promotes nerve precursor differentiation. J
Neurochem, 2006. 96(2): p. 444-53.

23.

Woo, W.M., et al., The C. elegans F-spondin family protein SPON-1 maintains
cell adhesion in neural and non-neural tissues. Development, 2008. 135(16):
p. 2747-56.

24.

Miyamoto, K., et al., Isolation and characterization of vascular smooth muscle
cell growth promoting factor from bovine ovarian follicular fluid and its cDNA
cloning from bovine and human ovary. Arch Biochem Biophys, 2001. 390(1):
p. 93-100.

25.

Cheng, Y.C., et al., F-spondin plays a critical role in murine neuroblastoma
survival by maintaining IL-6 expression. J Neurochem, 2009. 110(3): p. 94755.

203

26.

Palmer, G.D., et al., F-spondin regulates chondrocyte terminal differentiation
and endochondral bone formation. J Orthop Res, 2010. 28(10): p. 1323-9.

27.

Kitagawa, M., et al., F-spondin regulates the differentiation of human
cementoblast-like (HCEM) cells via BMP7 expression. Biochem Biophys Res
Commun, 2012. 418(2): p. 229-33.

28.

Oka, H., M. Mori, and H. Kihara, F-spondin inhibits migration and
differentiation of osteoclastic precursors. J Periodontol, 2011. 82(12): p. 177683.

29.

Chang, H., et al., Spondin 1 promotes metastatic progression through Fak and
Src dependent pathway in human osteosarcoma. Biochem Biophys Res
Commun, 2015. 464(1): p. 45-50.

30.

Terai, Y., et al., Vascular smooth muscle cell growth-promoting factor/Fspondin inhibits angiogenesis via the blockade of integrin alphavbeta3 on
vascular endothelial cells. J Cell Physiol, 2001. 188(3): p. 394-402.

31.

Pyle-Chenault, R.A., et al., VSGP/F-spondin: a new ovarian cancer marker.
Tumour Biol, 2005. 26(5): p. 245-57.

32.

Kobel, M., et al., Ovarian carcinoma subtypes are different diseases:
implications for biomarker studies. PLoS Med, 2008. 5(12): p. e232.

33.

Shepherd, T.G. and M.W. Nachtigal, Identification of a putative autocrine bone
morphogenetic protein-signaling pathway in human ovarian surface
epithelium and ovarian cancer cells. Endocrinology, 2003. 144(8): p. 3306-14.

34.

Peart, T.M., et al., BMP signalling controls the malignant potential of ascitesderived human epithelial ovarian cancer spheroids via AKT kinase activation.
Clin Exp Metastasis, 2012. 29(4): p. 293-313.

35.

Peterziel, H., et al., F-spondin regulates neuronal survival through activation of
disabled-1 in the chicken ciliary ganglion. Mol Cell Neurosci, 2011. 46(2): p.
483-97.

36.

Domcke, S., et al., Evaluating cell lines as tumour models by comparison of
genomic profiles. Nat Commun, 2013. 4: p. 2126.

37.

Shepherd, T.G., et al., Primary culture of ovarian surface epithelial cells and
ascites-derived ovarian cancer cells from patients. Nat Protoc, 2006. 1(6): p.
2643-9.

38.

Nishi, Y., et al., Establishment and characterization of a steroidogenic human
granulosa-like tumor cell line, KGN, that expresses functional folliclestimulating hormone receptor. Endocrinology, 2001. 142(1): p. 437-45.

204

39.

Kananen, K., et al., Gonadal tumorigenesis in transgenic mice bearing the
mouse inhibin alpha-subunit promoter/simian virus T-antigen fusion gene:
characterization of ovarian tumors and establishment of gonadotropinresponsive granulosa cell lines. Mol Endocrinol, 1995. 9(5): p. 616-27.

40.

Tlsty, T.D. and L.M. Coussens, Tumor stroma and regulation of cancer
development. Annu Rev Pathol, 2006. 1: p. 119-50.

41.

Koblinski, J.E., et al., Matrix cell adhesion activation by non-adhesion proteins. J
Cell Sci, 2005. 118(Pt 13): p. 2965-74.

42.

Kenny, H.A., et al., Use of a novel 3D culture model to elucidate the role of
mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and
invasion of ovarian cancer cells to the omentum. Int J Cancer, 2007. 121(7): p.
1463-72.

43.

Mazia, D., G. Schatten, and W. Sale, Adhesion of cells to surfaces coated with
polylysine. Applications to electron microscopy. J Cell Biol, 1975. 66(1): p. 198200.

44.

Roussos, E.T., J.S. Condeelis, and A. Patsialou, Chemotaxis in cancer. Nat Rev
Cancer, 2011. 11(8): p. 573-87.

45.

Hood, J.D. and D.A. Cheresh, Role of integrins in cell invasion and migration.
Nat Rev Cancer, 2002. 2(2): p. 91-100.

46.

Palecek, S.P., et al., Integrin-ligand binding properties govern cell migration
speed through cell-substratum adhesiveness. Nature, 1997. 385(6616): p. 53740.

47.

Mitjans, F., et al., An anti-alpha v-integrin antibody that blocks integrin
function inhibits the development of a human melanoma in nude mice. J Cell
Sci, 1995. 108 ( Pt 8): p. 2825-38.

48.

Hynes, R.O., The extracellular matrix: not just pretty fibrils. Science, 2009.
326(5957): p. 1216-9.

49.

Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1):
p. 57-70.

50.

Lengyel, E., Ovarian cancer development and metastasis. Am J Pathol, 2010.
177(3): p. 1053-64.

51.

Correa, R.J., et al., Modulation of AKT activity is associated with reversible
dormancy in ascites-derived epithelial ovarian cancer spheroids.
Carcinogenesis, 2012. 33(1): p. 49-58.

205

52.

Burleson, K.M., et al., Ovarian carcinoma ascites spheroids adhere to
extracellular matrix components and mesothelial cell monolayers. Gynecol
Oncol, 2004. 93(1): p. 170-81.

53.

Shepherd, T.G., M.L. Mujoomdar, and M.W. Nachtigal, Constitutive activation
of BMP signalling abrogates experimental metastasis of OVCA429 cells via
reduced cell adhesion. J Ovarian Res, 2010. 3: p. 5.

54.

Hapke, S., et al., Ovarian cancer cell proliferation and motility is induced by
engagement of integrin alpha(v)beta3/Vitronectin interaction. Biol Chem,
2003. 384(7): p. 1073-83.

55.

Oka, H., M. Kitagawa, and T. Takata, F-spondin inhibits differentiation of clastic
precursors via lipoprotein receptor-related protein 8 (LRP8). J Periodontol,
2015. 86(3): p. 465-72.

56.

Hoe, H.S. and G.W. Rebeck, Functional interactions of APP with the apoE
receptor family. J Neurochem, 2008. 106(6): p. 2263-71.

57.

Hoe, H.S., et al., F-spondin interaction with the apolipoprotein E receptor
ApoEr2 affects processing of amyloid precursor protein. Mol Cell Biol, 2005.
25(21): p. 9259-68.

58.

Ahmed, N., et al., Role of integrin receptors for fibronectin, collagen and
laminin in the regulation of ovarian carcinoma functions in response to a
matrix microenvironment. Clin Exp Metastasis, 2005. 22(5): p. 391-402.

59.

Dai, C. and W. Gu, p53 post-translational modification: deregulated in
tumorigenesis. Trends Mol Med, 2010. 16(11): p. 528-36.

60.

Olsson, A., et al., How important are post-translational modifications in p53 for
selectivity in target-gene transcription and tumour suppression? Cell Death
Differ, 2007. 14(9): p. 1561-75.

61.

Stolz, A., N. Ertych, and H. Bastians, Tumor suppressor CHK2: regulator of DNA
damage response and mediator of chromosomal stability. Clin Cancer Res,
2011. 17(3): p. 401-5.

62.

Miller, C.W., et al., Mutations of the CHK2 gene are found in some
osteosarcomas, but are rare in breast, lung, and ovarian tumors. Genes
Chromosomes Cancer, 2002. 33(1): p. 17-21.

63.

McCubrey, J.A., et al., GSK-3 as potential target for therapeutic intervention in
cancer. Oncotarget, 2014. 5(10): p. 2881-911.

64.

Tu, S.W., et al., WNK1 is required for mitosis and abscission. Proc Natl Acad Sci
U S A, 2011. 108(4): p. 1385-90.

206

65.

Sun, X., et al., Down-regulation of WNK1 protein kinase in neural progenitor
cells suppresses cell proliferation and migration. J Neurochem, 2006. 99(4): p.
1114-21.

66.

Wang, L., et al., PRAS40 regulates mTORC1 kinase activity by functioning as a
direct inhibitor of substrate binding. J Biol Chem, 2007. 282(27): p. 20036-44.

67.

White, D.E. and W.J. Muller, Multifaceted roles of integrins in breast cancer
metastasis. J Mammary Gland Biol Neoplasia, 2007. 12(2-3): p. 135-42.

68.

Aplin, A.E., A.K. Howe, and R.L. Juliano, Cell adhesion molecules, signal
transduction and cell growth. Curr Opin Cell Biol, 1999. 11(6): p. 737-44.

69.

Carreiras, F., et al., Migration properties of the human ovarian
adenocarcinoma cell line IGROV1: importance of alpha(v)beta3 integrins and
vitronectin. Int J Cancer, 1999. 80(2): p. 285-94.

70.

Sargiannidou, I., J. Zhou, and G.P. Tuszynski, The role of thrombospondin-1 in
tumor progression. Exp Biol Med (Maywood), 2001. 226(8): p. 726-33.

71.

Miao, W.M., et al., Thrombospondin-1 type 1 repeat recombinant proteins
inhibit tumor growth through transforming growth factor-beta-dependent and
-independent mechanisms. Cancer Res, 2001. 61(21): p. 7830-9.

72.

Zhang, X., et al., Antiangiogenic treatment with three thrombospondin-1 type 1
repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Clin Cancer Res, 2005. 11(15): p. 5622-30.

73.

Greenaway, J., et al., ABT-510 induces tumor cell apoptosis and inhibits ovarian
tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer.
Mol Cancer Ther, 2009. 8(1): p. 64-74.

74.

Said, N., I. Najwer, and K. Motamed, Secreted protein acidic and rich in cysteine
(SPARC) inhibits integrin-mediated adhesion and growth factor-dependent
survival signaling in ovarian cancer. Am J Pathol, 2007. 170(3): p. 1054-63.

75.

Beck, V., et al., ADAM15 decreases integrin alphavbeta3/vitronectin-mediated
ovarian cancer cell adhesion and motility in an RGD-dependent fashion. Int J
Biochem Cell Biol, 2005. 37(3): p. 590-603.

76.

Hong, G., L.M. Baudhuin, and Y. Xu, Sphingosine-1-phosphate modulates
growth and adhesion of ovarian cancer cells. FEBS Lett, 1999. 460(3): p. 5138.

77.

Cohen, M., et al., Acellular fraction of ovarian cancer ascites induce apoptosis
by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian
cancer cells. Oncoscience, 2014. 1(4): p. 262-71.

207

78.

Ahmed, N. and K.L. Stenvers, Getting to know ovarian cancer ascites:
opportunities for targeted therapy-based translational research. Front Oncol,
2013. 3: p. 256.

79.

Puiffe, M.L., et al., Characterization of ovarian cancer ascites on cell invasion,
proliferation, spheroid formation, and gene expression in an in vitro model of
epithelial ovarian cancer. Neoplasia, 2007. 9(10): p. 820-9.

80.

Carmeliet, P. and R.K. Jain, Angiogenesis in cancer and other diseases. Nature,
2000. 407(6801): p. 249-57.

81.

Bryant, C.S., et al., Reduction of hypoxia-induced angiogenesis in ovarian
cancer cells by inhibition of HIF-1 alpha gene expression. Arch Gynecol Obstet,
2010. 282(6): p. 677-83.

208

Figure S4-11: SPON1 affects EOC cell adhesion in a dose-dependent manner.
HEY (A), OVCAR8 (B) and OVCAR3 (C) cells were treated with vehicle, 1 µg/ml
recombinant human SPON1 or 5 µg/ml recombinant human SPON1 at the time of
seeding. After 48 h the cells were detached first with 0.06% trypsin. Any adherent cells
remaining were then detached with 0.25% trypsin. Cells from each pool were then
counted. The proportion of cells detached by 0.06% trypsin is shown. Cells remained
attached when incubated with 1 µg/ml SPON1 after weak trypsinization compared to
controls. Treatment with 5 µg/ml SPON1 significantly increased the proportion of total
cells that detached with weak trypsinization compared to vehicle. The data represent the
mean ± SD of triplicate measurements. *p<0.05 as determined by one-way ANOVA
followed by Tukey’s post-hoc test.
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Figure S4-12: SPON1 does not affect the adhesion of OVCAR5 and OVCA429 cell
lines.
OVCAR5 (A) and OVCA429 (B) cells were treated with vehicle, 5 µg/ml carrier-free
recombinant human SPON1 or 10 µg/ml carrier-free recombinant human SPON1 at the
time of seeding. After 48 h the cells were detached first with 0.06% trypsin (OVCAR5
incubated for 2 min, OVCA429 for 1 min in 0.06% trypsin). Any adherent cells
remaining were then detached with 0.25% trypsin. Cells from each pool were then
counted. The proportion of cells detached by 0.06% trypsin is shown. Treatment with
SPON1 did not have an affect on the proportion of total cells that detach with weak
trypsinization compared to vehicle. The data represent the mean ± SD of triplicate
measurements from two independent experiments. Differences in cell detachment
between vehicle and SPON1 treatments were analyzed by one-way ANOVA with
Tukey’s test.
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Figure S4-13: Ovarian cancer cell migration is not affected by SPON1.
EOC cell lines were treated at the time of seeding in the upper chamber of transwell
inserts with 5 µg/ml recombinant human SPON1 or left untreated. Cells were allowed to
migrate across the transwell membrane towards 5 µg/ml recombinant human SPON1 in
0.5% FBS or 10% FBS. EOC cell migration was not effected by the presence of SPON1.
Effect of treatment determined by one-way ANOVA. Treatments (Top of insert/ Bottom
of insert): (1) 0.5% FBS/ 0.5% FBS; (2) 0.5% FBS/ 10% FBS; (3) 0.5% FBS/ 0.5%
FBS+5 µg/ml SPON1; (4) 0.5% FBS+5 µg/ml SPON1/ 10% FBS; (5) 0.5% FBS+5 µg/ml
SPON1/ 10% FBS+5 µg/ml SPON1.
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Figure S4-14: SPON1 does not affect the chemotaxis of HEY cells.
The ibidi µ-Slide Chemotaxis2D system was used to determine whether SPON1 acts as a
chemoattractant or chemorepellant. HEY cells were seeded in the observation chamber of
the slide and the bottom chamber was filled with 0.5% FBS. The top chamber was filled
with (A) 0.5% FBS, (B) 10% FBS or (C) 0.5% FBS+10 µg/ml recombinant human
SPON1. Cells were allowed to migrate over 24 h. Images were captured at 0 h, 6 h and
24 h. The experiment was repeated three times and representative images are shown.
HEY cells migrated randomly indicating SPON1 does not affect their chemotaxis.
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Figure S4-15: SPON1 does not affect the viability of OVCAR5 and OVCA429
ovarian cancer cell lines.
Cell viability was assessed in OVCAR5 (A) and OVCA429 (B) cells by MTS assay in
the presence or absence of SPON1. Cells were cultured in BSA vehicle (black bars) or
5 µg/mL human recombinant SPON1 (grey bars). Each bar represents the mean ± SD of
triplicate measurements. Each assay is representative of three independent experiments.
SPON1 does not significantly affect the viability of these EOC cell lines. Two-way
ANOVA with Tukey’s test was performed.

213

214

Figure S4-16: The effect of serial dilutions of recombinant human SPON1 on the
viability of EOC cell lines.
Cell viability was assessed in HEY (A), OVCAR8 (B) and OVCAR3 (C) cells by MTS
assay. Cells were cultured in BSA (vehicle) or serial dilutions of human recombinant
SPON1 (1 µg/mL, 5 µg/mL or 10 µg/mL). Each bar represents the mean ± SD of
triplicate measurements. The viability of EOC cells was not affected by 1 µg/mL SPON1
treatment. HEY cell viability was significantly decreased with 5 µg/mL and 10 µg/mL
SPON1 treatment, but a dose response relationship does not exist because there was not a
significant difference in HEY cell viability between 5 µg/mL and 10 µg/mL SPON1. The
viability of OVCAR3 and OVCAR8 cells was not affected by SPON1 treatment.
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Figure S4-17: Replenishing recombinant human SPON1 treatment daily does not
increase the effect of exogenous SPON1 on viability of EOC cell lines.
Cell viability was assessed in HEY (A), OVCAR8 (B) and OVCAR3 (C) cells by MTS
assay. Cells were cultured with BSA (vehicle) or 5 µg/mL human recombinant SPON1,
and treatments were replenished daily. The effect on viability of EOC cell lines was the
same whether cells were treated with a single dose of recombinant SPON1 (Figure 4-7)
or when recombinant SPON1 was replenished daily. Two-way ANOVA with Tukey’s
test was performed (**p<0.01).
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Figure S4-18: siRNA-mediated knockdown of SPON1 was not achieved.
Western blot performed for SPON1 as indicated on HEY (A), OVCAR8 (B) and
OVCAR3 (C) cells 48 and 72 h after transfection. β-actin was used as a loading control.
Lanes: (1) 48 h No treatment (NT); (2) 48h 10nM siRNA 1; (3) 48h 10nM siRNA 2; (4)
48h 10nM siRNA 3; (5) 72 h NT; (6) 72h 10nM siRNA 1; (7) 72h 10nM siRNA 2; (8)
72h 10nM siRNA 3. Densitometric quantification was carried out using ImageJ software,
and calculating SPON1 expression relative to β-actin control. The NT controls (Lane 1
and Lane 5) were considered as 100% SPON1 expression and all values were normalized
to these values (Lanes 2-4 were normalized to Lane 1, Lanes 6-8 were normalized to
Lane 5).
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Figure S4-19: Anti-SPON1 antibodies did not block SPON1 function.
A) Cell viability was assessed using the MTS assay. Four antibodies generated against
SPON1 (1 µg/mL and 10 µg/mL) were co-incubated with HEY cells in an attempt to
block endogenous SPON1 function. Co-incubation with the antibodies did not increase
cell viability, which indicated SPON1 function was not blocked. Two-way ANOVA with
Tukey’s Test was performed (*p<0.05).
B) HEY cells were co-incubated with anti-SPON1 antibodies – ab40797 and 3 Santa
Cruz antibodies combined (SCC) ± 5 µg/ml recombinant human SPON1. After 48 h the
cells were detached first with 0.06% trypsin and any adherent cells remaining were then
detached with 0.25% trypsin. Cells from each pool were then counted. The proportion of
cells detached by 0.06% trypsin is shown. Co-culture with anti-SPON1 antibodies did not
block SPON1 function. The data represent the mean ± SD of triplicate measurements.
One-way ANOVA with Tukey’s Test was performed (*p<0.05)
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Figure S4-20: Phospho-kinase array in control and SPON1-treated EOC cells.
HEY (A) and OVCAR3 (B) cells were incubated for 15 min with 250 µg/ml BSA
(vehicle control) or 5 µg/ml SPON1. Total protein lysates were incubated with
membranes containing capture antibodies (spotted in duplicate) against kinase
phosphorylation sites (R&D Systems). The membranes were then incubated with
biotinylated detection antibodies, streptavidin-HRP, and proteins were detected using
chemiluminescence. Densitometric quantifications were done using ImageJ software,
data are presented in the graphs as a mean pixel density (n = 2 spots). Spots: 1) ERK1/2
(T202/Y204, T185/ Y187); 2) GSK-3α/β (S21/S9); 3) Akt 1/2/3 (S472); 4) Chk-2 (T68);
5) PRAS40 (T246); 6) p53 (S392); 7) p53 (S46); 8) p53 (S15); 9) WNK1 (T60).
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Chapter 5

5

Discussion

5.1 Summary of findings
The ECM plays an active and complex role in regulating cell growth, survival,
motility, polarity and differentiation. It also provides the structural foundation required
for tissue function and regulates the availability of growth factors and cytokines. The
studies within this thesis examined the expression of several ECM components within the
ovary of the ERβ-knockout mouse (βERKO) and the role of the ECM protein, Spondin 1,
in the progression of epithelial ovarian cancer (EOC).
Microarray analysis performed by Dr. Deroo indicates that ECM expression is
disrupted in βERKO GCs [1] and may contribute to the attenuated folliculogenesis
observed in βERKO ovaries. To further investigate these observations (Chapter 2), I used
qPCR and immunofluorescence (IF) assays to characterize the ovarian expression and
localization of two ECM proteins that had been identified as differentially expressed in
ERβ-null GCs, namely Collagen 11A1 (Col11a1) and Nidogen 2 (Nid2) [1]. I found that
expression of both Collagen11a1 and Nid2 is significantly higher in βERKO ovaries than
in wildtype ovaries as early as PND 13, and this heightened expression continues through
PND 23–29 into adulthood. Similarly, I examined the expression and localization of the
ECM proteins Collagen IV (Col4a1), Nidogen 1 (Nid1) and Laminin (Lama1), which had
not been identified by the original microarray, but are well-known mouse ovarian ECM
proteins. Collagen IV, Nidogen 2 and Laminin were also more highly expressed in the
βERKO ovary than in wildtype. This data suggests that ERβ represses the expression of
several ECM proteins in the mouse ovary. In addition, given that dysregulation was
observed as early as PND 13, my data also indicates that granulosa cell (GC) gene
expression is regulated by ERβ prior to puberty—an unexpected and novel finding.
In Chapter 3, I investigated a potential mechanism by which ERβ may be acting
as a transcriptional repressor in GCs. I used transient transfection assays to show that the
bHLH transcription factor, TCF21, regulates estradiol-dependent transcriptional activity
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in an ER isoform-specific manner, and represses ERβ, but not ERα-driven
transactivation. TCF21 represses ERβ-mediated transcription of a 3x-ERE reporter in
several cell lines, as well as three naturally occurring estrogen responsive promoters
(pS2, C3 and Lf). This repression does not require TCF21 heterodimerization with E12.
Lastly, the bHLH transcription factor Mist1 does not repress ERβ-mediated transcription
of the 3x-ERE reporter, suggesting that not all bHLH proteins repress ERβ-mediated
transcription. Despite our best efforts we were unable to show that TCF21 forms a
complex with ERβ in vivo. Therefore, we turned our focus to another ERβ-dependent
ECM protein identified in Dr. Deroo’s microarray, SPON1, and its potential role in
ovarian cancer progression.
SPON1 is highly overexpressed in ovarian cancer and has recently been identified
as a promising ovarian cancer marker, particularly for high-grade serous EOC. Therefore,
in Chapter 4, I examined whether SPON1 affects key ovarian cancer cell functions in
immortalized EOC cell lines and in human primary ascites-derived ovarian cancer cells. I
confirmed by Western blot that SPON1 is expressed and secreted by both immortalized
ovarian cancer cell lines and primary ascites-derived ovarian cancer cells. Although I was
unable to silence SPON1 expression in EOC cell lines using siRNA or functional
blocking with antibodies, I performed several functional assays to assess whether
treatment of EOC cells with recombinant SPON1 affects specific cellular processes. My
data demonstrated that SPON1 significantly reduced EOC cell adhesion, viability and
proliferation; however, it did not affect cell migration. Finally, using a non-adherent
culture system I examined whether SPON1 affects EOC spheroid formation and
subsequent reattachment to adherent tissue culture plastic. Treatment of EOC cells with
recombinant SPON1 prior to spheroid formation did not impact the formation or
reattachment of spheroids. However, treatment of spheroids with recombinant SPON1
following transfer to adherent tissue culture plastic did increase the cell dispersion area of
spheroids that had re-attached. These data suggest that SPON1 regulates a subset of
functions of ovarian cancer cells.
In summary, my thesis work has shown that ECM proteins are aberrantly
overexpressed in the βERKO mouse ovary, as well as high-grade serous EOC. The
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expression of the ECM proteins investigated herein is ERβ-dependent. This body of work
contributes to our understanding of the role ECM proteins have in ovarian development
and ovarian cancer progression.

5.2 Potential mechanisms by which the ECM regulates
ovarian follicle development/ growth and EOC
progression
The histological analysis of mammalian organs demonstrates the incredible
complexity of cellular organization required to build and maintain normal tissues [2]. The
disruption of this structural organization usually leads to disease and neoplastic
transformation. Several biological functions are mediated by the interaction of ECM
proteins with binding partners, which include other ECM components, growth factors,
signal receptors and adhesion molecules [3, 4]. Normal tissue organization requires two
key components: (1) organized cell-cell and cell-ECM adhesion, and (2) the
establishment and maintenance of cell polarity. The dysregulation of these two functions
is a hallmark of cancer. In this section of the Discussion, I will briefly introduce the key
features of organized adhesion and polarity, and describe how these features relate to
ovarian follicle growth and EOC progression. Finally, I will discuss how the ECM
proteins I investigated may be affecting these two critical components of tissue
organization. Specifically, I believe that the ECM proteins I investigated in Chapter 2
help maintain ovarian structural integrity, whereas Spondin 1 (Chapter 4) is a
matricellular protein that lacks a structural role but is involved in cell-matrix interactions.

5.2.1

Adhesion
Within tissues, cells physically interact with the ECM (cell-ECM adhesion) as

well as neighbouring cells (cell-cell adhesion). The correct adhesion of a cell to ECM
components determines whether the cell is in the correct location and consequently
regulates cell survival. Cells that lose cell-cell or cell-ECM adhesion undergo apoptosis
to restrict inappropriate cell growth [5]. Various adhesion molecules mediate cell-cell and
cell-ECM interactions, and functional units of cell adhesion can be grouped into three
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general classes: adhesion receptors, ECM proteins, and cytoplasmic membrane proteins
[6].
Cell adhesion receptors are typically transmembrane glycoproteins, and include
members of the cadherin, integrin, immunoglobulin, selectin and proteoglycan
superfamilies [6]. These receptors bind to other adhesion receptors on neighbouring cells
or to proteins of the ECM. ECM proteins include members of the collagen, fibronectin,
nidogen, laminin, and proteoglycan families.
Cadherins are one of the most important and ubiquitous cell adhesion receptors
involved in cell-cell adhesion and recognition [7]. They are associated with adherens
junctions, which link adjacent cells, and exhibit functional adhesion activity by forming a
complex with catenins and the actin cytoskeleton [6]. Classic members of the cadherin
family are named for the tissue in which they were originally discovered, and include E
(epithelial), N (neural), P (placental), and VE (vascular endothelial) cadherin [8].
Focal adhesions are large, dynamic, integrin-containing complexes that connect
cells to the ECM. Integrins are the major adhesion receptors within focal adhesions, and
facilitate crosstalk between the ECM and the cell. The stimulation of integrins triggers
intracellular signals and activates signalling proteins such as focal adhesion kinase (FAK)
[9]. Cells adhere to the ECM via specific integrin-matrix ligand interactions.
Several studies have demonstrated that cell-cell and cell-ECM adhesions are
interdependent, and that modulation of extracellular factors that alter cell-ECM
interactions can directly impact cell-cell interactions [10-12]. The interdependence of
cell-cell and cell-ECM forces is likely disrupted by the overexpression of ECM
components, which has implications in development and disease.
5.2.1.1

Adhesion in folliculogenesis and its disruption in the βERKO ovary

There are several changes to cell-cell and cell-matrix adhesions that occur during
the functional and morphological changes of folliculogenesis; consequently both
cadherins and integrins are involved in the maintenance and remodeling of the ovary [13,
14]. E-cadherin and N-cadherin are expressed throughout prepubertal development in the
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oocyte and GCs, respectively. Adherens junctions expressing N-cadherin exist between
GCs and between GCs and the oocyte [15]. Blocking N-cadherin reduces follicle
formation, whereas blocking E-cadherin accelerates follicle formation, suggesting the
latter is likely involved in maintaining oocytes in nests (clusters of germ cells that break
down to form primordial follicles) [16]. Multiple laboratories have reported the presence
of integrins in the ovary [14, 17]; however, unlike the cadherins, the role of integrins in
ovarian function is less clear. Integrin α6β1, for example, is likely necessary for
maintaining a healthy, nonluteal GC phenotype [14]. Burns et al. found that several
integrin subunits were expressed at various stages in folliculogenesis; however, their role
in follicle growth has not been pursued [14]. The integrin subunit β3 has been detected in
GCs, TCs and interstitial cells and it is postulated that FSH controls its expression [17].
My data suggest that cell-cell and/or cell-ECM interactions may be disrupted in
the βERKO ovary. The effect of overexpressed ECM components on GC adhesion and
adhesion complexes can be examined using several techniques. One mechanism, by
which the overexpressed ECM proteins may be affecting cell adhesion, is by
dysregulating the expression of adherens junction and/or focal adhesion components [1821]. A potential preliminary experiment to determine whether cell-cell or cell-ECM
adhesion complexes are disrupted in the βERKO mouse would be to characterize the
expression (qPCR and Western blot) and localization (IF) of cadherins and integrins
known to be expressed throughout folliculogenesis. Secondly, adhesion can be assessed
with the Detachment and Adhesion Assays that I used in Chapter 4; GC cell lines can be
treated with recombinant protein and cell adhesion measured using these established
techniques. Alternatively, we could create transgenic mice that overexpresses Col11a1 or
Nid2 using GC-specific promoters (CYP19A1-Cre for FSH-responsive stage, PRE-Cre
for the luteal stage), and examine the expression of adherens junction and focal adhesion
components.
The potential impact that ECM proteins within the focimatrix have on GC
adhesion is of particular interest, because unlike the follicular basal lamina, the function
of the focimatrix remains largely unknown. Although its punctate morphology suggests it
is does not perform typical basal lamina functions, such as filtering material or creating
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microenvironments for enclosed cells [22], it has been postulated by Irving-Rogers et al.
that GCs interact with the focimatrix via integrins [23]. I propose that the overexpressed
ECM proteins in the βERKO focimatrix compete for integrin receptors [24-26].
Therefore, the “integrin binding competition” disrupts accurate integrin-matrix adhesions,
thereby disrupting integrin-signaling. Of note, Nidogen 2, which was significantly
overexpressed in the βERKO mouse focimatrix, has previously been reported to interact
with integrin α6β1 in vitro [27], which is expressed in the mouse ovary [14]
There is compelling evidence in the literature that in addition to biochemical
signaling and hormonal cues, mechanical signaling from the physical environment
regulates the development and function of the ovary [28, 29]. This regulation can occur in
a number of ways. Firstly, the physical environment regulates follicle growth in culture
when hormonal stimulation is constant [29, 30]. For example, the substrate on which a
follicle is cultured (collagen, laminin or a poly-L-lysine control) affects theca cell (TC)
development and antrum formation [28]. Secondly, a rigid, dense environment within the
ovary maintains primordial follicles in a dormant state. As a follicle migrates towards the
medulla of the ovary it moves into a less dense matrix, which permits follicle growth;
therefore, the ovarian physical environment may initiate the growth of an immature,
dormant follicle [31]. In vitro, decreasing matrix stiffness and solids concentration of
alginate hydrogel enhances follicle growth and function, whereas a stiff environment
hinders follicle development [30]. If the overexpressed ECM proteins in the βERKO
ovary maintain a higher-than-normal ECM density compared to wildtype, the βERKO
follicles would be more rigid, thus restricting follicle growth. The movement of follicles
from a dense to a less dense environment may also be hindered by this increased matrix
density, and consequently contribute to the premature arrest of folliculogenesis observed
in the βERKO ovary.
In summary, I predict that the higher expression of ECM components disrupts the
maintenance of the adherens junction and focal adhesion complexes as well as matrix
stiffness within the follicle. Aberrant expression of adhesion complex proteins may
impact mechanical signals that are relayed to the cells by cell adhesion receptors.
Consequently, these dysregulated mechanically induced signaling cascades may impact
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cell form and function, ultimately leading to the arrest of follicle growth and subfertility
observed in βERKO mice.
5.2.1.2

Adhesion and EOC tumour progression

Reversible changes in cell-cell and cell-matrix adhesion occur to facilitate ovarian
tumour progression. The initial dissemination of cells from the primary tumour
necessitates a disruption of cadherin-mediated cell-cell adhesions as well as integrinmatrix contacts. Subsequently, tumour cells in suspension utilize cell-cell adhesions to
form multicellular spheroids. The development of metastases involves remodeling of the
cadherin-based adhesions as the spheroid disaggregates on the mesothelium of the
peritoneal cavity, while the integrin-matrix adhesions anchor the cells to the mesothelium
[32-34]. Therefore, it would be of interest to examine the role of SPON1 in mediating the
adhesion between tumour cells, as wells as its contribution to tumour-stroma interactions.
Furthermore, cell survival and proliferation are adhesion-dependent phenomenon in
anchorage-dependent tumor cells, therefore the decreased viability and proliferation of
EOC cells I have observed following treatment with recombinant SPON1 may be a result
of decreased cell adhesion.
The ovarian surface epithelium (OSE) is unlike the majority of epithelia because
it generally lacks E-cadherin expression; rather its cell-cell integrity is maintained by Ncadherin [35]. E-cadherin expression becomes more abundant during ovarian
carcinogenesis; however, its expression is reduced at advanced stages and in ascitesderived tumour cells. This is referred to as the “cadherin switching”, whereby N-cadherin
and P-cadherin compensate for the loss of E-cadherin in advanced tumours and EOC
spheroids [36]. The switch in cadherin expression is indicative of an EMT (discussed in
Section 5.2.2).
The ability to resist anoikis is a critical mechanism in tumour metastasis [37], and
EOC cells in suspension within the abdominal cavity form multicellular spheroids to
maintain cell-cell contact as part of their natural survival response [34]. Both integrins
and cadherins facilitate this cell compaction [38]. EOC spheroids acquire E-cadherinmediated adhesion as a means to suppress anoikis [35], and downregulation of E-
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cadherin has been shown to decrease EOC cell viability [39]. The formation of ovarian
cancer spheroids is also mediated by integrins, and spheroid formation is disrupted when
cells are treated with antibodies that block α5- or β1-integrin subunits [40]. In Chapter 4,
I found that treatment of spheroids with recombinant SPON1 after the spheroids were
transferred from non-adherent to adherent tissue culture dishes significantly increased the
cell dispersion area of the attaching spheroid. SPON1 is likely affecting cell adhesion
mechanisms in this model system. In the future, it would be interesting to investigate
whether SPON1 affects the cadherin switch by measuring the relative levels of Ecadherin, N-cadherin and P-cadherin, following spheroid formation, as well as the
expression of integrins involved in the disaggregation and re-attachment of spheroids.
The potential effect of exogeneous SPON1 on the mRNA and protein expression levels
of these adhesion components should also be examined.
As when formed into multicellular spheroids, individual ovarian cancer cells
express several integrins that allow them to bind ECM proteins, and many integrins have
been shown to affect the adhesion of EOC cells [41-44]. To examine whether integrins
and their associated signaling proteins are involved in the SPON1-mediated decrease in
EOC cell adhesion that I observed in both ovarian cancer cell lines and EOC patient
samples, select molecules can be investigated in future studies. FAK and αvβ3 integrin
would be ideal preliminary targets because both are expressed in ovarian cancers (both
promote tumour progression) [43, 45-47], and SPON1 has been shown to interact with or
signal through them in other model systems [25, 48]. Phosphorylation of FAK promotes
cancer cell growth; therefore, if SPON1 inhibits FAK phosphorylation (as observed in
HUVECs [25]) it may be a mechanism by which SPON1 reduces EOC cell adhesion and
proliferation, as I observed in Chapter 4. SPON1-induced changes in FAK
phosphorylation can be examined by immunoblot. Additionally, FAK can be silenced
using siRNAs, and functional assays can be performed to determine whether SPON1 is
acting through FAK to effect cell adhesion and proliferation.
Alternatively, SPON1 may be acting through integrin αvβ3 to exert its effects on
EOC cell adhesion, potentially by disrupting the interaction of this integrin with
vitronectin. Vitronectin is a ligand of integrin αvβ3, and this interaction promotes
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adhesion, proliferation, and motility of ovarian cancer cells [43]. Blocking αvβ3 integrin
function inhibits vitronectin-induced migration of ovarian cancer cells [47]. SPON1 has
previously been shown to block the integrin αvβ3/vitronectin interaction in HUVECs [25].
Therefore, binding of SPON1 to integrin αvβ3 (over vitronectin) may decrease integrin
αvβ3/vitronectin-mediated ovarian cancer cell adhesion and growth, thereby disrupting the
intracellular signals regulating cell survival and progression. The expression of integrin
αvβ3 can be blocked using neutralizing antibodies against its subunits, an approach that
has been successfully utilized with several integrins in ovarian cancer [41]. Considering
we were unable to successfully silence SPON1 expression with an siRNA approach,
identifying and silencing its downstream targets will be a valuable alternative method to
continue exploring the role of SPON1 in the metastatic progression of EOC.
There are many examples in the literature where a change in cell adhesion
corresponds to a change in cell motility and invasion [41, 43, 47-51]. Therefore, it was
surprising that the SPON1-induced decrease in adhesion did not correspond to an effect
on EOC cell migration in trans-well assays (Chapter 4, Fig. S3). This may be a limitation
of the technique I used. An alternative functional assay, for example the scratch-wound
assay, may demonstrate that SPON1 affects cell motility (as suggested by the increased
cell dispersion area following treatment of spheroids with SPON1).

5.2.2

Cell polarity
Cells have a defined organization, with an asymmetric distribution of proteins and

physical features of the cell, including the cell surface, cytoskeleton and organelles. An
internal axis of polarity is created during morphogenesis and this creates apical-basal
polarity of the cell. Polarity is involved in the biological processes of cells and tissues
that necessitate an asymmetrical symmetry. These processes include growth, survival,
migration and epithelial-to-mesenchymal transitions (EMT) [52].
The synchronized actions of three protein complexes direct the establishment and
maintenance of apical-basal polarity: the Crumbs (Crumbs–Patj–Pals), Scribble
(Scribble–Lgl–Dlg) and Par (Par3–Par6–aPKC) complexes [2]. Atypical protein kinase
(aPKC) is the catalytic component of the Par complex [53]. There are two homologues of
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aPCK, aPCKι and aPKCζ, both of which have been implicated in human cancers; aPCKι
expression is upregulated in ovarian cancer and correlated with poor prognosis [54].
Polarity is achieved by the interaction of these three complexes with the structural
components of the cytoskeleton and adherens junctions between cells. Several
extracellular cues are required for the epithelial cells to exhibit all aspects of polarity, and
attachment to the ECM prompts the formation of the apical-basal axis [2].
Adhesion and polarity are closely interrelated; cell polarity mechanisms rely on
the formation and maintenance of adherens junction complexes, and the activities of the
polarity complexes are required for the maintenance of adherens junction complexes [2].
EMT, which occurs in normal physiological processes but has also been linked to cancer
progression, requires the disruption of cell-cell and cell-matrix adhesions, as well as the
loss of apical-basal polarity [52]. EMT is a process by which a polarized epithelial cell,
which normally interacts with the basement membrane (BM), undergoes several
biochemical changes that allow it to take on a mesenchymal phenotype, which involves
greater motility, invasiveness, resistance to apoptosis and an increased production of
ECM components [55]. The establishment and maintenance of both somatic and germ
cell polarity are essential features in ovarian development and folliculogenesis [56].
5.2.2.1

Cell polarity and folliculogenesis

It has previously been established that aberrant polarization of GCs can affect all
stages of folliculogenesis, from the recruitment of primordial follicles to the atresia of
preovulatory follicles [57]. It remains a point of contention whether GCs lose their
polarity prior to ovulation or once they luteinize. The original theory was that GCs are
polarized, whereas luteal cells are not [58]. Mora and colleagues, however, have recently
suggested that GCs undergo a partial and contained EMT, which is completed at
ovulation [15]. A transition such as this is unusual in adult tissues, because EMT usually
occurs during development or tumour progression. In support of the concept of partial
EMT, Irving-Rodgers and colleagues have proposed that prior to the expression of the
focimatrix the follicular basal lamina dictates the polarity of GCs, which enables
directional secretion, uptake of molecules, and other polarized functions [59]. Once the
focimatrix is expressed basal lamina components are interspersed between the GCs,
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which may reduce the polarization cue from the follicular basal lamina. The change in
polarity may initiate the partial EMT, which is only completed after ovulation when GCs
luteinize and lose their epithelial nature.
Considering that the ECM can define positional information and differentiation
cues in tissues [52], I hypothesize that the elevated expression of ECM proteins in the
βERKO ovary disrupts cell polarity cues within the follicle, ultimately compromising
folliculogenesis.
The increased expression of Col11a1 around individual βERKO GCs may
influence the expression of adherens junction proteins, and therefore compromise
follicular cell polarity. The pattern of expression of Col11a1, specifically, encircling
individual GCs, very subtly resembles that of the adherens junction components Ncadherin and β-catenin in wildtype ovaries; unlike Col11a1, N-cadherin and β-catenin do
not encircle the GCs completely, they are are localized to one side of GCs [57].
Interestingly, the expression of N-cadherin and β-catenin is disrupted in another mouse
model with compromised ovarian folliculogenesis and fertility (Wnt4mCh/mCh ; transgenic
mouse with disrupted Wnt4 activity due to the insertion of the mCherry fluorescent
protein), and the disrupted expression pattern of both N-cadherin and β-catenin is
strikingly similar to that of Col11a1in the βERKO mouse ovary (completely encircling
individual GCs) [57]. Previously published results have shown that collagens can affect
the expression of cadherins and catenins [18, 20, 21]; therefore I postulate that the
overexpression of Col11a1 at sites of adherens junctions disrupts the expression of
cadherins and catenins in the mouse ovary, which dysregulates polarity. The Col11a1induced disruption of cadherin and catenin expression in the βERKO ovary can be
determined by measuring gene expression in isolated GCs using qPCR. Furthermore,
primary GC and GC cell lines can be plated on uncoated and Col11a1-coated dishes, and
the expression of adherens junction components determined by qPCR and Western blot
[19]. The assembly of adherens junctions can also be determined by IF [20]. If adherens
junction complexes are dysregulated, polarity markers should then be assessed using
similar techniques.
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My studies have also shown that the expression of Nidogen 2 is elevated in the
βERKO focimatrix. At present, the role of the focimatrix in follicle development remains
unknown; however, the suggestion that it impacts polarity is worth investigating.
Examining the role of the focimatrix in maintaining cell polarity would be difficult.
Specifically, replicating in vitro the punctate localization of the focimatrix around the
GCs, and thereby the polarity cues from all sides of the GCs would be challenging.
I have carried out preliminary IF experiments to investigate cell polarity in
βERKO and WT mouse ovaries by examining the relative expression aPKCζ in ovarian
sections (Appendix, Figure 6-1). Previous studies have shown that aPKCζ is expressed in
preovulatory GCs of the rat [60] and suggested aPKCζ may be involved in the regulation
of ovulation [61]. Interestingly, I found that the localization pattern of aPKCζ differs
between prepubertal (PND 23) βERKO and WT ovaries. In WT ovaries aPKCζ is easily
detected in GCs closest to the BM; however, its expression is low or undetectable in GCs
closer to the oocyte. In contrast, in βERKO ovaries I consistently observed expression of
aPKCζ in both GCs closer to the oocyte and BM. Future studies are required to confirm
and expand on these preliminary results. Initially, these preliminary results require
confirmation. Subsequently, the expression of aPKCζ in the βERKO mouse ovary can be
characterized at earlier (for example, PND 13 when we see dysregulation of ECM
proteins) and later stages to determine when this dysregulation is occurring. If this
disrupted aPKCζ expression persists to the antral stage, I postulate, based on the
localization at the pre-antral stage, that βERKO cumulus and mural GCs will express
aPKCζ, whereas only mural GCs will express aPKCζ in wildtype follicles. This disrupted
polarity may impair cumulus cell differentiation, thereby disrupting cumulus cell-oocyte
complex (COC) expansion, which is known to be inhibited in βERKO ovaries [62]. There
are several techniques that could be utilized to pursue these hypotheses, including the
development of a GC-specific aPKCζ, knockout mouse, as well as utilizing qPCR to
compare the levels of polarity markers (e.g. aPKCζ and Par6) between isolated COC and
mural GCs from βERKO and wildtype mice.
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5.2.2.2

Cell polarity and ovarian cancer

The loss of cell polarity and consequent tissue disorganization is a hallmark of
cancer and increased malignancy [52]. Several studies have demonstrated that changes in
the activation or expression of core cell polarity proteins are implicated in the
development of human cancers (reviewed in [2]). Importantly, the loss of apical-basal
cell polarity (along with the loss of cell-cell adhesion) is necessary for EMT, which is a
key step in cancer cell migration and invasion. The loss of polarity also permits growth
factors and receptors, which are normally compartmentalized by tight junctions in
polarized cells, to induce aberrant autocrine cell activation [53].
Oncogenic signaling has been shown to directly disrupt cell polarity mechanisms
[54]. It is well-accepted in the literature that TGFβ is a major inducer of EMT, and
TGFβ-induced EMT often coincides with a loss of E-cadherin expression [63]. TGF-β
receptors bind directly to Par6, leading to the recruitment of aPKC and interference with
apical-basal polarity by changing the binding partners, composition and localization of
Par6-aPKC [64, 65]. The TGF-β-induced inactivation of the Par complex induces the
cells to undergo EMT.
SPON1 signaling mechanisms in ovarian cancer cells (and most other cells)
remains to be elucidated. However, SPON1 has previously been shown to activate latent
TGFβ in embryonic and osteoarthritis articular chondrocytes [66, 67]. Therefore, SPON1
may have a role in TGFβ signaling in ovarian cancer and be indirectly involved in the
regulation of PKCι. It would also be of interest to examine whether treatment of EOC
cells with recombinant SPON1 or silencing SPON1 expression impacts EMT. Future
studies could utilize qPCR to determine whether SPON1 affects the cadherin switch (Ecadherin, N-cadherin) and examine the expression of several transcription factors
involved in EMT (e.g. Snail, Slug, Twist and ZEB) during the formation of spheroids and
subsequent re-attachment.
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5.3 An early role for ERβ-regulated ECM proteins in the
ovary
While it is well established that estradiol acting through ERβ is required to
augment the GC response to FSH for the formation of a preovulatory follicle, fewer
studies exist establishing a role for estradiol in folliculogenesis, prior to the gonadotropin
surge at puberty, and the role of ERβ prior to puberty remains largely unexplored. My
data demonstrate that ERβ regulates gene expression in the mouse ovary much earlier
than previously thought. Further studies are required to determine at what stage the
expression of ECM components is disrupted and when this disruption impacts follicle
growth.
I have performed preliminary IF experiments using βERKO ovaries that suggest
Col11a1 may be overexpressed as early as PND 5 or PND 8 (Appendix, Figure 6-2),
while the expression of Nid2 is comparable in βERKO and WT ovaries at these earlier
ages. Oktay et al. isolated ovaries from mice on PND 5 and showed that follicle growth
in vitro is not only affected by the presence of the ECM but also by the specific ECM
component on which the ovary is cultured [68]. Furthermore, the production of estradiol
is required for the optimal growth of follicles from the primordial to primary stage, and
specifically ERβ, but not ERα, is involved in this transition [69, 70]. Therefore, ERβregulated ECM composition may impact the growth of follicles from the primordial
stage.
Furthermore, ERβ-regulated ECM proteins could be involved during some of the
earliest stages of postnatal ovarian development, specifically by influencing oocyte nest
breakdown. In mice, the majority of nest breakdown occurs between PND 2 and PND 4;
however, small nests can be found in mice as old as PND 8 [71]. Nest breakdown and
primordial follicle formation are inhibited by estradiol, progesterone, and the
phytoestrogen genistein [72], and inhibition of nest breakdown can lead to the
development of multiple oocyte follicles (MOFs) in WT mice. βERKO mice, treated
neonatally with genistein, do not develop MOFs [73], suggesting that ERβ may be
involved in the regulation of nest breakdown. Future studies utilizing qPCR and IF will
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be required to assess whether ECM components are disrupted in βERKO ovaries at these
early stages.

5.4 TCF21-ERβ interactions: Novel findings and future
studies
Using a model of transient transfection of ERE-driven luciferase reporters, and
co-transfected expression plasmids of human ERβ and TCF21, I have shown that TCF21
represses ERβ-dependent activation of both synthetic and natural estrogen-responsive
promoters in several cell lines (Chapter 3). Based on these data, I hypothesized that
TCF21 and ERβ interact to form a complex in vivo. My objective was to utilize GSTpull-down analyses and co-immunoprecipitation (Co-IP) experiments to demonstrate and
further understand their interaction.
Despite our best efforts, we were unable to produce evidence of TCF21-ERβ
interactions using Co-IP. We tested a large variety of conditions including four different
lysis buffers, varying duration of cell lysis (20 min or 40 min), four cell lines, several
antibodies (three anti-ERβ and two anti-TCF21 antibodies), as well as transfection of
FLAG-ERβ and an anti-FLAG antibody. However, we were unable to show interaction,
regardless of which protein we used for the IP. Furthermore, all antibodies caused
technical difficulties due to inconsistent results, high background signal and non-specific
binding. One future approach to improving this assay might involve using a different tag
for ERβ, and using a tagged TCF21 construct. An alternative approach would be to create
our own ERβ antibody because the lack of a reliable, commercially available ERβ
antibody that does not cross-react with ERα is a well-known obstacle in the field [74, 75].
However, whether we could successfully create a specific ERβ antibody when so many
others have failed is unknown.
I was also unable to successfully purify GST-ERβ or GST-tagged ERβ deletion
mutants using an established protocol [76], and future troubleshooting is required. The
protein purification protocol will require optimization of several conditions including, but
not limited to, buffers, temperature at which bacterial cultures are grown as well as
incubation time, to achieve successful purification of functional proteins.
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Additional studies for consideration to investigate ERβ-TCF21 interaction include 1)
chromatin immunoprecipitation (ChIP) assays to determine whether TCF21 binds to the
ERβ promoter (using a tagged TCF21), and 2) qPCR and Western blot analysis to assess
whether TCF21 affects endogenous levels of ERβ mRNA and protein in granulosa cell
lines and primary granulosa cells. Binding of TCF21 to the ERβ promoter could
theoretically repress transcription of ERβ by either inhibiting the binding of RNA
polymerase to the promoter or inhibiting its release from the promoter [77].

5.5 ERβ- and 17β-estradiol-regulated ECM components:
An effect on ovarian cancer progression?
Epidemiological evidence indicates that the induction and progression of ovarian
cancer is related to estrogen exposure [78], and high estradiol levels are often observed in
EOC patients because both OSE and EOC cells secrete estradiol [79, 80]. Several studies,
using various model systems, have shown that estradiol treatment contributes to the
initiation and promotion of ovarian cancer growth. For example, treatment of
ovariectomized mice with estradiol increases tumour growth by over 400% compared to
controls [81]. Estradiol treatment has also been shown to promote growth, migration and
invasion of several ovarian cancer cell lines [78, 80]. Whether estradiol increases tumour
burden in vivo and decreases survival times is unclear because of variable results in the
literature [78, 82].
The expression of the ER in ovarian cancer is variable. Of the four EOC subtypes,
endometrioid ovarian cancer exhibits the highest occurrence of ER expression. Fujimura
et al. found that although all subtypes of clinically resected ovarian adenocarcinomas
express ERβ, ERβ expression is most often observed in endometrioid tumours (75% of
cases), as compared to serous (41%), clear cell (39%) and mucinous (30%). ERα is
expressed by all (100%) endometrioid tumours, 97% of serous tumours, 70% of
mucinous and is absent (0%) in clear cell samples. As in normal ovarian development,
the role of the two ERs differs in EOC development – high ERα levels are associated
with a worse prognosis, whereas high ERβ levels are associated with longer survival [80].
ERβ expression is weak in ovarian tumour tissues compared to normal ovarian tissues,
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likely decreasing over time with tumour progression, suggesting that ERβ has tumoursuppressive functions and a protective role [83, 84].

5.5.1

Spondin 1 in ovarian caner
The expression of Spon1 is disrupted in the βERKO ovary, suggesting it is

regulated by ERβ [1]. There is also evidence that Spon1 is regulated by 17β-estradiol;
when ovariectomized mice are treated with 17β-estradiol, Spon1 mRNA expression
increases in the uterus and mammary gland [85, 86]. Since endometrioid EOC is estradiol
responsive and has the highest occurrence of ER expression, future studies could utilize
this subtype, in addition to serous EOC, to assess whether estradiol and/or ERβ affect the
expression and activity of SPON1 in EOC cells. EOC cells can be treated with estradiol
and Spon1 expression measured by qPCR.
Repeating the functional assays used in Chapter 4 with endometrioid EOC cells
would be intriguing because survival analyses demonstrate that SPON1 is a higher risk
factor in endometrioid ovarian cancer, as compared to high-grade serous or all four
subtypes combined [87]. Although this thesis focused on high-grade serous cancer, the
most common and aggressive EOC subtype, it is possible that the other subtypes of
ovarian cancer would be affected differently by SPON1.

5.5.2

Collagen11A1 and Nidogen 2 in ovarian caner
Interestingly, both Col11a1 and Nid2, which are more highly expressed in the

βERKO ovary than in WT ovaries (Chapter 2), are elevated in serous histotypes of
ovarian cancer [88, 89]. There is no evidence in the literature that the disrupted
expression of these ECM components in EOC is related to ERβ or estradiol. However, it
is intriguing that their expression is elevated in two models where ERβ expression is lost
(βERKO ovary) or weakened (EOC). Furthermore, there is an inverse relationship
between the expressions of COL11A1 and NID2, and ERβ in ovarian tumours –
expressions of these ECM proteins is higher in more aggressive, late-stage serous ovarian
tumours than in earlier stages, whereas ERβ expression decreases with tumour
progression. Considering the ERβ-mediated repression of Col11a1 and Nid2 in the
normal mouse ovary, it would be of interest to determine whether their expression is also
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ERβ-dependent in EOC cells. Following the reintroduction of ERβ into EOC cells using
an adenoviral vector, the mRNA and protein expression of COL11A1 and NID2 could be
examined by qPCR and IF, respectively.

5.6 Does SPON1 have a dichotomous or context-specific
role in EOC progression?
My data suggest that SPON1 could be either tumour promoting or tumour
suppressive. I have shown that treatment with SPON1 decreases the viability and
proliferation of EOC cell lines as well as primary ascites-derived tumour cells, suggesting
that expression of SPON1 inhibits tumour growth. On the other hand, I have also shown
that treatment with SPON1 decreases EOC cell adhesion; however, it is unclear whether
this feature is oncogenic by promoting metastasis, or tumour suppressive, by impeding
the anchoring of cells within the peritoneal cavity to form secondary metastases. One
would expect that the overexpression of SPON1 in ovarian cancer tissues is oncogenic.
since it seems unlikely that EOC cells would make and secrete a protein that only hinders
their growth and metastasis. A possible explanation is that SPON1 has a dichotomous or
context-specific role in ovarian cancer development.
The concept of proteins having a dichotomous role in cancer development has
been described previously in several human cancers, including ovarian [90-95]. The
activity of a protein may vary based on the tumour environment, signaling pathways
driving tumour formation, available cellular binding partners (e.g. ECM, integrins), and
the status of malignancy. One of the most studied examples of this dichotomy is TCF-β,
which induces apoptosis and cell cycle arrest in normal or less transformed cells, but
enables metastasis in advanced tumours [96]. Transforming growth factor-beta-induced
protein (TGFBI/βig-H3) has been described as a “double-edged sword” in ovarian cancer
because its loss promotes tumourigenesis and a more chemoresistant phenotype;
however, in the peritoneal cavity the peritoneal cells express βig-H3 to facilitate
metastasis [93]. Furthermore, βig-H3 induces migration and invasion of OVCAR5 and
SKOV3 ovarian cancer cell lines, but does not affect the OVCAR3 cell line that is known
to be less metastatic [93].

237

Therefore, the role of SPON1 in ovarian cancer progression in vivo may depend on the
tumour microenvironment and tumour stage, and may not be defined simply as either
tumour suppressive or tumour promoting.

5.7 Would SPON1 make an appropriate therapeutic target
for EOC?
The high expression levels of SPON1 in ovarian carcinomas make it an
appropriate ovarian cancer biomarker. Its prospect as a therapeutic target remains to be
determined, especially considering it is unclear whether SPON1 has a tumour suppressive
or promoting role in ovarian cancer progression.
If SPON1 is shown to be tumour promoting, it may not be an ideal therapeutic
target because despite the diverse functions attributed to SPON1 in the literature, the
SPON1-/- mouse has a grossly normal phenotype, which suggests SPON1 is functionally
redundant. Therefore, silencing SPON1 expression or activity may result in the increased
expression of another protein(s), likely another member of the thrombospondin
superfamily that has similar domains (Section 1.7.3 - Proteins with similar domains),
which will compensate for the loss of SPON1 and assume its functions.
Alternatively, if SPON1 is tumour suppressive in certain contexts or stages of
malignancy, it may be beneficial to promote its expression once a mechanism for its
regulation is uncovered. For instance, if SPON1 expression is regulated by ERβ in EOC
cells (Section 5.5.1), using an ERβ-specific agonist may serve as an effective therapeutic
strategy. ERβ has previously been identified as a tumour suppressor in ovarian cancer in
vitro. The overexpression of ERβ in SKOV3 cells reduces proliferation, inhibits motility
and increases apoptosis [97]. SKOV3 cell growth is also inhibited following treatment
with an ERβ agonist (DPN) [98]. Furthermore, the proliferation of the EOC cell line, BG1, is decreased following introduction of ERβ, and the expression of ERβ strongly
inhibits the expression and activity of ERα [83].
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5.8 Summary
Either directly or indirectly, the ECM regulates almost all fundamental aspects of
cell biology. The goal of this thesis was to contribute to our knowledge of its role in
ovarian development and ovarian cancer progression. The data presented herein
characterizes aberrantly overexpressed ECM proteins in a model of subfertility (Chapter
2) as well as high-grade serous EOC (Chapter 4), and discusses the potential impact of
this dysregulation. This body of work provides rationale for future investigations into the
mechanisms by which these ECM components are regulated. The expression of the ECM
proteins investigated is ERβ-dependent, and Chapter 3 describes a novel corepressor of
ERβ-mediated transactivation. Understanding the unique roles of ECM components in
these model systems may improve current therapeutic options for infertility and ovarian
cancer.
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Appendix: Additional Figures

Figure 6- 1: PKCζ protein expression in prepubertal (PND 23) ERβ-null and
wildtype mouse ovaries.
Immunofluorescence with an anti-PKCζ antibody was used to detect PKCζ localization
and expression in ovaries isolated from (a) wildtype and (b) ERβ-null mice. 200x
magnification.
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Figure 6- 2: Col11a1 and Nid-2 protein expression in ERβ-null and wildtype mouse
ovaries on PND 5 and PND 8.
Immunofluorescence with an anti-Col11a1 (A) or anti-Nid2 (B) antibody was used to
detect Col11a1 and Nid2 localization and expression in ovaries isolated from wildtype
(+/+) and ERβ-null (-/-) mice at PND 5 (a, b) and (c, d) PND 8. 200x magnification.
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Figure 6- 3: Collagen 11A1 and Nidogen 2 expression in wildtype, ERβ+/- and ERβ-/mouse ovaries.
Whole cell extracts from adult wildtype (+/+), ERβ-het (+/-) and ERβ-null (-/-) mouse
ovaries were analyzed by Western blot to detect Col11a1 and Nid-2 protein expression.
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Figure 6- 4: Optimization of cell number and FBS% for viability assays.
The cell number and % FBS were optimized for MTS viability assays for the five
established cell lines. 1000, 2500 and 5000 cells/ well were tested. Two FBS
concentrations were tested: 1% FBS and 5% FBS. OVCAR3 cells were only tested in 5%
FBS due to their slow rate of proliferation. Optimization of conditions was performed to
ensure that the assay signal remains within the linear range throughout the assay (an
absorbance of ~0.5 – 1.5 at 490 nm).
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